-
Notifications
You must be signed in to change notification settings - Fork 5
/
FDA_approved_drugtarget.txt
673 lines (673 loc) · 272 KB
/
FDA_approved_drugtarget.txt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific RNA cell line category RNA CS RNA CS TPM
ABAT GABAT ENSG00000183044 4-aminobutyrate aminotransferase 16 8674565-8784575 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041528, HPA041690 Enhanced Supported Supported Mitochondria Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 164.5;kidney: 135.3;liver: 175.2 thyroid gland: 47.5 Cell line enhanced Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
ABCA1 ABC1, HDLDT1, TGD ENSG00000165029 ATP binding cassette subfamily A member 1 9 104781002-104928237 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057283, CAB069889 Approved Approved Nucleoplasm<br>Vesicles Expressed in all Mixed adrenal gland: 38.0 Cell line enhanced U-87 MG: 76.7
ABCC1 GS-X, MRP, MRP1 ENSG00000103222 ATP binding cassette subfamily C member 1 16 15949577-16143074 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002380 Uncertain Supported Plasma membrane Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.6 Cell line enhanced EFO-21: 84.1
ABCC2 CMOAT, cMRP, DJS, MRP2 ENSG00000023839 ATP binding cassette subfamily C member 2 10 99782732-99852192 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004860, CAB037271 Enhanced Renal cancer:1.93e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 43.5;gallbladder: 42.7;kidney: 20.9;liver: 67.6;small intestine: 49.5 breast: 4.4 Cell line enhanced A549: 203.8;Hep G2: 155.8
ABCC8 ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2 ENSG00000006071 ATP binding cassette subfamily C member 8 11 17392885-17476845 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB011451, HPA042318 Approved Approved Nucleoli<br>Golgi apparatus<br>Cytosol Tissue enriched Tissue enhanced cerebral cortex: 11.3 adrenal gland: 7.5 Cell line enhanced A549: 1.7;AN3-CA: 1.8;SCLC-21H: 9.0
ABL1 ABL, c-ABL, JTK7, p150 ENSG00000097007 ABL proto-oncogene 1, non-receptor tyrosine kinase 9 130713946-130887675 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002686, HPA027251, HPA027280, HPA028409 Supported Enhanced Nucleoplasm<br>Nuclear bodies Expressed in all Expressed in all parathyroid gland: 83.9 Expressed in all
ACAA1 ENSG00000060971 Acetyl-CoA acyltransferase 1 3 38103129-38137242 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006764, HPA007244 Enhanced Enhanced Peroxisomes Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable) Expressed in all Expressed in all liver: 328.4 Expressed in all
ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Enhanced Approved Vesicles Expressed in all Tissue enhanced duodenum: 178.9;small intestine: 291.6 testis: 83.7 Cell line enhanced ASC TERT1: 44.4;HUVEC TERT2: 28.2
ACE2 ENSG00000130234 Angiotensin I converting enzyme 2 X 15561033-15602148 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000288, CAB026174 Enhanced Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable) Tissue enhanced Group enriched 5 duodenum: 181.1;gallbladder: 100.2;kidney: 94.0;small intestine: 261.1;testis: 93.0 heart muscle: 27.9 Cell line enhanced HaCaT: 1.1
ACHE YT ENSG00000087085 Acetylcholinesterase (Cartwright blood group) 7 100889994-100896974 Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019704, HPA027098 Approved Golgi apparatus<br>Vesicles Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable) Mixed Tissue enhanced skeletal muscle: 58.5 cerebral cortex: 14.1 Cell line enhanced BEWO: 11.7;CACO-2: 17.5;K-562: 20.7;Karpas-707: 25.8
ADA ENSG00000196839 Adenosine deaminase 20 44619522-44652233 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001399, CAB004307, HPA023884 Enhanced Supported Plasma membrane<br>Cytosol Renal cancer:2.94e-14 (unfavourable), Endometrial cancer:1.23e-7 (unfavourable), Liver cancer:6.77e-5 (unfavourable), Lung cancer:2.20e-4 (unfavourable) Expressed in all Tissue enriched 13 duodenum: 487.7 lymph node: 36.5 Cell line enriched 9 MOLT-4: 1479.5
ADH1A ADH1 ENSG00000187758 Alcohol dehydrogenase 1A (class I), alpha polypeptide 4 99276367-99291028 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009562, HPA047814, HPA060902 Enhanced Approved Plasma membrane<br>Cytosol Liver cancer:2.38e-4 (favourable) Tissue enriched Tissue enriched 135 liver: 1367.7 gallbladder: 10.1 Cell line enhanced ASC diff: 3.7
ADH1B ADH2 ENSG00000196616 Alcohol dehydrogenase 1B (class I), beta polypeptide 4 99304964-99352760 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Approved Plasma membrane<br>Cytosol Renal cancer:7.87e-4 (unfavourable) Tissue enriched Group enriched 6 adipose tissue: 1624.6;liver: 3000.2 lung: 388.5 Cell line enriched 7 ASC diff: 4511.9
ADH1C ADH3 ENSG00000248144 Alcohol dehydrogenase 1C (class I), gamma polypeptide 4 99336492-99353027 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047814, HPA060902 Supported Supported Plasma membrane<br>Cytosol Lung cancer:2.99e-4 (favourable), Liver cancer:4.55e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 508.1;liver: 888.0;stomach: 477.4 colon: 276.3 Cell line enhanced ASC TERT1: 2.5;HSkMC: 7.7
ADK AK ENSG00000156110 Adenosine kinase 10 74151185-74709303 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB032876, HPA038391, HPA038409 Approved Supported Nucleoplasm<br>Cytosol Head and neck cancer:1.93e-4 (unfavourable), Liver cancer:9.91e-4 (favourable) Expressed in all Expressed in all liver: 77.6 Expressed in all
ADORA1 RDC7 ENSG00000163485 Adenosine A1 receptor 1 203090654-203167405 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA044383 Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 50.2;testis: 25.4 parathyroid gland: 18.9 Cell line enhanced CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
ADORA2A ADORA2, RDC8 ENSG00000128271 Adenosine A2a receptor 22 24417879-24442360 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001943, HPA065566, HPA075997 Enhanced Supported Not detected Tissue enhanced bone marrow: 24.6;lymph node: 22.7 appendix: 17.8 Cell line enhanced Karpas-707: 36.8;SK-BR-3: 55.0;U-266/70: 38.8;U-266/84: 50.0;U-698: 37.2
ADORA2B ENSG00000170425 Adenosine A2b receptor 17 15944917-15975746 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA073747 Uncertain Cytosol Mixed Mixed colon: 8.5 Cell line enhanced HMC-1: 142.9
ADORA3 AD026 ENSG00000282608 Adenosine A3 receptor 1 111499429-111503760 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Mixed adrenal gland: 18.4 Cell line enriched 12 HMC-1: 89.3
ADRA1A ADRA1C, ADRA1L1 ENSG00000120907 Adrenoceptor alpha 1A 8 26748150-26867273 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029678, HPA029679 Approved Tissue enhanced Tissue enhanced adipose tissue: 22.6;liver: 31.6;prostate: 20.8 seminal vesicle: 19.1 Not detected
ADRA1B ENSG00000170214 Adrenoceptor alpha 1B 5 159916783-159972544 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074416 Supported Plasma membrane Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.8;spleen: 17.0 ovary: 4.8 Cell line enhanced EFO-21: 12.8;TIME: 10.9;U-2 OS: 9.6
ADRA1D ADRA1, ADRA1A, ADRA1R ENSG00000171873 Adrenoceptor alpha 1D 20 4220631-4249074 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA038789 Uncertain Mixed Tissue enhanced cervix, uterine: 4.3;prostate: 4.5 seminal vesicle: 2.6 Cell line enhanced BJ: 6.7;CAPAN-2: 3.1;fHDF/TERT166: 3.7
ADRA2A ADRA2, ADRA2R, ADRAR ENSG00000150594 Adrenoceptor alpha 2A 10 111077163-111080907 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:8.06e-4 (favourable) Expressed in all Mixed cervix, uterine: 33.2 Cell line enhanced ASC diff: 7.4;ASC TERT1: 9.3;HEL: 18.7;HeLa: 7.4;HSkMC: 23.3
ADRA2C ADRA2L2, ADRA2RL2, ADRARL2 ENSG00000184160 Adrenoceptor alpha 2C 4 3766348-3768526 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057688 Uncertain Mixed Tissue enhanced cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8 fallopian tube: 7.9 Cell line enhanced Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
ADRB1 ADRB1R ENSG00000043591 Adrenoceptor beta 1 10 114044056-114046908 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA067972 Enhanced Tissue enriched Tissue enhanced placenta: 45.4 heart muscle: 10.8 Cell line enhanced HDLM-2: 6.7;THP-1: 3.2;TIME: 5.0
ADRB2 ADRB2R, ADRBR, B2AR, BAR ENSG00000169252 Adrenoceptor beta 2 5 148825245-148828687 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003431, HPA075322 Uncertain Uncertain Cytosol Renal cancer:3.15e-9 (favourable) Mixed Mixed lung: 16.3 Cell line enhanced hTCEpi: 28.8;hTERT-HME1: 31.6
ADRB3 ENSG00000188778 Adrenoceptor beta 3 8 37962991-37966965 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA061969 Uncertain Not detected Tissue enhanced ovary: 8.9;placenta: 3.7 gallbladder: 2.2 Not detected
AGTR1 AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R ENSG00000144891 Angiotensin II receptor type 1 3 148697784-148743008 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003596 Enhanced Uncertain Vesicles Group enriched Tissue enhanced placenta: 214.0 liver: 50.9 Cell line enhanced ASC diff: 127.9;BJ hTERT+ SV40 Large T+: 33.9;HBF TERT88: 54.9;HSkMC: 24.7
AKR1C2 BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD ENSG00000151632 Aldo-keto reductase family 1 member C2 10 4987400-5018031 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB047304, HPA068265 Enhanced Approved Nucleus<br>Nucleoli fibrillar center<br>Endoplasmic reticulum<br>Cytosol Group enriched Group enriched 5 adipose tissue: 330.4;breast: 105.2;esophagus: 94.9;gallbladder: 151.9;liver: 161.4;stomach: 126.5;urinary bladder: 143.0 duodenum: 29.8 Cell line enhanced A549: 1864.0;ASC diff: 1674.9;Hep G2: 2661.0;RT4: 940.6
AKR1D1 SRD5B1 ENSG00000122787 Aldo-keto reductase family 1 member D1 7 138002324-138117986 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA057002 Enhanced Approved Nucleoplasm<br>Cytosol Liver cancer:9.91e-5 (favourable) Tissue enriched Tissue enriched 31 liver: 229.4 breast: 7.2 Cell line enriched 16 Hep G2: 8.6
ALAD ALADH, PBGS ENSG00000148218 Aminolevulinate dehydratase 9 113386317-113401333 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021023, HPA022124 Enhanced Colorectal cancer:7.33e-5 (unfavourable), Liver cancer:8.80e-5 (favourable), Renal cancer:1.65e-4 (favourable), Endometrial cancer:5.64e-4 (favourable) Expressed in all Expressed in all adrenal gland: 147.1 Expressed in all
ALDH2 ENSG00000111275 Aldehyde dehydrogenase 2 family (mitochondrial) 12 111766887-111817529 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051065 Approved Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable) Expressed in all Expressed in all liver: 441.5 Cell line enhanced HHSteC: 81.5;SK-BR-3: 150.4
ALK CD246 ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase 2 29192774-29921566 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010694 Approved Supported Plasma membrane Group enriched Tissue enhanced cerebral cortex: 2.7;testis: 2.0 adrenal gland: 0.5 Cell line enriched 6 SH-SY5Y: 28.3
ALOX5 5-LOX ENSG00000012779 Arachidonate 5-lipoxygenase 10 45374176-45446119 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA071285 Enhanced Supported Nucleoplasm Renal cancer:1.80e-5 (unfavourable), Urothelial cancer:7.18e-4 (favourable) Expressed in all Tissue enhanced lung: 41.3 bone marrow: 28.8 Cell line enhanced BEWO: 10.4;Daudi: 22.8;HMC-1: 20.7;RT4: 14.0;U-266/70: 11.3
ALPPL2 ENSG00000163286 Alkaline phosphatase, placental like 2 2 232406843-232410714 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB020698, HPA038764, HPA038765, HPA051699 Supported Approved Plasma membrane Tissue enhanced Tissue enhanced fallopian tube: 1.5 lung: 0.7 Group enriched 29 BEWO: 6.5;CAPAN-2: 29.9;HaCaT: 22.2
AMY2A AMY2 ENSG00000243480 Amylase, alpha 2A (pancreatic) 1 103616811-103625780 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA045394, HPA045399, CAB045960, HPA046980 Enhanced Tissue enriched Tissue enriched 313 pancreas: 31329.4 ovary: 99.9 Not detected
ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148, HPA057356 Enhanced Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 220.9;seminal vesicle: 298.5 skin: 115.8 Group enriched 5 A-431: 121.8;CAPAN-2: 182.7;HaCaT: 224.5
ANXA1 ANX1, LPC1 ENSG00000135046 Annexin A1 9 73151757-73170393 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA011271, HPA011272, CAB013023, CAB035987, CAB058693 Enhanced Enhanced Nucleoplasm<br>Plasma membrane<br>Cytosol Urothelial cancer:6.19e-6 (unfavourable), Thyroid cancer:4.57e-5 (favourable), Endometrial cancer:5.71e-5 (favourable) Expressed in all Tissue enriched 6 esophagus: 7548.8 tonsil: 1217.6 Mixed
AOC3 HPAO, VAP-1, VAP1 ENSG00000131471 Amine oxidase, copper containing 3 17 42851184-42858130 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA000980, CAB025797 Enhanced Approved Golgi apparatus<br>Cytosol Renal cancer:1.79e-5 (unfavourable), Colorectal cancer:3.68e-4 (unfavourable), Urothelial cancer:6.98e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 450.1 smooth muscle: 205.7 Cell line enriched 17 ASC diff: 210.1
APEX1 APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1 ENSG00000100823 Apurinic/apyrimidinic endodeoxyribonuclease 1 14 20455191-20457772 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000956, HPA002564, CAB004294, CAB047307 Enhanced Enhanced Nucleus Liver cancer:7.82e-5 (unfavourable) Expressed in all Expressed in all ovary: 176.5 Expressed in all
APP AD1 ENSG00000142192 Amyloid beta precursor protein 21 25880550-26171128 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000157, HPA001462 Enhanced Approved Golgi apparatus<br>Vesicles Renal cancer:2.79e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 1203.4 Mixed
AR AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1 ENSG00000169083 Androgen receptor X 67544032-67730619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000001, HPA065701, CAB065764 Enhanced Approved Mitochondria Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable) Mixed Mixed fallopian tube: 42.3 Cell line enhanced AF22: 15.6;HAP1: 21.1;LHCN-M2: 14.9;RH-30: 28.3
ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing ion channel subunit 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus<br>Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 56.8 parathyroid gland: 5.7 Cell line enhanced SH-SY5Y: 30.8
ATIC AICARFT, IMPCHASE, PURH ENSG00000138363 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 2 215311817-215349773 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013462, HPA021012 Supported Enhanced Plasma membrane<br>Cytosol Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all placenta: 44.8 Expressed in all
ATP1A1 ENSG00000163399 ATPase Na+/K+ transporting subunit alpha 1 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Enhanced Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2487.1 Expressed in all
ATP2C1 ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1 ENSG00000017260 ATPase secretory pathway Ca2+ transporting 1 3 130850595-131016712 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010207, HPA035116, HPA069684 Supported Enhanced Golgi apparatus Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable) Expressed in all Expressed in all prostate: 138.3 Expressed in all
ATP4A ATP6A ENSG00000105675 ATPase H+/K+ transporting alpha subunit 19 35550043-35563658 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039154 Enhanced Tissue enriched Tissue enriched 260 stomach: 557.9 pancreas: 2.1 Not detected
ATP6V1B2 ATP6B2, HO57, VATB, Vma2, VPP3 ENSG00000147416 ATPase H+ transporting V1 subunit B2 8 20197367-20226819 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA008147 Enhanced Supported Vesicles Renal cancer:8.41e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 304.2 Expressed in all
AVPR1A AVPR1 ENSG00000166148 Arginine vasopressin receptor 1A 12 63142759-63150942 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced adrenal gland: 77.8 adipose tissue: 20.0 Group enriched 8 ASC diff: 3.9;Karpas-707: 9.4;U-266/84: 6.8
AVPR1B AVPR3 ENSG00000198049 Arginine vasopressin receptor 1B 1 206109692-206117699 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA075404 Supported Tissue enhanced Not detected stomach: 0.3 Not detected
AVPR2 DIR, DIR3, V2R ENSG00000126895 Arginine vasopressin receptor 2 X 153902531-153907166 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA046678 Approved Mixed Tissue enhanced adipose tissue: 5.8 kidney: 2.8 Cell line enhanced EFO-21: 3.0;SCLC-21H: 4.6;U-266/84: 2.7;U-698: 2.8
BCHE CHE1, CHE2, E1 ENSG00000114200 Butyrylcholinesterase 3 165772904-165837472 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001560 Approved Head and neck cancer:1.06e-4 (unfavourable) Group enriched Tissue enhanced liver: 265.5 endometrium: 67.7 Cell line enriched 7 Karpas-707: 542.1
BCL2 Bcl-2, PPP1R50 ENSG00000171791 BCL2, apoptosis regulator 18 63123346-63320128 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000003, HPA055295 Enhanced Supported Nucleoplasm<br>Nuclear membrane Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 69.3 parathyroid gland: 35.3 Cell line enhanced Karpas-707: 59.5;U-266/70: 217.8
BCR ALL, BCR1, CML, D22S11, D22S662, PHL ENSG00000186716 BCR, RhoGEF and GTPase activating protein 22 23179704-23318037 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010421, CAB018545, HPA038337 Approved Approved Nucleoplasm<br>Cytosol Renal cancer:9.15e-10 (favourable) Expressed in all Mixed cerebral cortex: 47.0 Expressed in all
BDKRB2 BK-2 ENSG00000168398 Bradykinin receptor B2 14 96204679-96244166 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050841 Approved Mixed Mixed gallbladder: 32.5 Cell line enhanced ASC TERT1: 34.0;BJ hTERT+: 75.7;U-87 MG: 38.4
BGLAP OCN ENSG00000242252 Bone gamma-carboxyglutamate protein 1 156241962-156243321 FDA approved drug targets, Predicted secreted proteins Evidence at protein level Mixed Mixed skin: 2.1 Cell line enhanced U-87 MG: 2.8
BLVRB FLR, SDR43U1 ENSG00000090013 Biliverdin reductase B 19 40447789-40465840 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041698, HPA041937 Enhanced Supported Nucleoplasm<br>Plasma membrane<br>Cytosol Pancreatic cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 338.3 Cell line enhanced A549: 442.0;K-562: 413.4
BRAF BRAF1 ENSG00000157764 B-Raf proto-oncogene, serine/threonine kinase 7 140719327-140924764 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001328, CAB004552, HPA071048 Approved Approved Vesicles<br>Cytosol Expressed in all Expressed in all testis: 41.8 Expressed in all
BTK AGMX1, ATK, IMD1, PSCTK1, XLA ENSG00000010671 Bruton tyrosine kinase X 101349447-101390796 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001198, HPA002028, CAB016689 Enhanced Supported Vesicles Expressed in all Tissue enhanced lymph node: 65.2;tonsil: 70.8 spleen: 52.7 Cell line enhanced Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
C1R ENSG00000159403 Complement C1r 12 7080209-7092607 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001251, HPA001551 Uncertain Uncertain Nucleoplasm<br>Cytosol Renal cancer:1.94e-14 (unfavourable) Expressed in all Expressed in all liver: 1226.4 Cell line enhanced ASC diff: 1273.8;ASC TERT1: 658.4;BJ hTERT+: 685.9;BJ hTERT+ SV40 Large T+ RasG12V: 496.0;HSkMC: 797.4
C1S ENSG00000182326 Complement C1s 12 6988259-7071032 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016722, HPA018852 Supported Approved Nucleus<br>Cytosol Renal cancer:7.44e-15 (unfavourable), Liver cancer:7.73e-4 (favourable) Expressed in all Expressed in all liver: 1326.7 Cell line enhanced ASC diff: 521.6;ASC TERT1: 703.0;BJ hTERT+: 271.2;HSkMC: 390.5
C3 ARMD9, C3a, C3b, CPAMD1 ENSG00000125730 Complement C3 19 6677704-6730562 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA003563, CAB004209, HPA020432 Enhanced Renal cancer:1.09e-5 (unfavourable), Liver cancer:8.11e-4 (favourable) Expressed in all Expressed in all liver: 2486.8 Group enriched 6 BJ hTERT+: 287.5;EFO-21: 689.2;Hep G2: 539.6;HSkMC: 386.3;SiHa: 220.2
C4A C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG ENSG00000244731 Complement C4A (Rodgers blood group) 6 31982024-32002681 Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB009811, CAB032603, HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced liver: 46.1 thyroid gland: 28.2 Group enriched 8 HDLM-2: 49.4;HSkMC: 51.4;U-266/70: 12.8;U-266/84: 23.9
C4B C4B1, C4B3, C4F, CH, CO4, CPAMD3 ENSG00000224389 Complement C4B (Chido blood group) 6 32014762-32035418 Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA046356, HPA048287, HPA050103 Approved Tissue enhanced Tissue enhanced adrenal gland: 59.4;liver: 65.5 fallopian tube,kidney: 18.3 Cell line enriched 5 Karpas-707: 92.1
C5 C5a, C5b, CPAMD4 ENSG00000106804 Complement C5 9 120952335-121050276 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA029339 Uncertain Liver cancer:9.43e-4 (favourable) Tissue enriched Tissue enriched 21 liver: 225.6 lung: 10.5 Cell line enhanced A549: 25.6;Hep G2: 20.6
CA1 Car1 ENSG00000133742 Carbonic anhydrase 1 8 85327608-85379014 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006558, CAB025790 Enhanced Group enriched Group enriched 30 bone marrow: 1216.6;colon: 1022.8;rectum: 2316.0 smooth muscle: 49.9 Cell line enriched 1560 HEL: 1145.7
CA14 ENSG00000118298 Carbonic anhydrase 14 1 150257159-150265078 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008482 Approved Approved Plasma membrane Group enriched Tissue enhanced cerebral cortex: 10.6;seminal vesicle: 21.2 skeletal muscle: 9.4 Group enriched 23 AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
CA2 CA-II, CAII, Car2 ENSG00000104267 Carbonic anhydrase 2 8 85463852-85481493 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001550, CAB010102 Enhanced Renal cancer:5.57e-6 (favourable) Expressed in all Tissue enhanced colon: 604.8;rectum: 627.5;stomach: 918.8 kidney: 308.3 Group enriched 11 HaCaT: 204.1;HEK 293: 884.1;THP-1: 278.7
CA3 CAIII, Car3 ENSG00000164879 Carbonic anhydrase 3 8 85373436-85449040 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004967, HPA021775, HPA026700 Enhanced Breast cancer:4.24e-6 (favourable) Group enriched Tissue enriched 13 skeletal muscle: 1838.7 prostate: 138.3 Group enriched 34 HEL: 44.2;RH-30: 77.2
CA4 CAIV, Car4, RP17 ENSG00000167434 Carbonic anhydrase 4 17 60149936-60170899 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011089, HPA017258 Enhanced Supported Vesicles Mixed Tissue enhanced colon: 253.5;rectum: 180.9 adipose tissue: 88.7 Not detected
CA7 ENSG00000168748 Carbonic anhydrase 7 16 66844379-66854153 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047237 Uncertain Tissue enhanced Tissue enhanced colon: 54.6;rectum: 49.8 small intestine: 10.7 Cell line enhanced REH: 1.0;SCLC-21H: 1.0;THP-1: 1.2
CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium voltage-gated channel subunit alpha1 A 19 13206442-13633025 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258, HPA071902 Enhanced Uncertain Endoplasmic reticulum Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 15.1 stomach: 3.5 Group enriched 7 SCLC-21H: 56.1;U-87 MG: 26.1
CACNA1B CACNL1A5, CACNN, Cav2.2 ENSG00000148408 Calcium voltage-gated channel subunit alpha1 B 9 137877789-138124624 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA044347 Uncertain Tissue enhanced Group enriched 8 adrenal gland: 3.7;cerebral cortex: 14.8;fallopian tube: 4.9;testis: 7.6 prostate: 0.9 Cell line enriched 6 SCLC-21H: 23.0
CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium voltage-gated channel subunit alpha1 C 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796, CAB079031 Enhanced Approved Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 Cell line enriched 17 HDLM-2: 188.9
CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium voltage-gated channel subunit alpha1 D 3 53328963-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.5 Cell line enhanced HMC-1: 19.6;RPMI-8226: 38.4;SK-BR-3: 7.4
CACNA1F AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2 ENSG00000102001 Calcium voltage-gated channel subunit alpha1 F X 49205063-49233371 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA068379 Supported Not detected Mixed lymph node: 1.6 Cell line enhanced U-266/70: 1.0
CACNA1G Cav3.1, NBR13 ENSG00000006283 Calcium voltage-gated channel subunit alpha1 G 17 50561068-50627474 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA004714 Uncertain Mixed Tissue enhanced cerebral cortex: 10.5;cervix, uterine: 8.5 endometrium: 5.2 Cell line enhanced A549: 8.5;SCLC-21H: 3.3
CACNA1H Cav3.2 ENSG00000196557 Calcium voltage-gated channel subunit alpha1 H 16 1153121-1221772 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039125 Approved Approved Nucleoplasm<br>Vesicles Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable) Expressed in all Tissue enhanced ovary: 44.9 seminal vesicle: 39.1 Cell line enhanced A549: 16.1;AN3-CA: 23.5;MCF7: 36.8;T-47d: 13.0
CACNA1I Cav3.3 ENSG00000100346 Calcium voltage-gated channel subunit alpha1 I 22 39570753-39689737 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 4.7;thyroid gland: 2.7 adrenal gland: 2.3 Cell line enhanced SK-BR-3: 1.4;T-47d: 1.0
CACNA1S CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5 ENSG00000081248 Calcium voltage-gated channel subunit alpha1 S 1 201039512-201112566 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB009507, HPA048892, HPA056815 Enhanced Tissue enhanced Tissue enriched 34 skeletal muscle: 103.0 esophagus: 3.0 Group enriched 20 BEWO: 2.0;HSkMC: 1.9
CACNA2D1 CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3 ENSG00000153956 Calcium voltage-gated channel auxiliary subunit alpha2delta 1 7 81946444-82443798 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA008213, HPA008621 Enhanced Renal cancer:1.16e-4 (unfavourable) Mixed Mixed cerebral cortex: 35.4 Cell line enhanced HUVEC TERT2: 45.6;SH-SY5Y: 66.1
CACNA2D2 KIAA0558 ENSG00000007402 Calcium voltage-gated channel auxiliary subunit alpha2delta 2 3 50362799-50504244 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA034771, HPA071829 Enhanced Approved Vesicles Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable) Tissue enhanced Tissue enriched 6 lung: 72.9 testis: 12.4 Cell line enriched 8 SH-SY5Y: 201.7
CACNB1 CACNLB1 ENSG00000067191 Calcium voltage-gated channel auxiliary subunit beta 1 17 39173456-39197703 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023343 Approved Endometrial cancer:3.80e-4 (unfavourable) Mixed Group enriched 6 cerebral cortex: 46.7;skeletal muscle: 108.5 skin: 12.3 Mixed
CACNB2 CACNLB2, MYSB ENSG00000165995 Calcium voltage-gated channel auxiliary subunit beta 2 10 18140677-18541869 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA035325, HPA035326 Uncertain Renal cancer:3.56e-5 (favourable) Mixed Mixed cerebral cortex: 26.3 Cell line enhanced HAP1: 8.3;HSkMC: 7.1
CACNB3 CACNLB3 ENSG00000167535 Calcium voltage-gated channel auxiliary subunit beta 3 12 48813794-48828941 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA059515 Approved Golgi apparatus<br>Vesicles Mixed Mixed endometrium: 40.0 Cell line enhanced U-937: 85.2
CACNB4 EJM4 ENSG00000182389 Calcium voltage-gated channel auxiliary subunit beta 4 2 151832768-152099475 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015601 Approved Mixed Tissue enhanced cerebral cortex: 25.9 skin: 8.0 Cell line enhanced HMC-1: 17.7
CACNG1 CACNLG ENSG00000108878 Calcium voltage-gated channel auxiliary subunit gamma 1 17 67044590-67056797 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 25 skeletal muscle: 113.4 esophagus: 4.4 Cell line enhanced HSkMC: 2.2;SH-SY5Y: 1.0
CALY CALCYON, DRD1IP, NSG3 ENSG00000130643 Calcyon neuron specific vesicular protein 10 133324072-133336935 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042283 Enhanced Pancreatic cancer:3.54e-4 (favourable) Group enriched Group enriched 13 adrenal gland: 23.5;cerebral cortex: 77.1 testis: 3.8 Not detected
CAMLG CAML, GET2 ENSG00000164615 Calcium modulating ligand 5 134738501-134752160 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052636, HPA056472 Approved Approved Nucleus<br>Nucleoli<br>Vesicles Renal cancer:1.09e-5 (unfavourable) Expressed in all Expressed in all testis: 99.6 Expressed in all
CARTPT CART ENSG00000164326 CART prepropeptide 5 71719163-71721048 FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB025515, HPA046278 Enhanced Stomach cancer:4.36e-4 (unfavourable) Tissue enriched Tissue enriched 8 adrenal gland: 132.5 cerebral cortex: 17.4 Not detected
CASR FHH, GPRC2A, HHC, HHC1, NSHPT ENSG00000036828 Calcium sensing receptor 3 122183683-122291629 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039686, HPA050335 Enhanced Tissue enriched Tissue enriched 58 parathyroid gland: 1441.4 kidney: 24.6 Not detected
CAT ENSG00000121691 Catalase 11 34438925-34472062 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001515, HPA051282, HPA055838 Enhanced Supported Vesicles<br>Cytosol Renal cancer:1.96e-8 (favourable), Liver cancer:9.67e-4 (favourable) Expressed in all Expressed in all liver: 625.4 Cell line enhanced HL-60: 310.1
CCKAR ENSG00000163394 Cholecystokinin A receptor 4 26481400-26490462 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Group enriched 10 gallbladder: 47.2;stomach: 15.2 tonsil: 3.1 Not detected
CCKBR ENSG00000110148 Cholecystokinin B receptor 11 6259736-6272127 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 13 cerebral cortex: 13.6;pancreas: 5.4;stomach: 16.4 prostate: 0.9 Cell line enriched 8 NTERA-2: 69.8
CCL2 GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF ENSG00000108691 C-C motif chemokine ligand 2 17 34255218-34257203 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB013676, HPA019163 Approved Approved Golgi apparatus<br>Vesicles Renal cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 411.3 Group enriched 5 BJ hTERT+: 1539.3;BJ hTERT+ SV40 Large T+ RasG12V: 503.9;HMC-1: 2137.8
CCND1 BCL1, D11S287E, PRAD1, U21B31 ENSG00000110092 Cyclin D1 11 69641087-69654474 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB000024, HPA027802 Uncertain Supported Nucleoplasm Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 340.4 skin: 140.5 Cell line enhanced WM-115: 1198.2
CCR5 CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22 ENSG00000160791 C-C motif chemokine receptor 5 (gene/pseudogene) 3 46370854-46376206 CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Endometrial cancer:7.42e-5 (favourable), Head and neck cancer:9.33e-5 (favourable) Expressed in all Mixed appendix: 20.4 Group enriched 17 Karpas-707: 4.9;U-266/84: 2.1
CD19 ENSG00000177455 CD19 molecule 16 28931939-28939346 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB016110 Enhanced Mixed Group enriched 11 appendix: 37.4;lymph node: 84.0;spleen: 47.4;tonsil: 68.3 urinary bladder: 5.5 Group enriched 40 Daudi: 103.6;REH: 70.5;U-698: 22.6
CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002430, HPA003883 Enhanced Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 131.1 tonsil: 70.8 Group enriched 27 HDLM-2: 201.2;MOLT-4: 129.2
CD247 CD3H, CD3Q, CD3Z ENSG00000198821 CD247 molecule 1 167430640-167518610 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004651, HPA008750 Enhanced Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable) Mixed Tissue enhanced lymph node: 65.1;spleen: 48.6 tonsil: 33.6 Group enriched 34 HDLM-2: 144.2;MOLT-4: 133.0
CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1 ENSG00000120217 CD274 molecule 9 5450503-5470566 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB030018, CAB076385 Enhanced Approved Cytosol Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable) Mixed Mixed appendix: 14.0 Cell line enhanced HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011442, HPA035832, HPA064807 Approved Supported Nucleus<br>Plasma membrane Mixed Tissue enhanced spleen: 33.1 bone marrow: 20.9 Cell line enhanced HEL: 77.8;HL-60: 92.6;HMC-1: 72.6;RPMI-8226: 43.3;THP-1: 45.3;U-937: 66.2
CD3D T3D ENSG00000167286 CD3d molecule 11 118338954-118342744 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013055 Enhanced Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced lymph node: 199.3;tonsil: 119.1 appendix: 86.9 Cell line enriched 7 MOLT-4: 903.0
CD3E ENSG00000198851 CD3e molecule 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Enhanced Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 200.5;tonsil: 113.4 spleen: 95.0 Cell line enriched 92 MOLT-4: 531.3
CD3G ENSG00000160654 CD3g molecule 11 118344344-118355161 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017520, HPA038494 Enhanced Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable) Mixed Tissue enhanced lymph node: 31.4;tonsil: 18.8 spleen: 16.1 Cell line enriched 69 MOLT-4: 160.9
CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Enhanced Supported Plasma membrane Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 549.0 spleen: 220.5 Group enriched 5 HEL: 90.7;HL-60: 32.7;NB-4: 37.0;THP-1: 77.1;U-937: 84.2
CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Enhanced Enhanced Golgi apparatus<br>Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 530.1 Mixed
CD52 CDW52 ENSG00000169442 CD52 molecule 1 26317957-26320523 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Breast cancer:1.85e-5 (favourable), Endometrial cancer:2.06e-4 (favourable), Head and neck cancer:4.45e-4 (favourable), Renal cancer:5.85e-4 (unfavourable) Expressed in all Tissue enriched 35 epididymis: 43887.5 lymph node: 1251.0 Group enriched 8 Daudi: 505.6;REH: 946.6;U-266/84: 745.1;U-698: 783.6
CD80 B7-1, B7.1, CD28LG, CD28LG1 ENSG00000121594 CD80 molecule 3 119524293-119559602 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025368, HPA050092 Enhanced Mixed Tissue enhanced appendix: 7.2;lymph node: 6.7;tonsil: 6.3 spleen: 4.7 Cell line enhanced Daudi: 8.5;HDLM-2: 39.3;Karpas-707: 12.2;U-266/70: 5.5
CD86 B7-2, B7.2, CD28LG2 ENSG00000114013 CD86 molecule 3 122055366-122121139 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004319 Uncertain Renal cancer:9.83e-5 (unfavourable) Expressed in all Mixed appendix: 47.8 Cell line enriched 10 HDLM-2: 275.8
CDK4 PSK-J3 ENSG00000135446 Cyclin dependent kinase 4 12 57747727-57756013 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006024, CAB013116, CAB069405 Enhanced Supported Nucleus<br>Nuclear membrane<br>Nucleoli<br>Cytosol Liver cancer:2.09e-7 (unfavourable), Renal cancer:3.15e-5 (unfavourable) Expressed in all Expressed in all endometrium: 121.7 Group enriched 9 HBEC3-KT: 1874.1;LHCN-M2: 2370.6;RH-30: 8554.0
CDK6 PLSTIRE ENSG00000105810 Cyclin dependent kinase 6 7 92604921-92836594 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002637, CAB004363 Enhanced Supported Nucleoplasm<br>Cytosol Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 34.2 Cell line enhanced MOLT-4: 366.7;REH: 201.1
CES1 CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1 ENSG00000198848 Carboxylesterase 1 16 55802851-55833337 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012023, HPA046717 Enhanced Enhanced Endoplasmic reticulum Urothelial cancer:9.92e-4 (unfavourable) Tissue enriched Group enriched 7 gallbladder: 399.2;liver: 1099.9;lung: 229.9 adipose tissue: 79.7 Group enriched 5 Hep G2: 414.0;THP-1: 439.1;U-937: 102.6
CFTR ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR ENSG00000001626 Cystic fibrosis transmembrane conductance regulator 7 117465784-117715971 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001951, HPA021939 Enhanced Liver cancer:9.44e-4 (unfavourable) Tissue enhanced Tissue enhanced gallbladder: 89.3 rectum: 49.0 Group enriched 19 CACO-2: 26.2;MOLT-4: 97.6;U-266/70: 47.9
CHD1 ENSG00000153922 Chromodomain helicase DNA binding protein 1 5 98853985-98928957 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA022236 Approved Supported Nucleus<br>Nucleoli fibrillar center Renal cancer:7.25e-6 (unfavourable) Expressed in all Expressed in all bone marrow: 44.3 Expressed in all
CHRM1 ENSG00000168539 Cholinergic receptor muscarinic 1 11 62908679-62921807 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014101, CAB022366 Enhanced Approved Nucleus<br>Cytosol Tissue enriched Group enriched 8 cerebral cortex: 39.9;prostate: 42.3;salivary gland: 11.0 adrenal gland: 3.8 Cell line enhanced MCF7: 2.7;SK-BR-3: 1.2;T-47d: 1.0
CHRM2 ENSG00000181072 Cholinergic receptor muscarinic 2 7 136868669-137020255 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022338, HPA029795 Approved Tissue enhanced Tissue enhanced gallbladder: 18.3;heart muscle: 25.8;smooth muscle: 13.7 urinary bladder: 5.9 Cell line enhanced BJ: 14.1;BJ hTERT+: 15.2;fHDF/TERT166: 71.3;HHSteC: 10.8
CHRM3 ENSG00000133019 Cholinergic receptor muscarinic 3 1 239386565-239915452 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA024106, HPA048036 Approved Supported Plasma membrane Mixed Tissue enhanced cerebral cortex: 15.7 esophagus: 8.4 Cell line enhanced RPMI-8226: 11.9;SH-SY5Y: 55.3;U-266/70: 16.6;U-266/84: 11.6
CHRM4 ENSG00000180720 Cholinergic receptor muscarinic 4 11 46385098-46386608 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022444, HPA072083 Uncertain Uncertain Nucleus<br>Golgi apparatus Mixed Tissue enhanced cerebral cortex: 8.1;small intestine: 7.8;spleen: 21.4 testis: 6.9 Cell line enhanced RH-30: 3.3;SCLC-21H: 11.7;U-2 OS: 3.0
CHRM5 ENSG00000184984 Cholinergic receptor muscarinic 5 15 33968720-34067457 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA013172 Uncertain Not detected Tissue enhanced cerebral cortex: 3.1;testis: 3.4 placenta: 2.3 Group enriched 7 BEWO: 4.5;HMC-1: 14.3
CHRNA10 ENSG00000129749 Cholinergic receptor nicotinic alpha 10 subunit 11 3665587-3671384 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enriched 21 skeletal muscle: 16.6 appendix,lung: 0.7 Mixed
CHRNA2 ENSG00000120903 Cholinergic receptor nicotinic alpha 2 subunit 8 27459761-27479883 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 24 prostate: 46.8 breast: 1.9 Not detected
CHRNA3 ENSG00000080644 Cholinergic receptor nicotinic alpha 3 subunit 15 78593052-78621295 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029430 Approved Mixed Tissue enriched 8 adrenal gland: 48.0 appendix: 6.3 Group enriched 25 SCLC-21H: 72.3;SH-SY5Y: 343.0
CHRNA4 BFNC, EBN, EBN1 ENSG00000101204 Cholinergic receptor nicotinic alpha 4 subunit 20 63343223-63378401 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB034064 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 6.9;parathyroid gland: 17.4 liver: 3.9 Cell line enhanced U-2 OS: 2.6
CHRNA7 ENSG00000175344 Cholinergic receptor nicotinic alpha 7 subunit 15 31923438-32173018 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029422, CAB033624 Enhanced Mixed Tissue enhanced adrenal gland: 9.4;small intestine: 10.4 stomach: 6.2 Cell line enhanced AN3-CA: 5.8;RT4: 9.8;SH-SY5Y: 7.1;SK-BR-3: 10.0;U-2 OS: 11.2
CHRNB2 ENSG00000160716 Cholinergic receptor nicotinic beta 2 subunit 1 154567781-154580026 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enriched 15 cerebral cortex: 21.2 adrenal gland: 1.4 Group enriched 7 SCLC-21H: 30.2;SH-SY5Y: 27.0
CHRNB4 ENSG00000117971 Cholinergic receptor nicotinic beta 4 subunit 15 78624119-78727754 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enhanced adrenal gland: 3.2;testis: 5.3 appendix: 0.8 Group enriched 23 SCLC-21H: 34.9;SH-SY5Y: 40.9
CKB CKBB ENSG00000166165 Creatine kinase B 14 103519659-103523111 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001254, CAB047313 Enhanced Supported Cytosol Renal cancer:4.02e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 475.1 Cell line enhanced CACO-2: 340.9;HEK 293: 940.9;SCLC-21H: 678.1
CKM CKMM ENSG00000104879 Creatine kinase, M-type 19 45306414-45322977 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA047859 Enhanced Group enriched Tissue enriched 17 skeletal muscle: 23798.9 heart muscle: 1418.8 Cell line enriched 6 SCLC-21H: 75.4
CKMT1A CKMT1 ENSG00000223572 Creatine kinase, mitochondrial 1A 15 43692886-43699222 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA043491 Uncertain Mixed Mixed rectum: 73.8 Cell line enhanced HaCaT: 113.0;SCLC-21H: 52.4;SK-BR-3: 74.4;T-47d: 83.6
CKMT1B CKMT, CKMT1, UMTCK ENSG00000237289 Creatine kinase, mitochondrial 1B 15 43593054-43604901 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA043491 Uncertain Endometrial cancer:2.55e-5 (unfavourable) Mixed Tissue enhanced colon: 78.0;rectum: 68.4 duodenum: 63.0 Cell line enhanced HaCaT: 120.7;SCLC-21H: 60.9;SK-BR-3: 124.3;T-47d: 91.0
CKMT2 SMTCK ENSG00000131730 Creatine kinase, mitochondrial 2 5 81233285-81266397 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051880 Enhanced Mixed Group enriched 22 heart muscle: 710.7;skeletal muscle: 505.3 adrenal gland: 27.9 Cell line enhanced BEWO: 3.3;T-47d: 5.1
CLCN2 ClC-2, CLC2, EJM6 ENSG00000114859 Chloride voltage-gated channel 2 3 184346185-184361651 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009397, HPA014545, HPA024108 Approved Approved Cytosol Liver cancer:4.67e-8 (unfavourable) Expressed in all Mixed testis: 17.7 Mixed
CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR ENSG00000118432 Cannabinoid receptor 1 6 88139864-88166359 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Tissue enriched Tissue enhanced cerebral cortex: 32.1 adipose tissue: 12.2 Group enriched 7 ASC diff: 55.8;HSkMC: 39.1
CNR2 CB2 ENSG00000188822 Cannabinoid receptor 2 1 23870526-23913362 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB009719 Uncertain Tissue enriched Group enriched 6 appendix: 3.1;lymph node: 8.7;spleen: 7.9;tonsil: 6.9 bone marrow: 1.0 Group enriched 5 Daudi: 3.8;HEL: 4.0;HMC-1: 17.3;U-698: 9.4
COMT ENSG00000093010 Catechol-O-methyltransferase 22 19941607-19969975 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001169, CAB011233 Enhanced Approved Endoplasmic reticulum<br>Vesicles Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable) Expressed in all Expressed in all placenta: 172.6 Expressed in all
CPS1 ENSG00000021826 Carbamoyl-phosphate synthase 1 2 210477682-210679107 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003781, HPA021400 Enhanced Approved Nucleoli Liver cancer:6.93e-5 (favourable) Tissue enriched Group enriched 23 duodenum: 234.5;liver: 697.8;small intestine: 144.1 testis: 15.3 Cell line enhanced HeLa: 249.1;SK-BR-3: 84.1
CPT1A CPT1, CPT1-L, L-CPT1 ENSG00000110090 Carnitine palmitoyltransferase 1A 11 68754620-68844410 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008835 Enhanced Supported Mitochondria Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable) Expressed in all Expressed in all small intestine: 78.9 Mixed
CPT2 CPT1, CPTASE ENSG00000157184 Carnitine palmitoyltransferase 2 1 53196429-53214197 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028201, HPA028202, HPA028214 Enhanced Supported Nucleoplasm<br>Nucleoli<br>Mitochondria Renal cancer:1.46e-12 (favourable), Colorectal cancer:5.27e-4 (favourable) Expressed in all Expressed in all liver: 25.9 Expressed in all
CRBN MRT2, MRT2A ENSG00000113851 Cereblon 3 3144628-3179727 Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA045910 Approved Approved Nucleoli Expressed in all Expressed in all testis: 87.7 Expressed in all
CRHR1 CRF-R, CRF1, CRHR ENSG00000120088 Corticotropin releasing hormone receptor 1 17 45784280-45835828 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB025251 Approved Mixed Tissue enhanced cerebral cortex: 4.0 endometrium: 0.8 Cell line enhanced RT4: 2.7;SH-SY5Y: 2.2
CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles<br>Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 147.7 Group enriched 6 BEWO: 118.6;SK-BR-3: 35.4
CSF2RA CD116, CSF2R ENSG00000198223 Colony stimulating factor 2 receptor alpha subunit X 1268800-1310381 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016148 Uncertain Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 93.3 appendix: 34.6 Group enriched 8 BEWO: 187.1;HMC-1: 51.2;SK-MEL-30: 109.5
CSF2RB CD131, IL3RB, IL5RB ENSG00000100368 Colony stimulating factor 2 receptor beta common subunit 22 36913628-36940449 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA078677 Approved Golgi apparatus Head and neck cancer:7.47e-5 (favourable) Expressed in all Tissue enhanced appendix: 89.7 tonsil: 57.2 Group enriched 7 HEL: 95.8;HMC-1: 281.8
CSF3R CD114, GCSFR ENSG00000119535 Colony stimulating factor 3 receptor 1 36466043-36483278 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017116, HPA048086 Enhanced Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable) Mixed Tissue enhanced appendix: 211.2;bone marrow: 243.4;placenta: 147.9 spleen: 96.5 Cell line enhanced BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
CTLA4 CD, CD152, CELIAC3, GSE, IDDM12 ENSG00000163599 Cytotoxic T-lymphocyte associated protein 4 2 203867786-203873960 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Head and neck cancer:4.48e-5 (favourable) Mixed Tissue enhanced appendix: 23.5;lymph node: 31.9 tonsil: 15.3 Group enriched 5 SK-MEL-30: 2.4;U-266/70: 3.5;U-266/84: 9.7
CXCR4 CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R ENSG00000121966 C-X-C motif chemokine receptor 4 2 136114349-136118165 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 771.6 tonsil: 495.9 Cell line enhanced Daudi: 410.1;MOLT-4: 425.1;REH: 252.8;U-266/70: 489.0;U-698: 459.8
CYP11A1 CYP11A, P450SCC ENSG00000140459 Cytochrome P450 family 11 subfamily A member 1 15 74337759-74367740 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA016436 Enhanced Mixed Tissue enriched 11 adrenal gland: 748.5 testis: 68.5 Group enriched 25 BEWO: 102.7;HEL: 79.0;SiHa: 23.2
CYP11B1 CPN1, CYP11B, FHI, P450C11 ENSG00000160882 Cytochrome P450 family 11 subfamily B member 1 8 142872356-142879846 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA049171, HPA056348, HPA057752 Supported Not detected Tissue enriched 916 adrenal gland: 1871.2 testis: 2.0 Not detected
CYP17A1 CPT7, CYP17, P450C17, S17AH ENSG00000148795 Cytochrome P450 family 17 subfamily A member 1 10 102830531-102837533 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA048533 Enhanced Renal cancer:5.43e-7 (favourable) Tissue enriched Tissue enriched 25 adrenal gland: 3751.4 testis: 152.4 Cell line enhanced HMC-1: 2.6;SCLC-21H: 1.3
CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450 family 19 subfamily A member 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Enhanced Approved Mitochondria Mixed Tissue enriched 15 placenta: 174.5 adrenal gland: 11.9 Group enriched 6 ASC TERT1: 65.0;HDLM-2: 16.2;HSkMC: 22.8
CYP51A1 CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1 ENSG00000001630 Cytochrome P450 family 51 subfamily A member 1 7 92112151-92142952 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041325, HPA043508 Enhanced Enhanced Endoplasmic reticulum Cervical cancer:6.12e-4 (unfavourable) Expressed in all Expressed in all testis: 174.1 Expressed in all
CYSLTR1 CysLT(1), CysLT1, CYSLT1R ENSG00000173198 Cysteinyl leukotriene receptor 1 X 78271464-78327691 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA010546 Approved Mixed Mixed spleen: 14.8 Cell line enhanced HL-60: 16.0;NB-4: 17.8;RPMI-8226: 29.5;THP-1: 17.5;U-937: 22.4
CYSLTR2 CysLT(2), CYSLT2R ENSG00000152207 Cysteinyl leukotriene receptor 2 13 48653711-48711226 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046528 Uncertain Group enriched Tissue enhanced placenta: 36.7;seminal vesicle: 25.0 spleen: 11.4 Cell line enriched 64 HDLM-2: 83.3
DBH DBM ENSG00000123454 Dopamine beta-hydroxylase 9 133636360-133659344 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002130, HPA005960, HPA070789 Enhanced Enhanced Endoplasmic reticulum<br>Vesicles Mixed Tissue enriched 28 adrenal gland: 356.8 liver: 12.6 Cell line enriched 370 SH-SY5Y: 1924.2
DCK ENSG00000156136 Deoxycytidine kinase 4 70992538-71030914 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA059609, HPA062773 Approved Supported Nucleus Liver cancer:6.90e-7 (unfavourable) Expressed in all Expressed in all lymph node: 93.9 Expressed in all
DDC AADC ENSG00000132437 Dopa decarboxylase 7 50458436-50565457 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA017742 Enhanced Approved Actin filaments Mixed Tissue enhanced duodenum: 155.2;kidney: 320.9;small intestine: 180.5 adrenal gland: 63.8 Group enriched 9 CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
DDR2 NTRKR3, TKT, TYRO10 ENSG00000162733 Discoidin domain receptor tyrosine kinase 2 1 162631373-162787400 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA070112 Supported Plasma membrane<br>Actin filaments Renal cancer:1.73e-7 (unfavourable) Expressed in all Mixed adrenal gland: 93.5 Cell line enhanced ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DHFR ENSG00000228716 Dihydrofolate reductase 5 80626228-80654983 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB037129, HPA051465 Uncertain Supported Mitochondria Expressed in all Mixed lymph node: 49.6 Expressed in all
DHODH ENSG00000102967 Dihydroorotate dehydrogenase (quinone) 16 72008588-72027664 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010123, HPA011942 Approved Supported Nucleoplasm<br>Mitochondria Expressed in all Mixed liver: 21.4 Expressed in all
DNMT1 CXXC9, DNMT, MCMT ENSG00000130816 DNA methyltransferase 1 19 10133345-10231286 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA002694, CAB005876 Enhanced Enhanced Nucleoplasm Liver cancer:1.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 51.2 Expressed in all
DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Enhanced Approved Nucleus<br>Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.6;small intestine: 418.9 pancreas: 92.8 Cell line enhanced Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
DPP4 ADCP2, CD26, DPPIV ENSG00000197635 Dipeptidyl peptidase 4 2 161992241-162074542 CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB045970 Enhanced Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 550.6 placenta: 169.1 Cell line enhanced ASC diff: 115.0;ASC TERT1: 118.1;BJ hTERT+: 131.1;RPTEC TERT1: 175.8
DRD1 ENSG00000184845 Dopamine receptor D1 5 175440039-175444208 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013393 Supported Mixed Tissue enhanced cerebral cortex: 8.0 prostate: 1.7 Group enriched 10 RT4: 20.9;U-2 OS: 5.4
DRD2 ENSG00000149295 Dopamine receptor D2 11 113409615-113475691 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015139, HPA015691 Supported Supported Mixed Tissue enhanced adrenal gland: 11.2 smooth muscle: 2.2 Cell line enriched 10 SCLC-21H: 104.3
DRD3 ENSG00000151577 Dopamine receptor D3 3 114128652-114199407 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 13 testis: 1.3 all non-specific tissues: 0.0 Not detected
DRD4 ENSG00000069696 Dopamine receptor D4 11 637293-640706 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Not detected skin: 0.3 Not detected
DRD5 DRD1B, DRD1L2 ENSG00000169676 Dopamine receptor D5 4 9781680-9784009 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA048930 Supported Not detected Tissue enhanced appendix: 1.7;cerebral cortex: 2.0;stomach: 3.8 testis: 0.8 Not detected
EDNRA ENSG00000151617 Endothelin receptor type A 4 147480917-147544954 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013774, CAB018957 Uncertain Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 146.8 cervix, uterine: 83.0 Cell line enhanced ASC TERT1: 11.8;LHCN-M2: 17.3;SH-SY5Y: 16.4
EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Supported Plasma membrane<br>Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 180.2 cerebral cortex: 88.8 Cell line enhanced AF22: 59.4;ASC diff: 35.4;SK-MEL-30: 42.0;U-266/70: 29.1;WM-115: 122.9
EGF ENSG00000138798 Epidermal growth factor 4 109912884-110012266 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level Mixed Tissue enriched 7 kidney: 122.1 pancreas: 18.5 Cell line enhanced EFO-21: 5.9;SK-BR-3: 8.5;U-251 MG: 3.0
EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55211628 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Enhanced Enhanced Plasma membrane Urothelial cancer:2.04e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 100.0 skin: 58.7 Cell line enriched 15 A-431: 4682.9
ELANE ELA2, HLE, HNE, NE ENSG00000197561 Elastase, neutrophil expressed 19 851014-856247 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB015409, HPA066836 Enhanced Group enriched Tissue enriched 320 bone marrow: 1199.6 skin: 3.7 Cell line enriched 56 THP-1: 1171.3
EPHA2 ECK ENSG00000142627 EPH receptor A2 1 16124337-16156087 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010464 Supported Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions Expressed in all Tissue enhanced esophagus: 86.8 gallbladder: 44.5 Cell line enhanced PC-3: 211.2;WM-115: 253.0
EPOR ENSG00000187266 Erythropoietin receptor 19 11377205-11384342 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA077613 Supported Vesicles Pancreatic cancer:3.17e-5 (favourable) Expressed in all Tissue enhanced parathyroid gland: 53.1 thyroid gland: 18.0 Mixed
ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Enhanced Supported Plasma membrane<br>Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 124.5 Cell line enriched 22 SK-BR-3: 2343.7
ERBB4 ALS19, HER4 ENSG00000178568 Erb-b2 receptor tyrosine kinase 4 2 211375717-212538841 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000276, HPA012016, CAB025522 Enhanced Tissue enhanced Tissue enhanced fallopian tube: 17.8 cerebral cortex: 7.6 Group enriched 5 AF22: 6.8;EFO-21: 4.8;HEK 293: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Enhanced Approved Nucleus<br>Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5 seminal vesicle: 13.5 Group enriched 11 MCF7: 34.7;T-47d: 53.2
ESR2 Erb, NR3A2 ENSG00000140009 Estrogen receptor 2 14 64084232-64338112 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB065126 Enhanced Not detected Tissue enhanced testis: 10.4 adrenal gland: 6.3 Cell line enhanced U-266/70: 7.3;U-698: 11.3
ESRRG NR3B3 ENSG00000196482 Estrogen related receptor gamma 1 216503246-217137755 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044678 Uncertain Approved Nucleus Renal cancer:1.13e-11 (favourable) Mixed Tissue enhanced parathyroid gland: 77.5 kidney: 31.3 Group enriched 7 RPMI-8226: 16.0;SCLC-21H: 9.4;SH-SY5Y: 44.7
F10 ENSG00000126218 Coagulation factor X 13 113122814-113149529 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.82e-5 (favourable), Renal cancer:5.14e-5 (unfavourable) Tissue enriched Tissue enhanced liver: 67.5 cervix, uterine: 51.6 Cell line enhanced BJ: 12.5;Hep G2: 40.8;SH-SY5Y: 30.0
F11 FXI ENSG00000088926 Coagulation factor XI 4 186265945-186288806 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA039808 Approved Vesicles Liver cancer:3.29e-5 (favourable) Tissue enriched Tissue enhanced liver: 180.1 kidney: 44.7 Cell line enriched 8 Hep G2: 6.0
F12 ENSG00000131187 Coagulation factor XII 5 177402140-177409576 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003825 Approved Liver cancer:4.63e-5 (favourable), Renal cancer:7.09e-4 (unfavourable) Tissue enriched Tissue enriched 78 liver: 141.6 bone marrow: 1.8 Cell line enhanced HDLM-2: 6.4;MCF7: 6.7;PC-3: 5.8;SH-SY5Y: 4.5
F2 ENSG00000180210 Coagulation factor II, thrombin 11 46719180-46739506 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016780, CAB018650, HPA051476, HPA054698 Enhanced Renal cancer:6.75e-12 (unfavourable) Tissue enriched Tissue enriched 1472 liver: 627.3 testis: 0.4 Cell line enriched 18 Hep G2: 186.7
F2R CF2R, PAR-1, PAR1, TR ENSG00000181104 Coagulation factor II thrombin receptor 5 76716043-76735781 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB008973, CAB012962 Approved Renal cancer:2.21e-7 (unfavourable) Expressed in all Expressed in all spleen: 94.1 Cell line enhanced HUVEC TERT2: 297.4;WM-115: 331.7
F3 CD142, TF ENSG00000117525 Coagulation factor III, tissue factor 1 94529225-94541800 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009438, HPA049292, HPA069132 Approved Enhanced Vesicles Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all placenta: 191.1 Cell line enhanced A-431: 929.2;HaCaT: 433.2;HBEC3-KT: 914.1;U-2197: 442.4
F5 ENSG00000198734 Coagulation factor V 1 169514166-169586588 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA002036 Uncertain Approved Golgi apparatus Stomach cancer:3.39e-4 (unfavourable) Tissue enriched Group enriched 11 gallbladder: 28.4;liver: 93.7;placenta: 68.2 fallopian tube: 5.9 Cell line enriched 7 Hep G2: 22.8
F7 ENSG00000057593 Coagulation factor VII 13 113105788-113120681 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004826 Approved Mitochondria Tissue enriched Tissue enriched 44 liver: 65.0 testis: 1.4 Group enriched 7 CACO-2: 11.8;Hep G2: 6.1
F8 DXS1253E, F8C, FVIII, HEMA ENSG00000185010 Coagulation factor VIII X 154835788-155026940 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018777 Enhanced Expressed in all Expressed in all lung: 23.4 Mixed
F9 FIX ENSG00000101981 Coagulation factor IX X 139530758-139563458 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Liver cancer:6.69e-4 (favourable) Tissue enriched Tissue enriched 2258 liver: 365.0 kidney: 0.1 Not detected
FADS1 D5D, FADS6, FADSD5, LLCDL1, TU12 ENSG00000149485 Fatty acid desaturase 1 11 61799625-61829318 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042705 Approved Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 89.1 Expressed in all
FADS2 D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13 ENSG00000134824 Fatty acid desaturase 2 11 61792980-61867354 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006741 Approved Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 414.3 Expressed in all
FASN FAS, SDR27X1 ENSG00000169710 Fatty acid synthase 17 82078333-82098332 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005192, HPA006461, CAB015417, HPA056108 Enhanced Enhanced Plasma membrane<br>Cytosol Cervical cancer:1.42e-5 (unfavourable), Renal cancer:7.16e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 290.7 Expressed in all
FCER1A FCE1A ENSG00000179639 Fc fragment of IgE receptor Ia 1 159289714-159308224 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022102, HPA036051, CAB055526 Approved Renal cancer:1.20e-4 (favourable) Expressed in all Mixed skin: 39.9 Cell line enriched 100 HEL: 401.2
FCER1G ENSG00000158869 Fc fragment of IgE receptor Ig 1 161215234-161220699 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022108, HPA026872 Supported Renal cancer:1.83e-6 (unfavourable) Expressed in all Expressed in all spleen: 462.9 Group enriched 5 HEL: 69.1;HMC-1: 265.2;THP-1: 185.7;U-266/84: 61.5;U-937: 67.6
FCGR1A CD64, CD64A ENSG00000150337 Fc fragment of IgG receptor Ia 1 149782671-149792518 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Renal cancer:4.83e-8 (unfavourable) Tissue enhanced Tissue enhanced epididymis: 91.1 appendix: 48.9 Cell line enriched 5 THP-1: 113.9
FCGR1B CD64b ENSG00000198019 Fc fragment of IgG receptor Ib 1 121087345-121096310 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level Tissue enhanced Tissue enhanced appendix: 27.5;epididymis: 61.7 placenta: 17.0 Cell line enhanced HMC-1: 6.6;NB-4: 12.8;THP-1: 51.9
FCGR2A CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2 ENSG00000143226 Fc fragment of IgG receptor IIa 1 161505430-161524013 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010718, HPA014730 Enhanced Renal cancer:6.49e-7 (unfavourable) Expressed in all Tissue enhanced placenta: 160.6 appendix: 148.6 Cell line enhanced HEL: 26.6;HMC-1: 50.4;K-562: 16.0;THP-1: 42.6;U-937: 21.3
FCGR2B CD32, CD32B, FCG2, FCGR2 ENSG00000072694 Fc fragment of IgG receptor IIb 1 161663147-161678654 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB007796, HPA014730 Enhanced Renal cancer:8.82e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 576.7 adipose tissue: 36.6 Cell line enhanced Daudi: 18.5;HMC-1: 27.5;RPMI-8226: 8.1
FCGR3A CD16, CD16a, FCG3, FCGR3 ENSG00000203747 Fc fragment of IgG receptor IIIa 1 161541759-161550737 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB032435, HPA055431 Supported Renal cancer:3.22e-6 (unfavourable) Expressed in all Expressed in all spleen: 419.4 Not detected
FCGR3B CD16, CD16b, FCG3, FCGR3 ENSG00000162747 Fc fragment of IgG receptor IIIb 1 161623196-161631963 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced appendix: 118.1;spleen: 115.2 urinary bladder: 36.3 Not detected
FDPS ENSG00000160752 Farnesyl diphosphate synthase 1 155308748-155320666 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028200 Approved Approved Nucleoplasm<br>Cytosol Liver cancer:7.35e-4 (unfavourable) Expressed in all Expressed in all liver: 186.4 Expressed in all
FFAR1 FFA1R, GPR40 ENSG00000126266 Free fatty acid receptor 1 19 35351552-35353862 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enhanced bone marrow: 1.9 ovary: 1.2 Cell line enhanced U-698: 1.1
FGA ENSG00000171560 Fibrinogen alpha chain 4 154583126-154590766 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB016776, HPA051370, HPA064755 Supported Renal cancer:4.23e-6 (unfavourable), Liver cancer:7.33e-4 (favourable) Tissue enriched Tissue enriched 237 liver: 9265.4 stomach: 39.0 Cell line enriched 11 Hep G2: 285.6
FGF1 AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1 ENSG00000113578 Fibroblast growth factor 1 5 142592178-142698070 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003265, CAB017519 Enhanced Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 129.9;kidney: 59.4 heart muscle: 32.8 Cell line enhanced BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
FGF2 FGFB ENSG00000138685 Fibroblast growth factor 2 4 122826708-122898236 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB000125 Approved Supported Nucleoplasm<br>Nuclear bodies Pancreatic cancer:9.85e-4 (unfavourable) Mixed Mixed adipose tissue: 26.1 Cell line enhanced BJ: 206.0;fHDF/TERT166: 215.4
FGFR1 BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM ENSG00000077782 Fibroblast growth factor receptor 1 8 38411138-38468834 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB033614, HPA056402, HPA076274 Approved Supported Nucleoli Expressed in all Expressed in all cervix, uterine: 109.5 Cell line enhanced AN3-CA: 602.2
FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25 ENSG00000066468 Fibroblast growth factor receptor 2 10 121478334-121598458 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010886, HPA035305, HPA056562 Uncertain Approved Vesicles Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable) Expressed in all Mixed skin: 129.4 Cell line enhanced AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3 ACH, CD333, CEK2, JTK4 ENSG00000068078 Fibroblast growth factor receptor 3 4 1793307-1808872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB004231, HPA067204 Enhanced Supported Endoplasmic reticulum Endometrial cancer:3.77e-4 (unfavourable) Expressed in all Tissue enriched 7 skin: 333.1 cerebral cortex: 49.4 Cell line enhanced CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4 CD334, JTK2 ENSG00000160867 Fibroblast growth factor receptor 4 5 177086886-177098144 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005196, HPA027273, HPA027369, HPA028251 Approved Mixed Tissue enhanced lung: 38.9 duodenum: 21.4 Cell line enhanced CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FKBP1A FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE ENSG00000088832 FK506 binding protein 1A 20 1368978-1393172 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004639, HPA051798 Uncertain Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 369.7 Expressed in all
FLT1 FLT, VEGFR1 ENSG00000102755 Fms related tyrosine kinase 1 13 28300344-28495145 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Enhanced Supported Plasma membrane<br>Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 622.5 thyroid gland: 81.9 Cell line enhanced BJ: 61.1;HMC-1: 308.1;WM-115: 126.2
FLT3 CD135, FLK2, STK1 ENSG00000122025 Fms related tyrosine kinase 3 13 28003274-28100592 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA047539 Approved Endoplasmic reticulum Tissue enhanced Tissue enhanced lymph node: 7.0;spleen: 7.7 appendix: 3.9 Group enriched 14 REH: 38.7;THP-1: 17.4
FLT4 PCL, VEGFR3 ENSG00000037280 Fms related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099, HPA046519, HPA067906 Approved Enhanced Nuclear speckles<br>Plasma membrane<br>Cell Junctions Expressed in all Mixed spleen: 18.3 Cell line enhanced BEWO: 11.8;HEK 293: 14.1;T-47d: 13.7;TIME: 12.7
FN1 CIG, FINC, GFND2, LETS, MSF ENSG00000115414 Fibronectin 1 2 215360440-215436172 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000126, HPA027066 Enhanced Renal cancer:3.44e-8 (unfavourable), Stomach cancer:8.82e-5 (unfavourable), Urothelial cancer:3.33e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 4284.3 lung: 1167.5 Cell line enhanced ASC TERT1: 24376.9;HSkMC: 11926.5;hTERT-HME1: 7509.7
FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Enhanced Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 298.8;prostate: 136.6;small intestine: 90.8 cerebral cortex: 31.0 Mixed
FRK GTK, PTK5, RAK ENSG00000111816 Fyn related Src family tyrosine kinase 6 115931149-116060758 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB025217, HPA030479 Approved Supported Nucleus<br>Cytosol Renal cancer:9.66e-7 (favourable) Mixed Mixed kidney: 10.0 Mixed
FSHR FSHRO, LGR1, ODG1 ENSG00000170820 Follicle stimulating hormone receptor 2 48962157-49154537 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Not detected Group enriched 9 ovary: 2.5;testis: 4.3 gallbladder: 0.3 Not detected
FTH1 FHC, FTH, FTHL6, PIG15, PLIF ENSG00000167996 Ferritin heavy chain 1 11 61959718-61967660 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008623 Approved Approved Microtubules Renal cancer:5.20e-5 (unfavourable), Head and neck cancer:7.56e-5 (unfavourable), Liver cancer:6.18e-4 (unfavourable) Expressed in all Expressed in all appendix: 4962.3 Expressed in all
FTL MGC71996, NBIA3 ENSG00000087086 Ferritin light chain 19 48965301-48966878 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB020769, HPA041602 Enhanced Approved Cytosol Renal cancer:4.40e-5 (unfavourable) Expressed in all Expressed in all lung: 8050.1 Expressed in all
FXYD2 ATP1G1, HOMG2, MGC12372 ENSG00000137731 FXYD domain containing ion transport regulator 2 11 117800844-117828698 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA064218, HPA068838 Supported Approved Mitochondria Renal cancer:3.23e-9 (favourable) Tissue enriched Group enriched 6 gallbladder: 571.3;kidney: 1433.1;salivary gland: 380.4 pancreas: 134.6 Group enriched 24 MOLT-4: 1801.2;RPTEC TERT1: 3683.4
GAA ENSG00000171298 Glucosidase alpha, acid 17 80101556-80119879 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026970, HPA029126 Enhanced Colorectal cancer:7.66e-4 (unfavourable) Expressed in all Expressed in all placenta: 69.7 Mixed
GABBR1 GPRC3A, hGB1a ENSG00000204681 Gamma-aminobutyric acid type B receptor subunit 1 6 29555629-29633976 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050483, HPA058459 Uncertain Approved Centrosome Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 20.8 spleen: 13.1 Cell line enhanced U-2 OS: 6.7
GABBR2 GABABR2, GPR51, GPRC3B, HG20 ENSG00000136928 Gamma-aminobutyric acid type B receptor subunit 2 9 98288082-98709197 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013820, HPA031684, CAB079065 Enhanced Approved Group enriched Tissue enriched 18 cerebral cortex: 77.9 adrenal gland: 4.3 Cell line enhanced BJ: 11.3;HUVEC TERT2: 22.8;U-138 MG: 10.3
GABRA1 EJM5 ENSG00000022355 Gamma-aminobutyric acid type A receptor alpha1 subunit 5 161847063-161899981 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022502, HPA055746 Enhanced Tissue enriched Tissue enriched 46 cerebral cortex: 85.0 adrenal gland: 1.8 Not detected
GABRA2 ENSG00000151834 Gamma-aminobutyric acid type A receptor alpha2 subunit 4 46248427-46475230 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB079061 Supported Tissue enhanced Tissue enriched 7 cerebral cortex: 74.3 epididymis: 11.3 Cell line enhanced U-2 OS: 4.9;U-87 MG: 2.2;WM-115: 2.5
GABRA3 ENSG00000011677 Gamma-aminobutyric acid type A receptor alpha3 subunit X 152166234-152451358 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000839 Approved Supported Tissue enriched Tissue enriched 7 cerebral cortex: 28.8 placenta: 4.1 Cell line enhanced HMC-1: 7.4;Karpas-707: 10.3;PC-3: 7.8;U-2 OS: 7.3;U-266/84: 9.5;U-87 MG: 8.1
GABRA4 ENSG00000109158 Gamma-aminobutyric acid type A receptor alpha4 subunit 4 46918900-46994407 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enriched 9 cerebral cortex: 15.1 heart muscle: 1.6 Cell line enriched 127 REH: 12.7
GABRA5 ENSG00000186297 Gamma-aminobutyric acid type A receptor alpha5 subunit 15 26866363-26949207 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077031, CAB079022 Supported Supported Plasma membrane Mixed Tissue enriched 43 cerebral cortex: 81.6 esophagus: 1.8 Group enriched 10 A549: 32.7;HAP1: 12.7;NTERA-2: 14.6;U-2 OS: 13.1
GABRA6 ENSG00000145863 Gamma-aminobutyric acid type A receptor alpha6 subunit 5 161547063-161702593 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level CAB022462 Approved Not detected Tissue enhanced testis: 1.1 cerebral cortex: 0.3 Not detected
GABRB1 ENSG00000163288 Gamma-aminobutyric acid type A receptor beta1 subunit 4 46993723-47426444 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051297 Uncertain Tissue enhanced Tissue enriched 12 cerebral cortex: 19.7 heart muscle: 1.5 Cell line enhanced REH: 1.4;U-87 MG: 2.4
GABRB2 ENSG00000145864 Gamma-aminobutyric acid type A receptor beta2 subunit 5 161288429-161549044 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB001964, HPA067632 Enhanced Tissue enriched Tissue enriched 12 cerebral cortex: 62.8 epididymis: 5.2 Cell line enriched 17 SCLC-21H: 27.6
GABRB3 ENSG00000166206 Gamma-aminobutyric acid type A receptor beta3 subunit 15 26543546-26939539 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cerebral cortex: 78.3 gallbladder: 21.5 Cell line enhanced A549: 61.5;HAP1: 28.7;NTERA-2: 48.0;SCLC-21H: 51.8
GABRD ENSG00000187730 Gamma-aminobutyric acid type A receptor delta subunit 1 2019298-2030758 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044371 Enhanced Uncertain Golgi apparatus<br>Vesicles Renal cancer:4.12e-8 (unfavourable) Expressed in all Tissue enriched 12 cerebral cortex: 34.0 testis: 2.7 Cell line enhanced EFO-21: 1.3;MCF7: 3.1;NB-4: 1.6;SH-SY5Y: 1.6
GABRE ENSG00000102287 Gamma-aminobutyric acid type A receptor epsilon subunit X 151953124-151974680 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA045918 Uncertain Renal cancer:4.05e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 10.1 heart muscle: 6.4 Cell line enhanced EFO-21: 10.9;HeLa: 3.5;SiHa: 5.9
GABRG1 ENSG00000163285 Gamma-aminobutyric acid type A receptor gamma1 subunit 4 46035769-46124081 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA035622 Approved Tissue enriched Tissue enriched 17 cerebral cortex: 26.0 ovary: 1.5 Cell line enhanced U-266/70: 1.1
GABRG2 ENSG00000113327 Gamma-aminobutyric acid type A receptor gamma2 subunit 5 162000057-162162977 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB079060 Supported Tissue enhanced Tissue enriched 12 cerebral cortex: 66.5 adrenal gland: 5.3 Cell line enhanced CACO-2: 11.6;U-266/70: 17.2;U-266/84: 13.6
GABRG3 ENSG00000182256 Gamma-aminobutyric acid type A receptor gamma3 subunit 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.5 cerebral cortex: 4.2 Cell line enhanced K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
GABRP ENSG00000094755 Gamma-aminobutyric acid type A receptor pi subunit 5 170763350-170814047 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB014883 Uncertain Cervical cancer:3.37e-4 (favourable) Mixed Expressed in all breast: 177.0 Cell line enhanced A-431: 184.7;EFO-21: 182.4;PC-3: 293.8
GABRQ THETA ENSG00000268089 Gamma-aminobutyric acid type A receptor theta subunit X 152638183-152657534 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Tissue enhanced Tissue enhanced cerebral cortex: 6.6;cervix, uterine: 12.9 adrenal gland: 3.0 Group enriched 7 HeLa: 8.2;SiHa: 12.7;U-87 MG: 37.4
GABRR1 ENSG00000146276 Gamma-aminobutyric acid type A receptor rho1 subunit 6 89177501-89231278 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 6 testis: 1.8 placenta: 0.3 Cell line enhanced NTERA-2: 1.2
GABRR2 ENSG00000111886 Gamma-aminobutyric acid type A receptor rho2 subunit 6 89257208-89315299 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Not detected Not detected adrenal gland,appendix,cerebral cortex,endometrium,gallbladder,lymph node,skin,spleen,testis,thyroid gland: 0.1 Not detected
GABRR3 ENSG00000183185 Gamma-aminobutyric acid type A receptor rho3 subunit (gene/pseudogene) 3 97986673-98035304 FDA approved drug targets, Predicted membrane proteins No evidence Not detected Not detected testis: 0.2 Not detected
GAMT PIG2, TP53I2 ENSG00000130005 Guanidinoacetate N-methyltransferase 19 1397026-1401570 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051806 Approved Stomach cancer:6.57e-4 (unfavourable) Tissue enriched Group enriched 5 epididymis: 173.0;liver: 158.9;skeletal muscle: 425.6 pancreas: 48.1 Mixed
GANAB G2AN, GIIA, GluII, KIAA0088 ENSG00000089597 Glucosidase II alpha subunit 11 62624826-62646726 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA026874, HPA061426 Enhanced Approved Nuclear membrane<br>Endoplasmic reticulum<br>Cytosol Liver cancer:1.27e-5 (unfavourable), Urothelial cancer:9.54e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 295.2 Expressed in all
GANC ENSG00000214013 Glucosidase alpha, neutral C 15 42273233-42356935 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA016949 Approved Approved Nucleoplasm<br>Actin filaments Lung cancer:9.76e-4 (favourable) Expressed in all Expressed in all lung: 29.8 Expressed in all
GART PGFT, PRGS ENSG00000159131 Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase 21 33503931-33543491 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002119, HPA005779 Approved Uncertain Nucleoplasm<br>Mitochondria<br>Cytosol Renal cancer:3.95e-6 (unfavourable), Head and neck cancer:5.05e-5 (unfavourable), Liver cancer:9.82e-5 (unfavourable), Pancreatic cancer:2.19e-4 (unfavourable) Expressed in all Expressed in all testis: 55.1 Expressed in all
GCGR GGR ENSG00000215644 Glucagon receptor 17 81804132-81814013 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071228 Approved Golgi apparatus Tissue enhanced Group enriched 7 adrenal gland: 6.6;kidney: 8.4;liver: 20.8;parathyroid gland: 8.0 skin: 1.6 Cell line enhanced HeLa: 1.2;MCF7: 2.2;SK-BR-3: 1.8;U-87 MG: 2.7
GGCX VKCFD1 ENSG00000115486 Gamma-glutamyl carboxylase 2 85544723-85561547 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA018284 Approved Endometrial cancer:1.82e-6 (unfavourable) Expressed in all Expressed in all liver: 61.3 Expressed in all
GGPS1 GGPPS1 ENSG00000152904 Geranylgeranyl diphosphate synthase 1 1 235327350-235344532 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029472 Enhanced Liver cancer:6.69e-4 (unfavourable) Expressed in all Expressed in all testis: 90.1 Expressed in all
GHR GHBP ENSG00000112964 Growth hormone receptor 5 42423777-42721878 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA045339, HPA057705 Enhanced Supported Plasma membrane<br>Cytosol<br>Cytoplasmic bodies Liver cancer:2.73e-6 (favourable) Mixed Group enriched 6 adipose tissue: 91.4;liver: 110.5 prostate: 18.0 Group enriched 7 HSkMC: 15.4;T-47d: 52.5
GHRHR ENSG00000106128 Growth hormone releasing hormone receptor 7 30938669-30993254 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level Tissue enhanced Not detected adrenal gland: 0.5 Not detected
GLP1R ENSG00000112164 Glucagon like peptide 1 receptor 6 39048798-39087743 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enhanced cerebral cortex: 1.9;heart muscle: 1.8 pancreas: 1.5 Cell line enhanced NTERA-2: 1.3;SCLC-21H: 3.7
GLP2R ENSG00000065325 Glucagon like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022690, HPA049244 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced gallbladder: 19.3 duodenum: 10.1 Cell line enhanced A549: 15.1;HeLa: 54.7;SiHa: 8.7
GLRA1 STHE ENSG00000145888 Glycine receptor alpha 1 5 151822513-151924842 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016502, CAB079042 Uncertain Supported Not detected Not detected adrenal gland: 0.4 Not detected
GLRA2 GLR ENSG00000101958 Glycine receptor alpha 2 X 14529298-14731812 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB070422 Approved Mixed Group enriched 10 cerebral cortex: 6.1;colon: 1.4;rectum: 4.3 testis: 0.3 Cell line enriched 41 AN3-CA: 16.1
GLRA3 ENSG00000145451 Glycine receptor alpha 3 4 174636914-174829314 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Group enriched 6 breast: 2.6;cerebral cortex: 9.1 adrenal gland: 1.0 Cell line enhanced Karpas-707: 1.4
GLRB ENSG00000109738 Glycine receptor beta 4 157076057-157172090 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052363 Approved Renal cancer:4.89e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 62.0;parathyroid gland: 63.1 cervix, uterine: 14.1 Mixed
GNRHR GRHR, LHRHR ENSG00000109163 Gonadotropin releasing hormone receptor 4 67739328-67754360 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA013424 Supported Not detected Tissue enhanced adrenal gland: 1.0 cerebral cortex: 0.6 Not detected
GRIA1 GluA1, GLUR1, GLURA ENSG00000155511 Glutamate ionotropic receptor AMPA type subunit 1 5 153489615-153813869 FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB001965, HPA035202 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 67.1 lung: 10.6 Cell line enhanced AF22: 11.5;BJ: 4.7;LHCN-M2: 6.9;U-266/70: 4.4
GRIK1 GluK1, GLUR5 ENSG00000171189 Glutamate ionotropic receptor kainate type subunit 1 21 29536933-29940033 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA014623 Uncertain Glioma:9.12e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 16.3;cerebral cortex: 9.0 prostate: 4.0 Not detected
GRIN1 GluN1, NMDAR1 ENSG00000176884 Glutamate ionotropic receptor NMDA type subunit 1 9 137138390-137168762 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB006831 Approved Mixed Tissue enriched 208 cerebral cortex: 151.8 prostate: 0.7 Cell line enhanced RPMI-8226: 1.8;SCLC-21H: 6.7;SH-SY5Y: 4.2
GRIN2A GluN2A, NMDAR2A ENSG00000183454 Glutamate ionotropic receptor NMDA type subunit 2A 16 9753404-10182754 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022725 Enhanced Mixed Tissue enhanced cerebral cortex: 25.8 testis: 6.1 Cell line enhanced fHDF/TERT166: 3.3;U-138 MG: 4.4
GRIN2B GluN2B, NMDAR2B ENSG00000273079 Glutamate ionotropic receptor NMDA type subunit 2B 12 13437942-13981957 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA069762 Approved Not detected Tissue enriched 23 cerebral cortex: 13.1 adipose tissue,testis: 0.5 Cell line enhanced AF22: 1.2;CACO-2: 1.2;NTERA-2: 1.8;RPTEC TERT1: 1.3
GRIN2C GluN2C, NMDAR2C ENSG00000161509 Glutamate ionotropic receptor NMDA type subunit 2C 17 74842023-74861504 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level Tissue enhanced Tissue enhanced cerebral cortex: 9.5;thyroid gland: 14.1 heart muscle: 6.1 Cell line enhanced BEWO: 6.1;SCLC-21H: 3.3
GRIN2D EB11, GluN2D, NMDAR2D, NR2D ENSG00000105464 Glutamate ionotropic receptor NMDA type subunit 2D 19 48394875-48444931 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced cerebral cortex: 2.3 placenta: 1.3 Cell line enhanced A549: 16.7;HMC-1: 27.0
GRIN3A GluN3A ENSG00000198785 Glutamate ionotropic receptor NMDA type subunit 3A 9 101569353-101738580 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Tissue enriched Group enriched 5 cerebral cortex: 12.3;cervix, uterine: 2.5 seminal vesicle: 1.3 Cell line enriched 6 SCLC-21H: 2.1
GRIN3B GluN3B ENSG00000116032 Glutamate ionotropic receptor NMDA type subunit 3B 19 1000419-1009732 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level Mixed Tissue enhanced fallopian tube: 2.1;spleen: 1.2 lung: 0.7 Cell line enhanced U-266/70: 2.6
GRM5 GPRC1E, mGlu5, MGLUR5, PPP1R86 ENSG00000168959 Glutamate metabotropic receptor 5 11 88504576-89065945 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 8 cerebral cortex: 27.2 testis: 3.2 Not detected
GSR ENSG00000104687 Glutathione-disulfide reductase 8 30678061-30727926 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001538, CAB008632 Approved Supported Plasma membrane<br>Cytosol Liver cancer:3.26e-5 (unfavourable), Colorectal cancer:4.08e-5 (favourable), Renal cancer:1.80e-4 (favourable), Cervical cancer:3.37e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 79.3 Expressed in all
GSS ENSG00000100983 Glutathione synthetase 20 34928430-34955817 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA054508, HPA059315 Enhanced Supported Nucleus Renal cancer:7.31e-6 (favourable), Liver cancer:7.21e-5 (unfavourable) Expressed in all Expressed in all epididymis: 105.8 Expressed in all
GUCY1A2 GC-SA2, GUC1A2 ENSG00000152402 Guanylate cyclase 1 soluble subunit alpha 2 11 106674012-107018524 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB009534 Uncertain Renal cancer:3.02e-5 (unfavourable) Mixed Tissue enhanced placenta: 25.6 endometrium: 21.1 Cell line enhanced BJ hTERT+: 9.5;BJ hTERT+ SV40 Large T+ RasG12V: 13.1;HBF TERT88: 6.9
GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 37.0;duodenum: 68.7;rectum: 45.4;small intestine: 73.2 appendix: 4.4 Cell line enhanced AN3-CA: 1.2;CAPAN-2: 1.4;SiHa: 1.6
HBA1 HBA-T3 ENSG00000206172 Hemoglobin subunit alpha 1 16 176680-177522 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB032534, HPA043780 Enhanced Tissue enhanced Group enriched 34 bone marrow: 17119.3;placenta: 3433.6 spleen: 303.5 Group enriched 51 HEL: 3255.0;K-562: 2173.8
HBA2 HBA-T2 ENSG00000188536 Hemoglobin subunit alpha 2 16 172847-173710 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB038417, HPA043780 Enhanced Expressed in all Group enriched 27 bone marrow: 18369.0;placenta: 4302.7 spleen: 427.2 Group enriched 18 HEL: 802.0;K-562: 265.1
HBB beta-globin, CD113t-C, HBD ENSG00000244734 Hemoglobin subunit beta 11 5225464-5229395 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB009526, HPA043234 Enhanced Approved Vesicles Expressed in all Tissue enriched 9 bone marrow: 78046.6 placenta: 9082.6 Cell line enhanced HEL: 5.3;SCLC-21H: 5.9;SH-SY5Y: 6.7;U-266/70: 17.4
HCAR2 GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG ENSG00000182782 Hydroxycarboxylic acid receptor 2 12 122701293-122703343 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Group enriched Tissue enhanced spleen: 36.0 esophagus: 25.5 Cell line enriched 7 HaCaT: 105.3
HCAR3 GPR109B, HCA3, HM74 ENSG00000255398 Hydroxycarboxylic acid receptor 3 12 122714756-122716892 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Mixed Tissue enhanced bone marrow: 16.6;spleen: 21.7 appendix: 12.4 Group enriched 6 HaCaT: 8.1;RT4: 28.3
HCRTR1 OX1R ENSG00000121764 Hypocretin receptor 1 1 31617686-31632518 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014018 Approved Not detected Tissue enhanced adrenal gland: 1.2 cerebral cortex: 0.9 Not detected
HCRTR2 OX2R ENSG00000137252 Hypocretin receptor 2 6 55106460-55282620 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA054516 Supported Not detected Not detected kidney: 0.6 Cell line enriched 7 AF22: 1.0
HDAC1 GON-10, HD1, RPD3L1 ENSG00000116478 Histone deacetylase 1 1 32292086-32333635 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005017, HPA029693, CAB068191 Enhanced Enhanced Nucleoplasm Liver cancer:5.76e-7 (unfavourable), Renal cancer:1.04e-5 (unfavourable) Expressed in all Expressed in all lymph node: 139.0 Expressed in all
HDAC10 DKFZP761B039 ENSG00000100429 Histone deacetylase 10 22 50245183-50251405 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB045977, HPA056514 Supported Approved Nucleoli fibrillar center Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable) Expressed in all Mixed spleen: 9.8 Mixed
HDAC11 ENSG00000163517 Histone deacetylase 11 3 13479724-13506424 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level Renal cancer:7.88e-10 (favourable), Liver cancer:1.20e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 66.7 Cell line enhanced T-47d: 39.9
HDAC2 RPD3, YAF1 ENSG00000196591 Histone deacetylase 2 6 113933028-114011308 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005054, HPA011727 Supported Enhanced Nucleus Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable) Expressed in all Expressed in all testis: 141.1 Expressed in all
HDAC3 HD3, RPD3, RPD3-2 ENSG00000171720 Histone deacetylase 3 5 141620876-141636870 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB005583, HPA052052 Supported Supported Nucleoplasm<br>Golgi apparatus Renal cancer:2.65e-6 (unfavourable), Colorectal cancer:3.39e-4 (favourable), Pancreatic cancer:3.95e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 52.1 Expressed in all
HDAC4 BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288 ENSG00000068024 Histone deacetylase 4 2 239048168-239401654 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB004431, HPA048723 Approved Supported Nucleoplasm<br>Cytosol Pancreatic cancer:1.13e-4 (favourable), Ovarian cancer:6.33e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 19.3 Cell line enhanced MOLT-4: 40.5
HDAC5 FLJ90614, KIAA0600, NY-CO-9 ENSG00000108840 Histone deacetylase 5 17 44076746-44123702 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB019400, HPA030991 Approved Supported Nuclear speckles<br>Golgi apparatus<br>Cytosol Liver cancer:3.12e-5 (unfavourable), Renal cancer:3.30e-5 (favourable), Cervical cancer:6.14e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 60.0 Mixed
HDAC6 FLJ16239, HD6, JM21, KIAA0901, PPP1R90 ENSG00000094631 Histone deacetylase 6 X 48801377-48824982 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003714, CAB004236, HPA026321 Approved Supported Nucleoplasm Urothelial cancer:3.34e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 51.4 Expressed in all
HDAC7 DKFZP586J0917, HDAC7A ENSG00000061273 Histone deacetylase 7 12 47782722-47833132 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004775 Supported Cytosol Urothelial cancer:4.65e-4 (favourable), Melanoma:5.16e-4 (unfavourable), Renal cancer:8.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 43.9 Expressed in all
HDAC8 HDACL1, MRXS6, RPD3, WTS ENSG00000147099 Histone deacetylase 8 X 72329516-72573103 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA048560 Supported Supported Nucleus<br>Plasma membrane Expressed in all Expressed in all epididymis: 27.1 Expressed in all
HDAC9 HD7, HDAC, HDAC7B, KIAA0744, MITR ENSG00000048052 Histone deacetylase 9 7 18086949-19002416 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028926 Uncertain Approved Nucleoplasm Mixed Mixed spleen: 24.6 Cell line enhanced HAP1: 176.1;SH-SY5Y: 71.2
HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.5 Expressed in all
HMMR CD168, RHAMM ENSG00000072571 Hyaluronan mediated motility receptor 5 163460203-163491945 CD markers, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB002433, HPA040025, HPA043926, HPA061524 Enhanced Enhanced Microtubules<br>Centrosome<br>Cytosol Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable) Mixed Tissue enhanced testis: 49.7 lymph node: 21.7 Expressed in all
HPD 4-HPPD, 4HPPD, GLOD3, PPD ENSG00000158104 4-hydroxyphenylpyruvate dioxygenase 12 121839527-121863596 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038321, HPA038322 Enhanced Uncertain Nuclear speckles Tissue enriched Group enriched 86 kidney: 529.9;liver: 1293.2 seminal vesicle: 10.5 Cell line enriched 24 Hep G2: 349.1
HPRT1 HGPRT, HPRT ENSG00000165704 Hypoxanthine phosphoribosyltransferase 1 X 134460153-134520513 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006360, CAB012200 Enhanced Supported Cytosol Head and neck cancer:1.35e-5 (unfavourable) Expressed in all Expressed in all testis: 139.1 Mixed
HRH1 ENSG00000196639 Histamine receptor H1 3 11137093-11263557 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029740 Uncertain Supported Plasma membrane<br>Cytosol Pancreatic cancer:1.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 12.4 Mixed
HRH2 ENSG00000113749 Histamine receptor H2 5 175658030-175710756 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013770 Approved Tissue enhanced Tissue enhanced bone marrow: 23.5 appendix: 16.7 Cell line enhanced RPMI-8226: 45.4;SK-MEL-30: 15.0;THP-1: 12.1;U-937: 16.9
HRH3 GPCR97 ENSG00000101180 Histamine receptor H3 20 62214970-62220267 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enriched 17 cerebral cortex: 11.1 adrenal gland: 0.6 Cell line enriched 7 SCLC-21H: 18.6
HSD3B1 HSD3B, HSDB3, SDR11E1 ENSG00000203857 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 1 119507198-119515054 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Urothelial cancer:4.59e-5 (favourable) Tissue enhanced Tissue enriched 13 placenta: 110.5 small intestine: 8.7 Cell line enriched 7 CACO-2: 52.9
HSD3B2 SDR11E2 ENSG00000203859 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 1 119414931-119423035 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Tissue enhanced Tissue enriched 433 adrenal gland: 2384.5 testis: 5.5 Cell line enhanced SK-MEL-30: 1.2
HTR1A 5-HT1A, ADRB2RL1, ADRBRL1 ENSG00000178394 5-hydroxytryptamine receptor 1A 5 63960356-63962507 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018073 Uncertain Not detected Group enriched 10 cerebral cortex: 1.9;ovary: 3.9 testis: 0.2 Group enriched 16 NTERA-2: 1.6;SCLC-21H: 1.5
HTR1B 5-HT1B, 5-HT1DB, HTR1D2, S12 ENSG00000135312 5-hydroxytryptamine receptor 1B 6 77461753-77463773 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA028808 Enhanced Uncertain Plasma membrane Mixed Tissue enhanced placenta: 10.0;stomach: 4.7 cerebral cortex: 2.4 Group enriched 16 HUVEC TERT2: 68.8;TIME: 29.9
HTR1D 5-HT1D, HT1DA, HTRL, RDC4 ENSG00000179546 5-hydroxytryptamine receptor 1D 1 23191895-23194729 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Liver cancer:1.86e-4 (unfavourable), Pancreatic cancer:5.30e-4 (unfavourable) Mixed Group enriched 8 duodenum: 9.4;gallbladder: 2.5;small intestine: 9.1 fallopian tube: 0.9 Cell line enhanced A549: 9.5;SiHa: 7.5;TIME: 21.6;U-2 OS: 9.0
HTR1E 5-HT1E ENSG00000168830 5-hydroxytryptamine receptor 1E 6 86937306-87016683 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA004931 Approved Not detected Tissue enhanced endometrium: 2.4;ovary: 4.9 cerebral cortex: 1.8 Group enriched 19 PC-3: 1.4;SH-SY5Y: 6.2
HTR1F 5-HT1F, HTR1EL ENSG00000179097 5-hydroxytryptamine receptor 1F 3 87990696-87993835 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA005555 Uncertain Not detected Tissue enhanced placenta: 2.7 cerebral cortex: 1.0 Cell line enhanced K-562: 1.1;LHCN-M2: 1.0
HTR2A 5-HT2A, HTR2 ENSG00000102468 5-hydroxytryptamine receptor 2A 13 46831550-46897076 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014011 Enhanced Not detected Tissue enriched 8 cerebral cortex: 32.2 smooth muscle: 3.9 Cell line enhanced ASC diff: 1.3;ASC TERT1: 3.2;BEWO: 1.4;HEL: 1.3;U-138 MG: 2.3;U-2 OS: 1.6
HTR2B 5-HT(2B), 5-HT2B ENSG00000135914 5-hydroxytryptamine receptor 2B 2 231108230-231125118 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA012867, HPA063658 Enhanced Approved Nucleoplasm Mixed Tissue enhanced cervix, uterine: 31.2;endometrium: 30.1;smooth muscle: 23.2 adrenal gland: 19.1 Cell line enhanced HHSteC: 7.0;HSkMC: 11.5;SK-MEL-30: 23.9
HTR2C 5-HT2C, 5HTR2C, HTR1C ENSG00000147246 5-hydroxytryptamine receptor 2C X 114584078-114910061 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Tissue enriched 6 cerebral cortex: 3.1 cervix, uterine: 0.5 Cell line enhanced EFO-21: 2.5;U-266/70: 3.6;U-266/84: 2.8
HTR3A 5-HT3A, 5-HT3R, HTR3 ENSG00000166736 5-hydroxytryptamine receptor 3A 11 113974881-113990313 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA069442 Supported Endometrial cancer:1.26e-4 (unfavourable), Cervical cancer:6.26e-4 (favourable) Tissue enriched Group enriched 5 appendix: 2.8;lymph node: 7.8;tonsil: 7.2 small intestine: 1.1 Cell line enhanced CAPAN-2: 5.3;Daudi: 4.2;NTERA-2: 3.6;SCLC-21H: 22.1
HTR3B 5-HT3B ENSG00000149305 5-hydroxytryptamine receptor 3B 11 113904677-113946565 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039559 Approved Not detected Tissue enhanced cerebral cortex: 2.7 testis: 1.1 Not detected
HTR3C ENSG00000178084 5-hydroxytryptamine receptor 3C 3 184053047-184060671 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced lung: 1.9 duodenum: 0.4 Not detected
HTR3D ENSG00000186090 5-hydroxytryptamine receptor 3D 3 184031544-184039369 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Not detected Not detected all non-specific tissues: 0.0 Not detected
HTR3E ENSG00000186038 5-hydroxytryptamine receptor 3E 3 184097064-184106995 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049764 Enhanced Not detected Tissue enhanced duodenum: 1.0 small intestine: 0.8 Cell line enriched 6 RH-30: 1.3
HTR4 5-HT4 ENSG00000164270 5-hydroxytryptamine receptor 4 5 148451032-148677235 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040591 Approved Not detected Tissue enhanced duodenum: 4.8;small intestine: 10.0 rectum: 3.1 Not detected
HTR6 5-HT6, 5-HT6R ENSG00000158748 5-hydroxytryptamine receptor 6 1 19665287-19679562 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enhanced Not detected cerebral cortex: 0.8 Cell line enhanced SH-SY5Y: 2.1
HTR7 5-HT7 ENSG00000148680 5-hydroxytryptamine receptor 7 10 90740823-90857698 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022708, HPA073617 Approved Supported Nuclear speckles<br>Plasma membrane<br>Cytosol Group enriched Group enriched 8 parathyroid gland: 44.8;testis: 16.1 urinary bladder: 3.8 Cell line enhanced hTERT-HME1: 25.8;LHCN-M2: 11.4;WM-115: 12.9
ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Enhanced Uncertain Plasma membrane<br>Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 255.9 Cell line enhanced Karpas-707: 302.5
IDE ENSG00000119912 Insulin degrading enzyme 10 92451684-92574076 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA063478 Approved Endometrial cancer:3.53e-4 (favourable), Colorectal cancer:3.69e-4 (favourable) Expressed in all Expressed in all skin: 63.4 Expressed in all
IFNAR1 IFNAR, IFRC ENSG00000142166 Interferon alpha and beta receptor subunit 1 21 33324477-33359862 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018015, HPA029226 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 61.3 Expressed in all
IFNAR2 IFNABR ENSG00000159110 Interferon alpha and beta receptor subunit 2 21 33229901-33265675 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Renal cancer:7.54e-7 (unfavourable) Expressed in all Expressed in all spleen: 58.7 Expressed in all
IFNG ENSG00000111537 Interferon gamma 12 68154768-68159747 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB010344 Approved Mixed Tissue enhanced appendix: 4.7;bone marrow: 7.6;lymph node: 7.9 lung: 2.5 Not detected
IFNGR1 CD119, IFNGR ENSG00000027697 Interferon gamma receptor 1 6 137197484-137219449 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025889, HPA063871 Approved Renal cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all spleen: 221.9 Expressed in all
IFNGR2 AF-1, IFNGT1 ENSG00000159128 Interferon gamma receptor 2 21 33402896-33479348 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA001535 Enhanced Approved Nucleoplasm<br>Golgi apparatus Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable) Expressed in all Mixed spleen: 10.0 Mixed
IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216 ENSG00000140443 Insulin like growth factor 1 receptor 15 98648971-98964530 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010268, HPA045563 Uncertain Uncertain Vesicles Renal cancer:3.75e-7 (favourable) Expressed in all Mixed prostate: 25.0 Mixed
IKBKB IKK-beta, IKK2, IKKB, NFKBIKB ENSG00000104365 Inhibitor of nuclear factor kappa B kinase subunit beta 8 42271302-42332653 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA001249, CAB004447 Enhanced Approved Cytosol Urothelial cancer:1.46e-6 (favourable) Expressed in all Mixed parathyroid gland: 18.7 Expressed in all
IL11RA ENSG00000137070 Interleukin 11 receptor subunit alpha 9 34650702-34661892 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013162, CAB032830, HPA036652 Supported Renal cancer:6.56e-4 (unfavourable) Expressed in all Expressed in all skin: 72.6 Mixed
IL12B CLMF, CLMF2, IL-12B, NKSF, NKSF2 ENSG00000113302 Interleukin 12B 5 159314783-159330887 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA040970 Approved Tissue enriched Not detected spleen: 0.6 Cell line enhanced SCLC-21H: 1.0
IL17A CTLA8, IL-17, IL-17A, IL17 ENSG00000112115 Interleukin 17A 6 52186387-52190638 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA052258 Uncertain Not detected Tissue enhanced appendix: 1.0;tonsil: 1.3;urinary bladder: 1.5 gallbladder: 0.3 Group enriched 16 Karpas-707: 1.9;U-266/84: 1.2
IL1B IL-1B, IL1-BETA, IL1F2 ENSG00000125538 Interleukin 1 beta 2 112829751-112836903 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Renal cancer:7.49e-5 (unfavourable), Cervical cancer:1.31e-4 (unfavourable) Mixed Tissue enhanced appendix: 68.0;bone marrow: 106.4 adipose tissue: 53.4 Cell line enhanced BJ hTERT+: 478.0;HBEC3-KT: 193.4;HMC-1: 189.1;hTEC/SVTERT24-B: 291.2;U-87 MG: 514.6
IL1R1 CD121A, D2S1473, IL1R, IL1RA ENSG00000115594 Interleukin 1 receptor type 1 2 102064544-102179874 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005823, CAB007779, HPA029560 Approved Renal cancer:6.92e-6 (unfavourable) Expressed in all Expressed in all cervix, uterine: 246.0 Cell line enhanced ASC diff: 431.3;ASC TERT1: 195.1;HHSteC: 165.4;HSkMC: 562.6
IL23A IL-23, IL-23A, IL23P19, P19, SGRF ENSG00000110944 Interleukin 23 subunit alpha 12 56334174-56340410 FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA001554 Approved Approved Cytosol Expressed in all Tissue enhanced tonsil: 8.0 urinary bladder: 6.5 Cell line enhanced A-431: 13.0;CAPAN-2: 22.3;U-266/70: 31.8;U-266/84: 14.0
IL2RA CD25, IDDM10, IL2R ENSG00000134460 Interleukin 2 receptor subunit alpha 10 6010689-6062325 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002419, HPA054622 Enhanced Renal cancer:2.08e-9 (unfavourable) Mixed Tissue enhanced adipose tissue: 24.2;appendix: 19.8;lymph node: 20.4 tonsil: 12.0 Cell line enriched 80 HDLM-2: 1041.6
IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor subunit beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062657 Enhanced Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable) Expressed in all Tissue enhanced placenta: 52.7;spleen: 67.1 lymph node: 39.8 Cell line enriched 10 HDLM-2: 476.9
IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor subunit gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046641, HPA049691 Enhanced Approved Vesicles Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable) Expressed in all Tissue enhanced lymph node: 273.3;tonsil: 279.4 appendix: 182.3 Cell line enriched 5 Karpas-707: 1646.4
IL3RA CD123 ENSG00000185291 Interleukin 3 receptor subunit alpha X 1336616-1382689 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003539, CAB018374 Approved Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable) Expressed in all Mixed lung: 33.2 Cell line enhanced HDLM-2: 109.2;RPMI-8226: 33.2
IL5 EDF, IL-5, TRF ENSG00000113525 Interleukin 5 5 132541444-132556838 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB010304 Approved Not detected Tissue enriched 9 testis: 9.6 small intestine: 1.0 Cell line enhanced Hep G2: 1.9;TIME: 1.0
IL6 BSF2, HGF, HSF, IFNB2, IL-6 ENSG00000136244 Interleukin 6 7 22725884-22732002 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB023406, CAB072821 Supported Approved Vesicles Renal cancer:1.10e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 136.4 urinary bladder: 73.6 Group enriched 7 BJ hTERT+: 1844.6;hTEC/SVTERT24-B: 429.5
IL6R CD126 ENSG00000160712 Interleukin 6 receptor 1 154405193-154469450 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.65e-4 (favourable) Expressed in all Mixed appendix: 33.4 Cell line enhanced THP-1: 147.4;U-266/84: 186.8
IMPDH1 LCA11, RP10, sWSS2608 ENSG00000106348 Inosine monophosphate dehydrogenase 1 7 128392277-128410252 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001400 Approved Supported Cytosol<br>Rods & Rings Renal cancer:1.78e-12 (unfavourable), Liver cancer:1.12e-7 (unfavourable), Urothelial cancer:3.72e-5 (unfavourable), Glioma:1.17e-4 (unfavourable), Cervical cancer:3.87e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 47.2 Expressed in all
IMPDH2 ENSG00000178035 Inosine monophosphate dehydrogenase 2 3 49024325-49029408 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001400, CAB020717 Approved Enhanced Cytosol<br>Rods & Rings Liver cancer:3.22e-4 (unfavourable) Expressed in all Expressed in all ovary: 422.5 Expressed in all
INSR CD220 ENSG00000171105 Insulin receptor 19 7112255-7294034 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA036302, HPA036303 Uncertain Approved Vesicles Expressed in all Expressed in all ovary: 35.5 Cell line enhanced Karpas-707: 42.9
ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin subunit alpha 2b 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Enhanced Mixed Tissue enhanced bone marrow: 11.2;epididymis: 29.3 testis: 4.4 Group enriched 18 HEL: 396.8;HMC-1: 636.9
ITGA4 CD49D ENSG00000115232 Integrin subunit alpha 4 2 181457202-181536187 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074961 Approved Plasma membrane Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Mixed Tissue enhanced spleen: 67.6 appendix: 49.6 Cell line enhanced fHDF/TERT166: 148.2;HEL: 275.3;MOLT-4: 291.8
ITGAL CD11A, LFA-1 ENSG00000005844 Integrin subunit alpha L 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025011 Enhanced Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable) Expressed in all Tissue enhanced lymph node: 79.0;spleen: 80.9 appendix: 52.5 Cell line enriched 5 HMC-1: 570.1
ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin subunit alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002499, HPA004856 Supported Approved Focal adhesion sites<br>Cytosol Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 191.2 Cell line enhanced RT4: 294.1
ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin subunit beta 1 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB003434, HPA059297, HPA069003 Enhanced Supported Endoplasmic reticulum<br>Plasma membrane<br>Focal adhesion sites Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1069.5 Expressed in all
ITGB3 CD61, GP3A, GPIIIa ENSG00000259207 Integrin subunit beta 3 17 47253846-47311816 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027852 Supported Group enriched Tissue enhanced thyroid gland: 95.6 smooth muscle: 36.8 Cell line enhanced EFO-21: 179.0;HEL: 158.0;WM-115: 275.8
ITGB7 ENSG00000139626 Integrin subunit beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane<br>Cytosol Mixed Mixed spleen: 32.5 Group enriched 97 Karpas-707: 3399.5;RPMI-8226: 2658.1
JAK1 JAK1A, JAK1B, JTK3 ENSG00000162434 Janus kinase 1 1 64833229-64966504 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013088 Approved Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable) Expressed in all Expressed in all lymph node: 115.6 Expressed in all
JAK2 JTK10 ENSG00000096968 Janus kinase 2 9 4984390-5128183 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013089, HPA040820, HPA043870 Approved Supported Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites Expressed in all Mixed appendix: 28.1 Group enriched 6 ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAK3 JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK ENSG00000105639 Janus kinase 3 19 17824780-17848071 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA070314 Enhanced Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable) Expressed in all Tissue enhanced appendix: 48.4;lymph node: 46.6 tonsil: 27.2 Cell line enhanced HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
JUN AP-1, c-Jun ENSG00000177606 Jun proto-oncogene, AP-1 transcription factor subunit 1 58780788-58784327 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB003801, CAB007780, HPA059474 Enhanced Enhanced Nucleoplasm Expressed in all Expressed in all thyroid gland: 314.6 Cell line enhanced RH-30: 282.2
KCNA1 AEMK, HUK1, Kv1.1, MBK1, RBK1 ENSG00000111262 Potassium voltage-gated channel subfamily A member 1 12 4909893-4918256 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB022365 Uncertain Not detected Tissue enriched 6 cerebral cortex: 13.4 parathyroid gland: 2.1 Cell line enhanced SCLC-21H: 1.2;U-2 OS: 1.0
KCNA10 Kv1.8 ENSG00000143105 Potassium voltage-gated channel subfamily A member 10 1 110517217-110519175 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA015061, CAB022564 Uncertain Nucleoplasm<br>Cytosol Not detected Not detected testis: 0.8 Not detected
KCNA2 HK4, Kv1.2 ENSG00000177301 Potassium voltage-gated channel subfamily A member 2 1 110519837-110631474 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001976 Enhanced Tissue enhanced Tissue enriched 6 cerebral cortex: 23.2 thyroid gland: 4.1 Cell line enhanced Karpas-707: 4.4;SCLC-21H: 1.8;U-2 OS: 1.4;U-266/70: 1.5;U-266/84: 2.3;WM-115: 1.6
KCNA3 HLK3, HPCN3, Kv1.3, MK3 ENSG00000177272 Potassium voltage-gated channel subfamily A member 3 1 110672465-110675033 FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016625 Approved Mixed Mixed lymph node: 10.5 Cell line enhanced HDLM-2: 20.5;Karpas-707: 31.5;U-266/70: 23.9;U-266/84: 21.1
KCNA4 HK1, HPCN2, KCNA4L, Kv1.4 ENSG00000182255 Potassium voltage-gated channel subfamily A member 4 11 30009741-30017023 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB001977, HPA016422 Approved Not detected Tissue enhanced adrenal gland: 7.9;cerebral cortex: 4.3 heart muscle: 1.4 Not detected
KCNA5 HK2, HPCN1, Kv1.5 ENSG00000130037 Potassium voltage-gated channel subfamily A member 5 12 5043989-5046788 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA021516, CAB022562 Approved Mixed Tissue enhanced heart muscle: 16.1 esophagus: 5.6 Cell line enriched 20 NTERA-2: 4.3
KCNA6 HBK2, Kv1.6, PPP1R96 ENSG00000151079 Potassium voltage-gated channel subfamily A member 6 12 4809176-4813412 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level CAB011539, HPA014418 Approved Not detected Not detected appendix,duodenum,lymph node: 0.1 Not detected
KCNA7 HAK6, Kv1.7 ENSG00000104848 Potassium voltage-gated channel subfamily A member 7 19 49067418-49072941 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level Not detected Tissue enriched 37 skeletal muscle: 26.2 esophagus: 0.7 Not detected
KCNB1 Kv2.1 ENSG00000158445 Potassium voltage-gated channel subfamily B member 1 20 49293394-49484297 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001979, HPA042434 Enhanced Mixed Tissue enhanced adipose tissue: 10.9;cerebral cortex: 21.6 fallopian tube,smooth muscle: 7.4 Cell line enhanced CACO-2: 1.8;U-2 OS: 1.8
KCNB2 Kv2.2 ENSG00000182674 Potassium voltage-gated channel subfamily B member 2 8 72537391-72938349 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA065970 Approved Nucleoli<br>Plasma membrane<br>Midbody Not detected Tissue enhanced cerebral cortex: 3.2;spleen: 3.3 fallopian tube,testis: 0.7 Cell line enhanced HaCaT: 1.3;HDLM-2: 1.4;HEK 293: 3.2;SCLC-21H: 3.4
KCNC1 Kv3.1 ENSG00000129159 Potassium voltage-gated channel subfamily C member 1 11 17734774-17856804 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA047634, HPA048249 Enhanced Approved Nucleus<br>Nuclear membrane<br>Vesicles<br>Cytosol Tissue enhanced Tissue enriched 8 cerebral cortex: 18.6 testis: 2.2 Cell line enhanced RH-30: 3.6;SCLC-21H: 4.2;SH-SY5Y: 2.3
KCNC2 Kv3.2 ENSG00000166006 Potassium voltage-gated channel subfamily C member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane<br>Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.4 prostate: 4.3 Not detected
KCNC3 Kv3.3, SCA13 ENSG00000131398 Potassium voltage-gated channel subfamily C member 3 19 50311937-50333515 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018041 Approved Renal cancer:1.23e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 39.9 cerebral cortex: 19.8 Cell line enhanced HMC-1: 26.4;SK-BR-3: 15.3;T-47d: 18.4;U-2 OS: 13.8
KCND1 Kv4.1 ENSG00000102057 Potassium voltage-gated channel subfamily D member 1 X 48961378-48971569 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA000524, HPA001066 Approved Approved Nucleus Pancreatic cancer:2.66e-6 (favourable) Mixed Mixed gallbladder: 3.9 Mixed
KCND2 KIAA1044, Kv4.2, RK5 ENSG00000184408 Potassium voltage-gated channel subfamily D member 2 7 120273668-120750331 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029068 Approved Tissue enhanced Tissue enhanced cerebral cortex: 20.7 gallbladder: 6.8 Cell line enhanced ASC TERT1: 3.5;SCLC-21H: 15.6
KCND3 KSHIVB, Kv4.3, SCA19, SCA22 ENSG00000171385 Potassium voltage-gated channel subfamily D member 3 1 111770662-111989155 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029452 Approved Mixed Mixed cerebral cortex: 26.7 Cell line enhanced SCLC-21H: 14.0;WM-115: 2.8
KCNE1 ISK, JLNS2, LQT5, minK ENSG00000180509 Potassium voltage-gated channel subfamily E regulatory subunit 1 21 34446688-34512275 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced fallopian tube: 16.6 heart muscle: 3.6 Cell line enhanced BJ hTERT+ SV40 Large T+: 1.2;CACO-2: 3.3
KCNH2 erg1, HERG, Kv11.1, LQT2 ENSG00000055118 Potassium voltage-gated channel subfamily H member 2 7 150944961-150978315 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable) Mixed Tissue enhanced bone marrow: 24.1;testis: 27.3 parathyroid gland: 13.2 Group enriched 6 K-562: 170.9;NB-4: 59.5;SH-SY5Y: 79.9
KCNJ1 Kir1.1, ROMK1 ENSG00000151704 Potassium voltage-gated channel subfamily J member 1 11 128836315-128867373 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026962 Enhanced Tissue enriched Tissue enriched 117 kidney: 210.8 epididymis: 1.7 Cell line enriched 42 RPTEC TERT1: 87.0
KCNJ11 BIR, Kir6.2 ENSG00000187486 Potassium voltage-gated channel subfamily J member 11 11 17385859-17389331 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA048891 Approved Renal cancer:1.56e-4 (favourable) Mixed Tissue enhanced skeletal muscle: 32.7 cerebral cortex: 10.2 Cell line enhanced HEK 293: 12.0;MCF7: 8.2;SCLC-21H: 10.3
KCNJ12 hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v ENSG00000184185 Potassium voltage-gated channel subfamily J member 12 17 21376197-21419872 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA027021 Approved Uncertain Nucleoplasm<br>Golgi apparatus<br>Cytosol Endometrial cancer:7.84e-5 (unfavourable) Mixed Group enriched 5 parathyroid gland: 19.2;skeletal muscle: 23.1 heart muscle: 3.9 Cell line enhanced HeLa: 2.6;PC-3: 3.9;SCLC-21H: 5.6;SiHa: 2.6;U-2197: 3.9
KCNJ8 Kir6.1 ENSG00000121361 Potassium voltage-gated channel subfamily J member 8 12 21764955-21775581 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031066 Uncertain Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 32.0 Cell line enhanced CACO-2: 71.9;SH-SY5Y: 31.1
KCNK2 K2p2.1, TREK-1 ENSG00000082482 Potassium two pore domain channel subfamily K member 2 1 215005775-215237093 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Mixed Tissue enhanced adrenal gland: 75.2 thyroid gland: 17.0 Cell line enhanced ASC TERT1: 58.1;fHDF/TERT166: 59.9;T-47d: 108.4;U-2197: 38.1
KCNK3 K2p3.1, TASK, TASK-1 ENSG00000171303 Potassium two pore domain channel subfamily K member 3 2 26692690-26733420 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Renal cancer:2.37e-7 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 111.8;placenta: 35.8 lung: 19.9 Group enriched 6 EFO-21: 10.3;SCLC-21H: 30.6
KCNK9 K2p9.1, TASK-3, TASK3 ENSG00000169427 Potassium two pore domain channel subfamily K member 9 8 139600838-139703056 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Group enriched 7 adrenal gland: 4.7;cerebral cortex: 4.8 cervix, uterine: 0.7 Cell line enhanced PC-3: 2.0;SCLC-21H: 1.1
KCNMA1 KCa1.1, mSLO1, SLO ENSG00000156113 Potassium calcium-activated channel subfamily M alpha 1 10 76869601-77638369 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA054648 Approved Mixed Tissue enhanced smooth muscle: 137.0 endometrium: 109.5 Cell line enhanced PC-3: 148.0;U-138 MG: 111.0;U-87 MG: 107.5
KCNN4 hIKCa1, hKCa4, hSK4, IK, KCa3.1 ENSG00000104783 Potassium calcium-activated channel subfamily N member 4 19 43766533-43781257 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053841, HPA059622 Approved Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable) Expressed in all Tissue enhanced salivary gland: 73.7 stomach: 36.6 Cell line enhanced CAPAN-2: 93.3;WM-115: 264.9
KCNQ1 JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1 ENSG00000053918 Potassium voltage-gated channel subfamily Q member 1 11 2444684-2849109 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB018656, HPA048553 Enhanced Stomach cancer:9.85e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 133.6;thyroid gland: 102.7 seminal vesicle: 60.6 Cell line enhanced HMC-1: 25.7;RPMI-8226: 14.2;U-266/70: 8.9;U-937: 8.8
KCNQ2 BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2 ENSG00000075043 Potassium voltage-gated channel subfamily Q member 2 20 63400210-63472677 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016642, HPA057112 Enhanced Approved Endoplasmic reticulum Tissue enriched Tissue enriched 7 cerebral cortex: 57.2 testis: 8.2 Cell line enhanced AN3-CA: 32.4;SCLC-21H: 79.6;SH-SY5Y: 126.1
KCNQ3 EBN2, Kv7.3 ENSG00000184156 Potassium voltage-gated channel subfamily Q member 3 8 132120858-132481019 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Tissue enriched 14 cerebral cortex: 26.7 adrenal gland: 1.9 Cell line enhanced hTERT-HME1: 5.1;U-2 OS: 4.5;U-87 MG: 3.5
KDR CD309, FLK1, VEGFR, VEGFR2 ENSG00000128052 Kinase insert domain receptor 4 55078477-55125589 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB004028 Enhanced Supported Plasma membrane Renal cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 119.2 thyroid gland: 54.7 Group enriched 9 HUVEC TERT2: 178.6;TIME: 148.0
KEAP1 INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454 ENSG00000079999 Kelch like ECH associated protein 1 19 10486120-10503741 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA005558, CAB025337 Approved Supported Nucleoplasm<br>Microtubule organizing center<br>Cytosol Cervical cancer:3.28e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 49.4 Expressed in all
KIT C-Kit, CD117, PBT, SCFR ENSG00000157404 KIT proto-oncogene receptor tyrosine kinase 4 54657918-54740715 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB003288, HPA004471, CAB068253, CAB072867, HPA073252 Enhanced Supported Supported Plasma membrane Renal cancer:5.63e-4 (favourable) Mixed Tissue enhanced breast: 133.6 thyroid gland: 78.7 Group enriched 14 HEL: 220.1;HMC-1: 434.1
KLKB1 KLK3 ENSG00000164344 Kallikrein B1 4 186208979-186258471 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enriched 45 liver: 155.0 gallbladder,kidney: 3.4 Cell line enhanced NTERA-2: 2.9;SCLC-21H: 2.3
LCK ENSG00000182866 LCK proto-oncogene, Src family tyrosine kinase 1 32251239-32286165 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA003494, CAB003816 Enhanced Approved Golgi apparatus Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable) Mixed Tissue enhanced lymph node: 125.9;tonsil: 72.4 appendix: 66.3 Group enriched 7 MOLT-4: 429.5;U-698: 207.6
LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Approved Vesicles Tissue enriched Mixed liver: 67.9 Cell line enhanced K-562: 102.4;RPTEC TERT1: 39.6
LHCGR HHG, LCGR, LGR2, LHR, ULG5 ENSG00000138039 Luteinizing hormone/choriogonadotropin receptor 2 48686775-48755730 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009814 Uncertain Not detected Tissue enhanced ovary: 1.6;testis: 4.3 adipose tissue: 1.3 Not detected
LIPF HGL, HLAL ENSG00000182333 Lipase F, gastric type 10 88664441-88678814 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA045930 Enhanced Tissue enriched Tissue enriched 86 stomach: 22415.5 duodenum: 259.5 Cell line enhanced HMC-1: 3.6;MOLT-4: 2.7;NTERA-2: 3.5;THP-1: 4.5;U-2 OS: 2.4;U-266/70: 2.4
LPL LIPD ENSG00000175445 Lipoprotein lipase 8 19901717-19967258 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA048749 Supported Vesicles Urothelial cancer:6.07e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 976.8 heart muscle: 239.2 Cell line enriched 7 AF22: 363.8
M6PR CD-M6PR, CD-MPR ENSG00000003056 Mannose-6-phosphate receptor, cation dependent 12 8940363-8949955 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB034464, HPA040445 Approved Liver cancer:3.89e-4 (unfavourable) Expressed in all Expressed in all spleen: 175.3 Expressed in all
MAOA ENSG00000189221 Monoamine oxidase A X 43654907-43746824 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009437, HPA054807, HPA059299 Enhanced Enhanced Mitochondria Expressed in all Mixed small intestine: 248.3 Cell line enhanced ASC diff: 108.7;HHSteC: 249.1;hTCEpi: 61.9;RT4: 102.5
MAOB ENSG00000069535 Monoamine oxidase B X 43766611-43882447 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA002328, CAB037200 Enhanced Approved Nucleoli<br>Mitochondria Expressed in all Mixed seminal vesicle: 215.4 Group enriched 9 Hep G2: 28.1;SiHa: 82.8
MAP1A MAP1L ENSG00000166963 Microtubule associated protein 1A 15 43510958-43531620 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039063, HPA039064, HPA066488 Enhanced Approved Cytosol Thyroid cancer:1.09e-5 (unfavourable), Urothelial cancer:1.66e-5 (unfavourable), Renal cancer:6.59e-5 (unfavourable) Tissue enhanced Tissue enriched 9 cerebral cortex: 165.6 smooth muscle: 18.9 Cell line enhanced fHDF/TERT166: 72.9;U-87 MG: 119.0
MAP2 MAP2A, MAP2B, MAP2C ENSG00000078018 Microtubule associated protein 2 2 209424058-209734118 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001984, HPA008273, HPA012828 Enhanced Supported Supported Nucleoli<br>Cytosol Endometrial cancer:1.98e-6 (unfavourable) Tissue enhanced Tissue enriched 11 cerebral cortex: 296.5 thyroid gland: 27.9 Cell line enhanced AF22: 293.3;NTERA-2: 106.5;SCLC-21H: 174.9;SH-SY5Y: 88.2
MAP2K1 MAPKK1, MEK1, PRKMK1 ENSG00000169032 Mitogen-activated protein kinase kinase 1 15 66386817-66492312 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003834, HPA026430 Approved Enhanced Plasma membrane<br>Cytosol Glioma:2.68e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.4 Expressed in all
MAP2K2 MEK2, PRKMK2 ENSG00000126934 Mitogen-activated protein kinase kinase 2 19 4090321-4124129 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB003835, HPA051993 Supported Supported Cytosol Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable) Expressed in all Expressed in all duodenum: 135.0 Expressed in all
MAP4 ENSG00000047849 Microtubule associated protein 4 3 47850690-48089272 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038149, HPA038150 Enhanced Supported Plasma membrane<br>Microtubules<br>Cytosol Liver cancer:1.82e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 241.9 Expressed in all
MAPK1 ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2 ENSG00000100030 Mitogen-activated protein kinase 1 22 21754500-21867680 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA003995, CAB004229, HPA005700, HPA030069 Approved Liver cancer:4.95e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 132.4 Expressed in all
MAPK11 p38-2, p38Beta, PRKM11, SAPK2 ENSG00000185386 Mitogen-activated protein kinase 11 22 50263713-50270767 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB012961, HPA045069 Approved Approved Mitochondria Renal cancer:6.02e-6 (unfavourable) Expressed in all Mixed cerebral cortex: 27.7 Mixed
MAPK3 ERK1, p44erk1, p44mapk, PRKM3 ENSG00000102882 Mitogen-activated protein kinase 3 16 30114105-30123506 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB002683, HPA003995, HPA005700, HPA030069 Approved Approved Nucleoplasm Liver cancer:1.11e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 133.7 Expressed in all
MAPT DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau ENSG00000186868 Microtubule associated protein tau 17 45894382-46028334 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000151, HPA048895, HPA069524, HPA069570, CAB072344 Enhanced Supported Nuclear speckles<br>Plasma membrane Group enriched Tissue enriched 8 cerebral cortex: 116.2 skeletal muscle: 13.7 Cell line enhanced HDLM-2: 37.4;SCLC-21H: 16.3;T-47d: 16.5
MC2R ACTHR ENSG00000185231 Melanocortin 2 receptor 18 13882044-13915707 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enriched 23 adrenal gland: 50.6 epididymis: 2.1 Not detected
MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane<br>Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Expressed in all placenta: 39.0 Mixed
METAP2 MAP2, MNPEP, p67 ENSG00000111142 Methionyl aminopeptidase 2 12 95473520-95515839 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB013025, HPA019095 Enhanced Supported Plasma membrane<br>Cytosol Liver cancer:4.51e-6 (unfavourable) Expressed in all Expressed in all seminal vesicle: 142.4 Expressed in all
MGAM MGA ENSG00000257335 Maltase-glucoamylase 7 141907813-142106747 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002270 Enhanced Renal cancer:6.16e-5 (favourable) Tissue enriched Tissue enhanced duodenum: 59.4;small intestine: 97.2 epididymis: 31.1 Cell line enhanced A549: 1.6;BJ hTERT+: 1.3;HL-60: 2.2;U-937: 3.4
MME CALLA, CD10, NEP ENSG00000196549 Membrane metalloendopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Enhanced Mixed Tissue enhanced duodenum: 428.2;kidney: 384.2;small intestine: 401.5 prostate: 162.5 Cell line enhanced ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
MMP1 CLG ENSG00000196611 Matrix metallopeptidase 1 11 102789920-102798160 Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA004920 Approved Vesicles Renal cancer:9.86e-10 (unfavourable), Liver cancer:4.22e-6 (unfavourable), Cervical cancer:4.66e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 39.2;gallbladder: 126.4 urinary bladder: 29.1 Cell line enhanced BJ hTERT+: 921.1;HBF TERT88: 1061.5;HUVEC TERT2: 2464.5;WM-115: 1436.5
MMP10 STMY2 ENSG00000166670 Matrix metallopeptidase 10 11 102770503-102780628 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002159 Uncertain Approved Plasma membrane<br>Cytosol Urothelial cancer:7.12e-4 (favourable) Tissue enhanced Tissue enriched 40 endometrium: 443.1 appendix: 11.1 Cell line enhanced BJ: 10.0;HUVEC TERT2: 12.6;SCLC-21H: 5.6
MMP11 STMY3 ENSG00000099953 Matrix metallopeptidase 11 22 23768226-23784316 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB002593, HPA068864 Approved Renal cancer:2.62e-4 (unfavourable) Expressed in all Group enriched 9 cervix, uterine: 31.6;endometrium: 123.1;placenta: 28.0 smooth muscle: 6.9 Cell line enhanced AN3-CA: 17.4;REH: 7.4
MMP12 HME ENSG00000262406 Matrix metallopeptidase 12 11 102862736-102875034 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Liver cancer:1.42e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 54.6;urinary bladder: 28.7 tonsil: 17.3 Group enriched 11 BJ: 2.7;fHDF/TERT166: 8.5;hTEC/SVTERT24-B: 6.1
MMP13 CLG3 ENSG00000137745 Matrix metallopeptidase 13 11 102942995-102955734 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Tissue enhanced Tissue enhanced lung: 1.5;urinary bladder: 1.3 appendix: 0.3 Cell line enhanced HaCaT: 15.8;PC-3: 6.2
MMP14 MT1-MMP ENSG00000157227 Matrix metallopeptidase 14 14 22836557-22849027 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009918, HPA051432 Approved Approved Intermediate filaments<br>Cytosol Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable) Expressed in all Mixed endometrium: 236.6 Cell line enhanced HHSteC: 664.7
MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm<br>Plasma membrane<br>Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 70.1 placenta: 39.3 Cell line enhanced BEWO: 86.0;WM-115: 73.7
MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles<br>Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 Cell line enhanced AN3-CA: 27.2;SH-SY5Y: 17.2;WM-115: 28.4
MMP17 MT4-MMP ENSG00000198598 Matrix metallopeptidase 17 12 131828393-131851783 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced cerebral cortex: 24.0 skin: 8.2 Group enriched 5 REH: 53.0;SK-MEL-30: 109.1;WM-115: 201.0
MMP19 MMP18, RASI-1 ENSG00000123342 Matrix metallopeptidase 19 12 55835433-55842966 Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA070804 Approved Endoplasmic reticulum<br>Vesicles Renal cancer:8.56e-9 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 64.2;gallbladder: 97.3 placenta: 28.2 Cell line enriched 7 BEWO: 141.1
MMP2 CLG4, CLG4A, TBE-1 ENSG00000087245 Matrix metallopeptidase 2 16 55389700-55506691 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001939, CAB002788 Approved Uncertain Vesicles<br>Cytosol Expressed in all Tissue enhanced gallbladder: 1682.1 urinary bladder: 910.7 Cell line enhanced ASC diff: 3859.6;U-138 MG: 1525.4;U-87 MG: 1772.5
MMP20 ENSG00000137674 Matrix metallopeptidase 20 11 102576835-102625332 Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 6 testis: 1.1 appendix,breast,kidney,tonsil: 0.1 Not detected
MMP21 ENSG00000154485 Matrix metallopeptidase 21 10 125766453-125775821 Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level Not detected Tissue enriched 27 epididymis: 59.2 ovary: 2.1 Not detected
MMP23B MIFR, MIFR-1, MMP22 ENSG00000189409 Matrix metallopeptidase 23B 1 1632095-1635263 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level Tissue enhanced Mixed gallbladder,placenta: 4.1 Cell line enhanced HHSteC: 3.5;NTERA-2: 1.8;U-266/70: 2.5
MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli<br>Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.0 Cell line enhanced A549: 32.8;CACO-2: 46.1;RPTEC TERT1: 18.5;U-2 OS: 18.9
MMP25 MMP20, MMPL1, MT6-MMP ENSG00000008516 Matrix metallopeptidase 25 16 3046681-3060726 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025177 Uncertain Head and neck cancer:1.09e-5 (favourable) Tissue enhanced Tissue enhanced appendix: 23.3;bone marrow: 24.7;spleen: 20.7 adipose tissue: 6.4 Cell line enriched 11 HMC-1: 95.7
MMP26 endometase, MGC126590, MGC126592 ENSG00000167346 Matrix metallopeptidase 26 11 4704927-4992429 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at transcript level Group enriched Tissue enriched 63 endometrium: 23.9 prostate,testis: 0.3 Not detected
MMP27 ENSG00000137675 Matrix metallopeptidase 27 11 102691487-102705806 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA069097 Approved Not detected Group enriched 5 breast: 6.0;skin: 2.8 bone marrow: 0.8 Not detected
MMP28 EPILYSIN, MM28, MMP-25, MMP-28 ENSG00000271447 Matrix metallopeptidase 28 17 35756249-35795707 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:6.28e-6 (unfavourable) Mixed Tissue enhanced testis: 6.5 adipose tissue: 4.2 Cell line enriched 9 HaCaT: 32.1
MMP3 STMY, STMY1 ENSG00000149968 Matrix metallopeptidase 3 11 102835801-102843803 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007875 Uncertain Supported Vesicles Pancreatic cancer:4.09e-4 (unfavourable), Cervical cancer:9.73e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 26.5;endometrium: 58.6 urinary bladder: 9.0 Group enriched 15 BJ: 1172.2;BJ hTERT+: 3041.4;fHDF/TERT166: 1276.8
MMP7 MPSL1, PUMP-1 ENSG00000137673 Matrix metallopeptidase 7 11 102520508-102530753 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025869, HPA051358 Supported Approved Nucleoplasm<br>Vesicles Liver cancer:2.53e-4 (unfavourable), Lung cancer:3.38e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 820.8 breast: 201.7 Cell line enhanced A549: 133.0;CAPAN-2: 715.3;EFO-21: 178.3;RPTEC TERT1: 262.4
MMP8 CLG1 ENSG00000118113 Matrix metallopeptidase 8 11 102711795-102727050 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA021221, HPA022935 Enhanced Tissue enriched Tissue enriched 103 bone marrow: 335.8 endometrium: 3.2 Cell line enriched 10 WM-115: 69.6
MMP9 CLG4B ENSG00000100985 Matrix metallopeptidase 9 20 46008908-46016561 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201 Enhanced Approved Cytosol Renal cancer:4.05e-5 (unfavourable), Endometrial cancer:2.55e-4 (favourable), Liver cancer:7.19e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 252.6;lymph node: 117.7 appendix: 82.8 Cell line enriched 8 NB-4: 227.3
MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337849-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Mixed ovary: 1.3 Cell line enriched 97 HEL: 51.8
MR1 HLALS ENSG00000153029 Major histocompatibility complex, class I-related 1 181033425-181061938 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048304 Supported Plasma membrane Expressed in all Mixed thyroid gland: 28.2 Mixed
MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane spanning 4-domains A1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000015, HPA014341, HPA014391 Enhanced Supported Plasma membrane Breast cancer:4.34e-5 (favourable) Mixed Group enriched 15 appendix: 240.0;lymph node: 770.3;spleen: 468.8;tonsil: 789.8 urinary bladder: 38.3 Group enriched 19 Daudi: 534.8;U-698: 258.0
MS4A2 APY, FCER1B, IGER, MS4A1 ENSG00000149534 Membrane spanning 4-domains A2 11 60088261-60098466 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA059967 Enhanced Mixed Tissue enhanced lung: 24.8 gallbladder: 18.4 Cell line enhanced HEL: 2.4;THP-1: 1.0
MTNR1A MEL-1A-R ENSG00000168412 Melatonin receptor 1A 4 186533655-186555567 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level Not detected Tissue enhanced kidney: 2.2;testis: 1.9 colon: 1.2 Not detected
MTNR1B ENSG00000134640 Melatonin receptor 1B 11 92969720-92985066 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced placenta: 1.4 testis: 0.8 Not detected
MTOR FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1 ENSG00000198793 Mechanistic target of rapamycin 1 11106535-11262507 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB069425, HPA071227 Approved Approved Vesicles<br>Cytosol Renal cancer:1.49e-5 (favourable) Expressed in all Expressed in all testis: 62.2 Expressed in all
MTR cblG ENSG00000116984 5-methyltetrahydrofolate-homocysteine methyltransferase 1 236795281-236903981 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA044474, HPA054915 Approved Supported Cytosol Thyroid cancer:5.75e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 28.7 Expressed in all
MTTP ABL, MTP ENSG00000138823 Microsomal triglyceride transfer protein 4 99563761-99623999 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051170, HPA054862 Uncertain Approved Cytosol Tissue enriched Group enriched 16 duodenum: 236.3;liver: 133.9;small intestine: 292.6 testis: 13.5 Cell line enhanced AF22: 10.2;Hep G2: 8.0
MUT ENSG00000146085 Methylmalonyl-CoA mutase 6 49430360-49463191 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035971, HPA035972 Enhanced Approved Mitochondria<br>Cytosol Renal cancer:8.71e-13 (favourable) Expressed in all Expressed in all liver: 104.1 Expressed in all
NFKB1 KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50 ENSG00000109320 Nuclear factor kappa B subunit 1 4 102501329-102617302 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors Evidence at protein level CAB004031, HPA027305 Enhanced Supported Nucleoplasm<br>Cytosol Renal cancer:1.76e-4 (favourable) Expressed in all Expressed in all bone marrow: 56.9 Expressed in all
NISCH I-1, IRAS, KIAA0975 ENSG00000010322 Nischarin 3 52455118-52493071 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023189 Approved Pancreatic cancer:1.91e-4 (favourable) Expressed in all Expressed in all testis: 96.0 Expressed in all
NNMT ENSG00000166741 Nicotinamide N-methyltransferase 11 114257787-114313285 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA059180 Approved Approved Nucleoplasm<br>Golgi apparatus<br>Cytosol Renal cancer:1.02e-6 (unfavourable), Stomach cancer:1.75e-4 (unfavourable), Head and neck cancer:2.07e-4 (unfavourable) Expressed in all Tissue enhanced liver: 197.2 adipose tissue: 107.8 Cell line enhanced HSkMC: 300.0;RPTEC TERT1: 491.7
NOS2 HEP-NOS, iNOS, NOS, NOS2A ENSG00000007171 Nitric oxide synthase 2 17 27756766-27800499 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002014 Approved Tissue enhanced Group enriched 5 appendix: 18.9;colon: 7.0;duodenum: 12.3;rectum: 9.8;small intestine: 24.1;urinary bladder: 6.5 smooth muscle: 2.5 Group enriched 8 CACO-2: 13.0;SCLC-21H: 14.7
NOS3 ECNOS, eNOS ENSG00000164867 Nitric oxide synthase 3 7 150990995-151014588 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002168 Enhanced Renal cancer:3.63e-4 (unfavourable) Expressed in all Tissue enriched 7 spleen: 71.8 adipose tissue: 10.6 Cell line enhanced BEWO: 22.3;HUVEC TERT2: 37.6;TIME: 67.7
NOXO1 P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28 ENSG00000196408 NADPH oxidase organizer 1 16 1978917-1984192 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA071540 Enhanced Not detected Tissue enhanced appendix: 6.3;colon: 7.4;rectum: 6.5 duodenum: 3.3 Cell line enhanced CAPAN-2: 2.4;HaCaT: 1.4;SCLC-21H: 1.6
NPC1L1 ENSG00000015520 NPC1 like intracellular cholesterol transporter 1 7 44512535-44541315 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB070127, CAB070128 Enhanced Group enriched Tissue enhanced duodenum: 57.1;small intestine: 57.9 liver: 14.2 Group enriched 7 CACO-2: 5.9;Hep G2: 12.2;SCLC-21H: 17.4
NPR1 ANPa, ANPRA, GUCY2A, NPRA ENSG00000169418 Natriuretic peptide receptor 1 1 153678637-153693992 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA031087 Approved Nucleus<br>Nucleoli<br>Plasma membrane Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 72.0;fallopian tube: 58.2 placenta: 25.4 Cell line enriched 6 ASC diff: 107.2
NPR2 AMDM, ANPb, ANPRB, GUCY2B, NPRB ENSG00000159899 Natriuretic peptide receptor 2 9 35792154-35809732 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Expressed in all Mixed endometrium: 31.1 Cell line enhanced ASC diff: 37.7
NR1H4 FXR, HRR-1, HRR1, RIP14 ENSG00000012504 Nuclear receptor subfamily 1 group H member 4 12 100473708-100564413 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters Evidence at protein level HPA047699 Approved Nucleoplasm Group enriched Tissue enhanced liver: 66.6;small intestine: 44.4 kidney: 29.9 Group enriched 26 Hep G2: 20.2;HHSteC: 14.1;RPTEC TERT1: 34.8
NR1I2 BXR, ONR1, PAR2, PXR, SXR ENSG00000144852 Nuclear receptor subfamily 1 group I member 2 3 119780484-119818485 FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029309, HPA055121, HPA073926 Enhanced Nucleoplasm Group enriched Group enriched 10 colon: 10.3;duodenum: 27.2;gallbladder: 6.4;liver: 20.0;rectum: 10.7;small intestine: 30.0 stomach: 1.7 Group enriched 7 Hep G2: 9.8;RH-30: 3.3
NR3C1 GR, GRL ENSG00000113580 Nuclear receptor subfamily 3 group C member 1 5 143277931-143435512 Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004248, CAB010435 Supported Enhanced Nucleoplasm<br>Mitochondria<br>Cytosol Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 67.0 Mixed
NR3C2 MLR, MR ENSG00000151623 Nuclear receptor subfamily 3 group C member 2 4 148078762-148444698 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009155, HPA074979 Enhanced Supported Nucleoplasm Renal cancer:3.10e-11 (favourable) Mixed Mixed thyroid gland: 32.3 Cell line enhanced HUVEC TERT2: 4.9;Karpas-707: 4.5;PC-3: 5.4;RPTEC TERT1: 5.9;TIME: 6.4
NTRK1 MTC, TRK, TRKA ENSG00000198400 Neurotrophic receptor tyrosine kinase 1 1 156815640-156881850 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004606, HPA035799, HPA076570 Approved Uncertain Vesicles<br>Cytosol Tissue enhanced Tissue enriched 6 adrenal gland: 9.5 testis: 1.6 Cell line enhanced HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NTSR2 NTR2 ENSG00000169006 Neurotensin receptor 2 2 11658178-11670164 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Tissue enriched Tissue enriched 25 cerebral cortex: 25.0 ovary: 0.9 Not detected
ODC1 ODC ENSG00000115758 Ornithine decarboxylase 1 2 10439968-10448504 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001536, CAB035996 Approved Approved Plasma membrane<br>Cytosol Liver cancer:3.07e-5 (unfavourable) Expressed in all Expressed in all testis: 242.0 Expressed in all
OPRD1 ENSG00000116329 Opioid receptor delta 1 1 28812142-28871267 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA070831 Approved Tissue enhanced Tissue enhanced cerebral cortex: 2.6 adrenal gland: 0.8 Group enriched 12 RH-30: 15.8;SCLC-21H: 7.6;SH-SY5Y: 6.9;WM-115: 21.7
OPRK1 KOR, OPRK ENSG00000082556 Opioid receptor kappa 1 8 53225716-53251697 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022595, HPA067549 Uncertain Supported Nucleus<br>Plasma membrane<br>Cytosol Tissue enhanced Group enriched 7 cerebral cortex: 3.6;prostate: 2.8;testis: 1.3 placenta,skeletal muscle: 0.3 Group enriched 7 AF22: 4.5;U-937: 17.3
OPRM1 MOR1 ENSG00000112038 Opioid receptor mu 1 6 154010496-154246867 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA014509, HPA067435 Enhanced Supported Not detected Tissue enhanced testis: 4.1 adrenal gland,esophagus: 1.2 Cell line enriched 29 SH-SY5Y: 7.7
OXTR ENSG00000180914 Oxytocin receptor 3 8750408-8769628 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Mixed Tissue enriched 13 breast: 65.4 fallopian tube: 4.9 Cell line enhanced BJ: 357.1;BJ hTERT+: 104.6;BJ hTERT+ SV40 Large T+: 111.8;fHDF/TERT166: 330.6
P2RX4 P2X4 ENSG00000135124 Purinergic receptor P2X 4 12 121209857-121234106 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA039494 Enhanced Approved Actin filaments<br>Cytosol Endometrial cancer:6.30e-10 (favourable) Expressed in all Mixed placenta: 33.8 Mixed
P2RY12 HORK3, P2Y12, SP1999 ENSG00000169313 Purinergic receptor P2Y12 3 151337380-151384812 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013796, HPA014518 Enhanced Tissue enriched Tissue enriched 6 cerebral cortex: 83.8 lymph node: 13.1 Not detected
P2RY2 P2U ENSG00000175591 Purinergic receptor P2Y2 11 73218298-73236352 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB022642 Uncertain Uncertain Cytosol Pancreatic cancer:2.19e-5 (unfavourable) Mixed Tissue enhanced esophagus: 18.9 skeletal muscle: 14.9 Cell line enhanced HaCaT: 31.0;HL-60: 27.2;THP-1: 53.1
PAH PH ENSG00000171759 Phenylalanine hydroxylase 12 102836885-102958410 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA028407, HPA031642 Enhanced Approved Endoplasmic reticulum<br>Vesicles Liver cancer:4.30e-4 (favourable) Tissue enriched Tissue enhanced kidney: 504.6;liver: 722.4 gallbladder: 125.9 Cell line enriched 26 Hep G2: 161.3
PARP1 ADPRT, PARP, PPOL ENSG00000143799 Poly(ADP-ribose) polymerase 1 1 226360691-226408079 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727 Supported Supported Enhanced Nucleus Renal cancer:1.35e-5 (unfavourable), Liver cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 198.4 Expressed in all
PARP2 ADPRTL2 ENSG00000129484 Poly(ADP-ribose) polymerase 2 14 20343582-20357905 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA052003 Approved Approved Nucleus<br>Nucleoli Liver cancer:6.48e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 46.3 Expressed in all
PARP3 ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3 ENSG00000041880 Poly(ADP-ribose) polymerase family member 3 3 51942345-51948867 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA067657 Supported Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable) Expressed in all Mixed parathyroid gland: 53.0 Expressed in all
PCSK9 FH3, HCHOLA3, NARC-1 ENSG00000169174 Proprotein convertase subtilisin/kexin type 9 1 55039548-55064852 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level Urothelial cancer:2.40e-4 (unfavourable) Mixed Tissue enhanced liver: 6.1;lung: 11.1 colon: 3.4 Cell line enhanced A-431: 72.0;HaCaT: 94.8;HeLa: 62.7;RPTEC TERT1: 39.4
PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2 ENSG00000188389 Programmed cell death 1 2 241849881-241858908 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035981, CAB038418, CAB076386 Enhanced Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable) Mixed Tissue enhanced lymph node: 12.0 appendix: 3.3 Group enriched 13 MOLT-4: 4.6;RPMI-8226: 4.0
PDE10A ENSG00000112541 Phosphodiesterase 10A 6 165327287-165986603 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB045998, HPA047200 Supported Renal cancer:4.44e-7 (unfavourable) Mixed Tissue enhanced thyroid gland: 14.5 testis: 12.2 Cell line enhanced LHCN-M2: 14.4;SH-SY5Y: 11.1;TIME: 14.8
PDE3A CGI-PDE ENSG00000172572 Phosphodiesterase 3A 12 20369245-20684381 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014492 Uncertain Supported Cytosol Renal cancer:1.72e-6 (unfavourable) Expressed in all Mixed heart muscle: 35.4 Group enriched 8 AF22: 15.4;HEL: 26.9;HeLa: 53.3;HUVEC TERT2: 11.9;SH-SY5Y: 31.0;U-138 MG: 22.1
PDE4A DPDE2 ENSG00000065989 Phosphodiesterase 4A 19 10416773-10469631 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB017632, HPA043310, HPA076091 Uncertain Supported Plasma membrane Expressed in all Mixed parathyroid gland: 34.0 Cell line enhanced HMC-1: 32.2
PDE4B DPDE4 ENSG00000184588 Phosphodiesterase 4B 1 65792514-66374579 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003005 Uncertain Approved Golgi apparatus<br>Cytosol Renal cancer:5.04e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 67.0 Cell line enhanced AN3-CA: 57.3;HUVEC TERT2: 77.6;NTERA-2: 56.0
PDE4C DPDE1 ENSG00000105650 Phosphodiesterase 4C 19 18207961-18255419 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA048975 Enhanced Mixed Mixed endometrium: 7.4 Cell line enhanced BEWO: 3.8;U-87 MG: 5.5
PDE4D DPDE3 ENSG00000113448 Phosphodiesterase 4D 5 58969038-60522120 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA045895 Approved Approved Nuclear membrane<br>Plasma membrane<br>Cytosol Renal cancer:4.00e-5 (favourable) Mixed Mixed bone marrow: 47.7 Cell line enhanced A549: 56.1;AN3-CA: 65.2;HeLa: 68.4
PDE5A ENSG00000138735 Phosphodiesterase 5A 4 119494395-119628991 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA004729, HPA012873 Approved Approved Cytosol Urothelial cancer:1.17e-4 (unfavourable), Cervical cancer:5.20e-4 (favourable) Expressed in all Mixed prostate: 97.7 Cell line enhanced BJ hTERT+: 38.5;HHSteC: 55.3
PDE7A HCP1 ENSG00000205268 Phosphodiesterase 7A 8 65717510-65842322 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB018770, HPA027340 Approved Renal cancer:1.35e-4 (unfavourable), Liver cancer:5.64e-4 (unfavourable) Expressed in all Expressed in all lymph node: 68.9 Expressed in all
PDE7B ENSG00000171408 Phosphodiesterase 7B 6 135851696-136195574 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023967 Uncertain Approved Nucleoplasm Renal cancer:1.59e-4 (favourable) Mixed Mixed ovary: 16.2 Cell line enhanced EFO-21: 15.3;HSkMC: 16.3;U-2197: 10.6
PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet derived growth factor receptor alpha 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus<br>Plasma membrane<br>Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.6 Cell line enhanced ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet derived growth factor receptor beta 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB003842, CAB018144, HPA028499 Enhanced Supported Golgi apparatus<br>Vesicles Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable) Expressed in all Mixed gallbladder: 193.8 Cell line enhanced ASC diff: 923.6;ASC TERT1: 324.4
PDXK C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79 ENSG00000160209 Pyridoxal kinase 21 43719094-43762307 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030196, HPA030197, HPA030198, CAB033918 Approved Enhanced Nucleus Expressed in all Expressed in all cerebral cortex: 47.5 Expressed in all
PGF D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760 ENSG00000119630 Placental growth factor 14 74941834-74955784 Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA041624 Approved Nucleoplasm<br>Mitochondria<br>Cytosol Renal cancer:1.33e-6 (unfavourable), Liver cancer:1.40e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 71.1;thyroid gland: 64.5 cervix, uterine: 30.1 Group enriched 6 BEWO: 398.0;HUVEC TERT2: 164.7
PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Enhanced Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 96.2;endometrium: 172.3;fallopian tube: 53.3;smooth muscle: 114.9 ovary: 19.5 Cell line enriched 349 T-47d: 157.7
PLA2G1B PLA2, PLA2A, PPLA2 ENSG00000170890 Phospholipase A2 group IB 12 120322111-120327789 Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB022329, HPA047822, HPA060803 Enhanced Enhanced Cytosol Tissue enriched Tissue enriched 246 pancreas: 23843.3 ovary: 96.9 Cell line enhanced Hep G2: 1.7;U-2 OS: 1.8
PLA2G2A PLA2B, PLA2L ENSG00000188257 Phospholipase A2 group IIA 1 19975431-19980416 Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA015236 Enhanced Uncertain Nucleus<br>Nucleoli Melanoma:1.49e-4 (favourable) Expressed in all Tissue enhanced colon: 108.4;rectum: 177.5;small intestine: 233.7 duodenum: 85.7 Group enriched 11 Hep G2: 50.2;RT4: 53.3
PLA2G4A cPLA2-alpha, PLA2G4 ENSG00000116711 Phospholipase A2 group IVA 1 186828953-186988981 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level CAB010050, HPA050062, HPA054206 Approved Supported Cytosol Endometrial cancer:2.85e-4 (favourable), Breast cancer:9.07e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 200.5 seminal vesicle: 68.3 Cell line enhanced RPMI-8226: 50.7;U-2197: 61.7
PLA2G6 iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9 ENSG00000184381 Phospholipase A2 group VI 22 38111495-38205690 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA001171 Approved Approved Microtubule organizing center<br>Cytosol Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable) Expressed in all Expressed in all testis: 60.2 Cell line enhanced HEL: 55.1
PLAT ENSG00000104368 Plasminogen activator, tissue type 8 42175233-42207724 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003412, CAB009335 Supported Approved Actin filaments Renal cancer:4.95e-4 (unfavourable), Breast cancer:7.57e-4 (favourable) Expressed in all Tissue enriched 5 parathyroid gland: 709.4 urinary bladder: 135.9 Cell line enhanced CAPAN-2: 590.7;HMC-1: 372.4;U-2197: 417.3;WM-115: 889.6
PLAU UPA, URK ENSG00000122861 Plasminogen activator, urokinase 10 73909177-73917497 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA008719 Approved Pancreatic cancer:1.32e-4 (unfavourable), Head and neck cancer:2.70e-4 (unfavourable), Endometrial cancer:3.38e-4 (favourable), Renal cancer:3.51e-4 (unfavourable), Lung cancer:4.04e-4 (unfavourable) Expressed in all Expressed in all appendix: 60.3 Cell line enhanced CAPAN-2: 757.8;LHCN-M2: 690.9;RPTEC TERT1: 2356.8;U-251 MG: 715.9
PLAUR CD87, UPAR, URKR ENSG00000011422 Plasminogen activator, urokinase receptor 19 43646095-43670547 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050843, CAB073533 Uncertain Supported Plasma membrane Renal cancer:7.83e-9 (unfavourable), Lung cancer:2.33e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 428.5 Cell line enhanced U-251 MG: 341.1;U-87 MG: 336.6;WM-115: 338.6
PLCL1 PLC-L, PLCE, PLCL, PPP1R127, PRIP ENSG00000115896 Phospholipase C like 1 2 197804702-198572581 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA031849 Enhanced Renal cancer:3.91e-7 (favourable) Mixed Mixed kidney: 34.3 Cell line enhanced HUVEC TERT2: 7.3;K-562: 13.7;Karpas-707: 7.9;MOLT-4: 8.6
PLG ENSG00000122194 Plasminogen 6 160702238-160753315 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB000668, CAB016678, HPA021602, HPA048823, HPA053770 Supported Uncertain Vesicles Renal cancer:4.22e-4 (favourable) Tissue enriched Tissue enriched 6 liver: 1749.3 kidney: 313.4 Cell line enhanced RH-30: 1.0
PLIN3 M6PRBP1, PP17, TIP47 ENSG00000105355 Perilipin 3 19 4838341-4867768 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006427, HPA066538 Uncertain Enhanced Lipid droplets<br>Cytosol Renal cancer:9.15e-7 (unfavourable), Lung cancer:7.67e-6 (unfavourable), Liver cancer:3.27e-5 (unfavourable), Endometrial cancer:2.62e-4 (favourable) Expressed in all Expressed in all esophagus: 115.7 Expressed in all
PNLIP PL ENSG00000175535 Pancreatic lipase 10 116545931-116567855 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA062430, HPA062494 Enhanced Tissue enriched Tissue enriched 325 pancreas: 93703.0 ovary: 288.0 Cell line enhanced U-2 OS: 1.3
PNP NP, PUNP ENSG00000198805 Purine nucleoside phosphorylase 14 20468954-20477094 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001625 Enhanced Supported Cytosol Renal cancer:2.24e-4 (favourable), Liver cancer:4.43e-4 (unfavourable) Expressed in all Expressed in all epididymis: 698.2 Expressed in all
POLA1 NSX, p180, POLA ENSG00000101868 DNA polymerase alpha 1, catalytic subunit X 24693919-24996986 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA002947, CAB012274 Enhanced Supported Nucleoplasm<br>Cytosol Liver cancer:4.80e-5 (unfavourable) Expressed in all Mixed lymph node: 8.7 Expressed in all
POLB ENSG00000070501 DNA polymerase beta 8 42338454-42371808 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB011616, HPA049104 Enhanced Approved Vesicles Renal cancer:2.15e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Urothelial cancer:5.65e-4 (favourable) Expressed in all Expressed in all testis: 92.7 Expressed in all
POLE POLE1 ENSG00000177084 DNA polymerase epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Enhanced Nucleus<br>Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.1 Expressed in all
POLE2 DPE2 ENSG00000100479 DNA polymerase epsilon 2, accessory subunit 14 49643555-49688422 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA027555 Uncertain Supported Nucleoplasm<br>Nuclear bodies<br>Vesicles Expressed in all Mixed bone marrow: 10.7 Mixed
POLE3 CHARAC17, CHRAC17, p17, Ybl1 ENSG00000148229 DNA polymerase epsilon 3, accessory subunit 9 113407235-113410672 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047945 Uncertain Approved Nucleus<br>Nucleoli Liver cancer:8.35e-4 (unfavourable) Expressed in all Expressed in all testis: 76.4 Expressed in all
POLE4 p12 ENSG00000115350 DNA polymerase epsilon 4, accessory subunit 2 74958492-74970128 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA054979, HPA071815 Approved Approved Nucleus<br>Cytosol Liver cancer:6.49e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 12.8 Mixed
PPARA hPPAR, NR1C1, PPAR ENSG00000186951 Peroxisome proliferator activated receptor alpha 22 46150521-46243756 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058901, HPA067049, CAB075701 Supported Enhanced Nucleus Renal cancer:4.39e-9 (favourable) Expressed in all Expressed in all kidney: 24.2 Mixed
PPARD FAAR, NR1C2, NUC1, NUCII ENSG00000112033 Peroxisome proliferator activated receptor delta 6 35342558-35428191 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017635 Approved Liver cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all placenta: 40.2 Expressed in all
PPARG NR1C3, PPARG1, PPARG2, PPARgamma ENSG00000132170 Peroxisome proliferator activated receptor gamma 3 12287368-12434356 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004282, HPA051239, HPA063663 Approved Enhanced Nucleus<br>Vesicles Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 173.3 placenta: 59.2 Cell line enhanced ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
PPP3R2 PPP3RL ENSG00000188386 Protein phosphatase 3 regulatory subunit B, beta 9 101591615-101595021 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047157 Uncertain Approved Plasma membrane<br>Cytosol Not detected Tissue enriched 1372 testis: 137.1 all non-specific tissues: 0.0 Not detected
PRDX5 ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10 ENSG00000126432 Peroxiredoxin 5 11 64318088-64321811 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB008661, HPA037915, HPA037916 Enhanced Enhanced Mitochondria<br>Cytosol Renal cancer:1.24e-5 (favourable) Expressed in all Expressed in all fallopian tube: 606.1 Expressed in all
PRKAA1 AMPKa1 ENSG00000132356 Protein kinase AMP-activated catalytic subunit alpha 1 5 40759379-40798374 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB005050, HPA035409, HPA064946 Supported Supported Nuclear speckles Expressed in all Expressed in all testis: 74.4 Expressed in all
PRKAB1 ENSG00000111725 Protein kinase AMP-activated non-catalytic subunit beta 1 12 119667753-119681630 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA004247, CAB005058 Enhanced Approved Nucleoplasm<br>Cytosol Renal cancer:5.40e-9 (favourable), Endometrial cancer:8.66e-4 (favourable) Expressed in all Expressed in all kidney: 53.5 Expressed in all
PRLR ENSG00000113494 Prolactin receptor 5 35048756-35230589 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Tissue enriched Tissue enhanced placenta: 70.9 kidney: 33.1 Cell line enriched 22 T-47d: 356.8
PROC ENSG00000115718 Protein C, inactivator of coagulation factors Va and VIIIa 2 127418427-127429246 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005550, CAB016721, CAB016792 Supported Tissue enriched Tissue enriched 12 liver: 140.4 kidney: 12.0 Cell line enriched 12 Hep G2: 105.5
PROS1 PROS ENSG00000184500 Protein S (alpha) 3 93873033-93974066 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007724, HPA023974 Enhanced Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable) Expressed in all Tissue enhanced liver: 177.6 heart muscle: 78.3 Cell line enhanced ASC diff: 98.8;SK-MEL-30: 127.4
PSMB1 HC5, PMSB1 ENSG00000008018 Proteasome subunit beta 1 6 170535117-170553341 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029635, HPA029637, CAB033911 Enhanced Supported Nucleus Renal cancer:3.76e-6 (unfavourable) Expressed in all Expressed in all epididymis: 320.2 Expressed in all
PSMB10 beta2i, LMP10, MECL1, MGC1665 ENSG00000205220 Proteasome subunit beta 10 16 67934502-67937087 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030224, HPA030225, CAB034384 Enhanced Enhanced Cytosol Urothelial cancer:5.44e-4 (favourable) Expressed in all Expressed in all lymph node: 91.2 Mixed
PSMB2 HC7-I ENSG00000126067 Proteasome subunit beta 2 1 35599544-35641844 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026322, HPA026324 Approved Enhanced Nucleoplasm Liver cancer:3.49e-7 (unfavourable), Renal cancer:2.80e-6 (unfavourable) Expressed in all Expressed in all placenta: 43.3 Expressed in all
PSMB5 MB1, X ENSG00000100804 Proteasome subunit beta 5 14 23016543-23035230 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA049518, HPA061796 Approved Supported Nucleus<br>Centrosome Liver cancer:2.90e-5 (unfavourable), Ovarian cancer:1.08e-4 (favourable), Head and neck cancer:2.85e-4 (unfavourable), Urothelial cancer:4.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 141.7 Expressed in all
PSMB8 beta5i, D6S216E, LMP7, PSMB5i, RING10 ENSG00000204264 Proteasome subunit beta 8 6 32840717-32844703 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA046995, HPA050327 Enhanced Approved Vesicles<br>Cytokinetic bridge Breast cancer:5.08e-4 (favourable), Endometrial cancer:7.16e-4 (favourable) Expressed in all Mixed lymph node: 23.0 Mixed
PSMB9 beta1i, LMP2, PSMB6i, RING12 ENSG00000240065 Proteasome subunit beta 9 6 32844136-32859585 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015180, HPA042818, HPA053280 Enhanced Supported Cytosol Renal cancer:1.33e-4 (unfavourable) Expressed in all Mixed spleen: 39.1 Cell line enhanced Daudi: 46.2;REH: 43.8
PTGER1 EP1 ENSG00000160951 Prostaglandin E receptor 1 19 14472466-14475362 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level Tissue enhanced Tissue enhanced kidney: 2.9;spleen: 2.5 lung: 0.7 Cell line enhanced HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
PTGER2 EP2 ENSG00000125384 Prostaglandin E receptor 2 14 52314305-52328606 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level Renal cancer:4.16e-4 (unfavourable) Mixed Mixed cervix, uterine: 27.3 Cell line enhanced ASC TERT1: 50.0;HHSteC: 38.3;HSkMC: 41.8
PTGER3 EP3 ENSG00000050628 Prostaglandin E receptor 3 1 70852353-71047808 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA010689 Uncertain Renal cancer:3.50e-4 (unfavourable) Group enriched Group enriched 7 adipose tissue: 58.6;endometrium: 115.3;kidney: 88.3;smooth muscle: 105.2 skin: 13.9 Group enriched 5 ASC diff: 19.6;HAP1: 21.6;HDLM-2: 30.4;HEL: 14.0;T-47d: 68.0
PTGER4 EP4 ENSG00000171522 Prostaglandin E receptor 4 5 40679498-40693735 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA011226, HPA012756 Approved Urothelial cancer:2.48e-4 (favourable) Expressed in all Expressed in all bone marrow: 48.1 Cell line enhanced HDLM-2: 33.9;RT4: 28.7;TIME: 37.0
PTGFR FP ENSG00000122420 Prostaglandin F receptor 1 78303884-78539749 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level Mixed Tissue enhanced endometrium: 30.5;smooth muscle: 25.7 urinary bladder: 12.9 Group enriched 7 ASC TERT1: 193.6;HSkMC: 63.3
PTGIR IP ENSG00000160013 Prostaglandin I2 (prostacyclin) receptor (IP) 19 46620468-46625118 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Renal cancer:2.09e-8 (unfavourable), Testis cancer:1.74e-4 (unfavourable) Mixed Tissue enhanced lung: 13.9 appendix: 8.2 Cell line enhanced BJ: 9.0;BJ hTERT+: 9.8;fHDF/TERT166: 11.8;HEL: 25.3
PTGIS CYP8A1, PGIS ENSG00000124212 Prostaglandin I2 synthase 20 49503874-49568146 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009517, HPA014193, HPA052244 Enhanced Approved Endoplasmic reticulum Renal cancer:4.74e-8 (unfavourable), Urothelial cancer:9.99e-5 (unfavourable) Expressed in all Mixed fallopian tube: 78.2 Cell line enhanced ASC diff: 30.9;ASC TERT1: 31.6;U-2197: 133.1
PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Enhanced Supported Golgi apparatus<br>Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.6 fallopian tube: 86.1 Cell line enhanced ASC diff: 104.2;BJ: 149.8;BJ hTERT+: 187.6;HMC-1: 391.6
PTGS2 COX2 ENSG00000073756 Prostaglandin-endoperoxide synthase 2 1 186671791-186680427 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level CAB000113, HPA001335 Approved Supported Endoplasmic reticulum Renal cancer:9.79e-4 (unfavourable) Mixed Tissue enhanced seminal vesicle: 180.6 cervix, uterine: 99.3 Group enriched 7 BJ: 78.6;BJ hTERT+: 327.8
PTH2R PTHR2 ENSG00000144407 Parathyroid hormone 2 receptor 2 208359714-208854503 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA010655 Approved Tissue enhanced Mixed bone marrow: 2.9 Group enriched 9 EFO-21: 10.1;HEL: 14.3;HL-60: 3.1;SH-SY5Y: 6.7
QPRT QPRTase ENSG00000103485 Quinolinate phosphoribosyltransferase 16 29679008-29698699 Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA011887 Approved Breast cancer:5.10e-5 (unfavourable), Glioma:7.45e-4 (unfavourable) Expressed in all Expressed in all kidney: 112.3 Cell line enhanced EFO-21: 469.3
RAF1 c-Raf, CRAF, Raf-1 ENSG00000132155 Raf-1 proto-oncogene, serine/threonine kinase 3 12583601-12664226 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins Evidence at protein level HPA002640, CAB019291 Approved Approved Nuclear speckles Expressed in all Expressed in all parathyroid gland: 100.7 Expressed in all
RAMP1 ENSG00000132329 Receptor activity modifying protein 1 2 237858893-237912114 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA057814 Supported Nucleoplasm<br>Nuclear membrane Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable) Expressed in all Tissue enhanced endometrium: 234.1 smooth muscle: 171.5 Cell line enhanced HDLM-2: 126.9;PC-3: 142.8;SH-SY5Y: 202.6
RAMP2 ENSG00000131477 Receptor activity modifying protein 2 17 42758447-42763041 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052020 Approved Vesicles Expressed in all Mixed lung: 178.6 Cell line enhanced ASC diff: 78.4;EFO-21: 72.9;HUVEC TERT2: 29.7
RAMP3 ENSG00000122679 Receptor activity modifying protein 3 7 45157791-45186302 FDA approved drug targets, Predicted membrane proteins Evidence at protein level Liver cancer:2.50e-6 (favourable), Cervical cancer:2.89e-4 (favourable) Expressed in all Tissue enhanced lung: 120.2 thyroid gland: 66.3 Cell line enhanced Karpas-707: 1.8
RARA NR1B1, RAR ENSG00000131759 Retinoic acid receptor alpha 17 40309192-40357643 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058282 Supported Nucleus<br>Cytosol Endometrial cancer:2.60e-4 (favourable) Expressed in all Expressed in all gallbladder: 68.6 Expressed in all
RARB HAP, NR1B2, RRB2 ENSG00000077092 Retinoic acid receptor beta 3 25174332-25597932 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002617, HPA004174 Enhanced Enhanced Nucleoplasm Renal cancer:3.43e-5 (favourable) Expressed in all Mixed placenta: 20.6 Cell line enhanced HEK 293: 14.7;HUVEC TERT2: 11.2;WM-115: 36.1
RARG NR1B3, RARC ENSG00000172819 Retinoic acid receptor gamma 12 53210567-53232980 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053883 Supported Supported Nucleoplasm Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable) Expressed in all Tissue enhanced skin: 143.4 esophagus: 77.3 Mixed
REN ENSG00000143839 Renin 1 204154819-204190324 Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005131, CAB025903 Approved Renal cancer:6.45e-5 (unfavourable) Tissue enriched Tissue enhanced kidney: 51.2;placenta: 21.0 endometrium: 8.9 Cell line enhanced BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
RET CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51 ENSG00000165731 Ret proto-oncogene 10 43077027-43130351 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002581, HPA008356, HPA008495, CAB018342 Approved Supported Supported Vesicles<br>Plasma membrane<br>Cytosol Endometrial cancer:5.02e-4 (unfavourable) Tissue enhanced Tissue enriched 5 parathyroid gland: 154.5 adrenal gland: 29.8 Cell line enriched 5 SH-SY5Y: 404.3
RFK FLJ11149, RIFK ENSG00000135002 Riboflavin kinase 9 76385517-76394517 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA023259, CAB033887, HPA057163 Approved Approved Golgi apparatus Expressed in all Expressed in all cerebral cortex: 37.8 Expressed in all
RPL3 L3 ENSG00000100316 Ribosomal protein L3 22 39312882-39320389 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins Evidence at protein level HPA003365, HPA055361 Uncertain Supported Nucleoli<br>Cytosol Expressed in all Expressed in all ovary: 5675.2 Expressed in all
RRM1 ENSG00000167325 Ribonucleotide reductase catalytic subunit M1 11 4094707-4138876 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022093, HPA057265, HPA064297 Enhanced Enhanced Cytosol Liver cancer:1.53e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 60.4 Expressed in all
RRM2 ENSG00000171848 Ribonucleotide reductase regulatory subunit M2 2 10122328-10131419 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056994 Enhanced Supported Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable) Expressed in all Mixed bone marrow: 47.5 Mixed
RRM2B p53R2 ENSG00000048392 Ribonucleotide reductase regulatory TP53 inducible subunit M2B 8 102204502-102239118 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006854, HPA028812 Approved Supported Nucleoplasm<br>Cytosol Expressed in all Expressed in all parathyroid gland: 75.1 Expressed in all
RXRA NR2B1 ENSG00000186350 Retinoid X receptor alpha 9 134317098-134440585 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004565, CAB005352 Supported Supported Nucleus<br>Golgi apparatus Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable) Expressed in all Mixed esophagus: 25.8 Mixed
RXRB H-2RIIBP, NR2B2, RCoR-1 ENSG00000204231 Retinoid X receptor beta 6 33193588-33200688 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002003, HPA063653 Supported Supported Nucleus Expressed in all Mixed epididymis: 15.7 Cell line enhanced RH-30: 8.5;T-47d: 8.2
RXRG NR2B3 ENSG00000143171 Retinoid X receptor gamma 1 165400917-165445355 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002615, HPA012933 Uncertain Supported Nucleoplasm<br>Nuclear bodies Thyroid cancer:9.40e-5 (favourable) Group enriched Tissue enhanced skeletal muscle: 16.7 cervix, uterine: 4.7 Cell line enriched 6 SK-MEL-30: 29.1
RYR1 CCO, MHS, MHS1, PPP1R137, RYR ENSG00000196218 Ryanodine receptor 1 19 38433699-38587564 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA056416 Enhanced Approved Golgi apparatus<br>Vesicles<br>Cytosol Mixed Tissue enriched 31 skeletal muscle: 572.4 esophagus: 18.6 Cell line enhanced HaCaT: 16.8;RH-30: 14.8;SiHa: 32.7;U-2 OS: 13.2
RYR2 ARVC2, ARVD2, VTSIP ENSG00000198626 Ryanodine receptor 2 1 237042205-237833988 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020028 Approved Approved Nucleoplasm<br>Plasma membrane<br>Cytosol Mixed Tissue enriched 8 heart muscle: 65.9 cerebral cortex: 7.9 Cell line enhanced HDLM-2: 4.8;HEK 293: 6.3;K-562: 2.0;NTERA-2: 2.5;U-937: 2.5
S1PR1 CD363, D1S3362, edg-1, EDG1 ENSG00000170989 Sphingosine-1-phosphate receptor 1 1 101236888-101241518 Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB010104, HPA075568 Supported Supported Vesicles Urothelial cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 86.8 Cell line enhanced BJ: 53.9;HUVEC TERT2: 149.1;TIME: 81.9;U-251 MG: 103.4
S1PR5 Edg-8, EDG8 ENSG00000180739 Sphingosine-1-phosphate receptor 5 19 10512742-10517931 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029683 Enhanced Renal cancer:6.71e-7 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 14.9;skin: 22.1 spleen: 12.0 Cell line enhanced HaCaT: 25.0;RT4: 14.8;T-47d: 10.9;U-2 OS: 10.7
SCN10A hPN3, Nav1.8, PN3, SNS ENSG00000185313 Sodium voltage-gated channel alpha subunit 10 3 38696802-38794010 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Not detected Not detected testis: 0.3 Not detected
SCN11A NaN, Nav1.9, SCN12A, SNS-2 ENSG00000168356 Sodium voltage-gated channel alpha subunit 11 3 38845769-38950561 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA036746, HPA036747 Uncertain Not detected Tissue enhanced placenta: 3.7;spleen: 5.3 testis: 2.0 Cell line enhanced HDLM-2: 1.1
SCN1A FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI ENSG00000144285 Sodium voltage-gated channel alpha subunit 1 2 165989160-166149214 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA078664 Supported Nucleoplasm<br>Nuclear bodies<br>Plasma membrane Tissue enriched Group enriched 41 cerebral cortex: 10.3;fallopian tube: 2.9;lung: 2.2 adrenal gland,placenta,testis: 0.1 Cell line enhanced AF22: 1.1;ASC TERT1: 4.4;Hep G2: 1.1
SCN1B ENSG00000105711 Sodium voltage-gated channel beta subunit 1 19 35030466-35040449 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level Pancreatic cancer:1.38e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 145.1 cerebral cortex: 52.4 Cell line enhanced A549: 15.7;TIME: 21.3
SCN2A HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2 ENSG00000136531 Sodium voltage-gated channel alpha subunit 2 2 165194993-165392310 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022567 Enhanced Tissue enhanced Tissue enriched 26 cerebral cortex: 56.6 kidney: 2.1 Cell line enhanced U-138 MG: 3.6;U-266/84: 5.7;U-87 MG: 2.2
SCN2B ENSG00000149575 Sodium voltage-gated channel beta subunit 2 11 118161951-118176673 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level Mixed Group enriched 9 cerebral cortex: 34.7;heart muscle: 7.1 smooth muscle: 2.4 Cell line enhanced U-2197: 1.6
SCN3A Nav1.3 ENSG00000153253 Sodium voltage-gated channel alpha subunit 3 2 165087522-165204067 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA035396 Approved Tissue enriched Tissue enriched 7 cerebral cortex: 13.6 adrenal gland: 1.9 Cell line enhanced Karpas-707: 7.8;MOLT-4: 26.0;RPTEC TERT1: 11.6;SH-SY5Y: 7.3
SCN3B HSA243396 ENSG00000166257 Sodium voltage-gated channel beta subunit 3 11 123629187-123655244 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041707 Approved Intermediate filaments<br>Cytosol Tissue enhanced Tissue enriched 11 cerebral cortex: 132.1 adrenal gland: 11.5 Cell line enhanced hTCEpi: 4.6;RH-30: 2.8;SCLC-21H: 7.5;SH-SY5Y: 5.0
SCN4A HYKPP, HYPP, Nav1.4, SkM1 ENSG00000007314 Sodium voltage-gated channel alpha subunit 4 17 63938554-63972918 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053992 Approved Nucleoplasm<br>Microtubule organizing center Tissue enhanced Group enriched 9 adipose tissue: 12.4;skeletal muscle: 47.2 thyroid gland: 3.3 Group enriched 13 REH: 13.6;RH-30: 43.5
SCN4B LQT10 ENSG00000177098 Sodium voltage-gated channel beta subunit 4 11 118133377-118152888 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017293 Approved Mixed Tissue enhanced adipose tissue: 25.0 thyroid gland: 17.0 Cell line enhanced AN3-CA: 1.2;NTERA-2: 1.4;U-2 OS: 1.4
SCN5A CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1 ENSG00000183873 Sodium voltage-gated channel alpha subunit 5 3 38548057-38649673 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Mixed Tissue enriched 18 heart muscle: 27.8 cervix, uterine: 1.5 Cell line enhanced LHCN-M2: 23.1;RH-30: 22.0
SCN9A ETHA, Nav1.7, NE-NA, NENA, PN1 ENSG00000169432 Sodium voltage-gated channel alpha subunit 9 2 166195185-166375993 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB013679, HPA061843 Uncertain Approved Plasma membrane<br>Actin filaments<br>Focal adhesion sites Renal cancer:2.30e-5 (unfavourable) Mixed Tissue enhanced testis: 9.1 placenta: 5.9 Cell line enhanced BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
SCNN1A ENaCalpha, SCNN1 ENSG00000111319 Sodium channel epithelial 1 alpha subunit 12 6346843-6377730 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA012743 Enhanced Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable) Mixed Mixed cervix, uterine: 95.1 Cell line enhanced CAPAN-2: 264.6;HBEC3-KT: 145.5;RPTEC TERT1: 78.8;RT4: 91.1;SK-BR-3: 72.7
SCNN1B ENaCbeta ENSG00000168447 Sodium channel epithelial 1 beta subunit 16 23278231-23381299 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015612 Uncertain Renal cancer:2.09e-6 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 72.0 esophagus: 44.8 Cell line enhanced hTCEpi: 24.0;RT4: 14.6;U-266/70: 41.7;U-266/84: 14.3
SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel epithelial 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026884 Enhanced Supported Plasma membrane<br>Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 Mixed
SCNN1G ENaCgamma, SCNEG ENSG00000166828 Sodium channel epithelial 1 gamma subunit 16 23182715-23216883 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071194 Supported Nucleoplasm<br>Plasma membrane Renal cancer:3.20e-7 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 24.6;kidney: 46.7 thyroid gland: 9.5 Group enriched 5 hTCEpi: 33.4;RT4: 17.1
SCTR ENSG00000080293 Secretin receptor 2 119439843-119525301 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA007269 Uncertain Tissue enhanced Tissue enhanced duodenum: 26.7;lung: 12.7;pancreas: 14.4 stomach: 4.1 Cell line enhanced Karpas-707: 2.2
SDHD cybS, PGL, PGL1 ENSG00000204370 Succinate dehydrogenase complex subunit D 11 112086773-112120013 Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045727 Approved Renal cancer:1.99e-10 (favourable) Expressed in all Expressed in all kidney: 305.5 Expressed in all
SDHD cybS, PGL, PGL1 ENSG00000255292 Succinate dehydrogenase complex subunit D 11 112086824-112193805 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA045727 Uncertain Not detected Tissue enriched 13 colon: 7.8 parathyroid gland: 0.5 Cell line enhanced A549: 23.8;CACO-2: 57.0;Hep G2: 19.6;hTEC/SVTERT24-B: 20.1;RT4: 30.5
SERPINB2 HsT1201, PAI2, PLANH2 ENSG00000197632 Serpin family B member 2 18 63871692-63903890 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA015480 Supported Urothelial cancer:1.55e-5 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 260.7;placenta: 70.3;skin: 105.8;tonsil: 72.9 bone marrow: 22.2 Group enriched 6 HaCaT: 611.4;U-138 MG: 792.9;U-2197: 1151.1
SERPINC1 AT3, ATIII, MGC22579 ENSG00000117601 Serpin family C member 1 1 173903804-173917378 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA001816, CAB016790, HPA024007 Supported Liver cancer:3.40e-5 (favourable) Tissue enriched Tissue enriched 670 liver: 2517.8 kidney: 3.7 Cell line enriched 26 Hep G2: 55.1
SERPIND1 D22S673, HC-II, HC2, HCF2, HLS2 ENSG00000099937 Serpin family D member 1 22 20773879-20787720 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB008639, HPA055767 Supported Approved Vesicles Endometrial cancer:4.09e-4 (favourable) Tissue enriched Tissue enriched 16 liver: 585.3 parathyroid gland: 36.2 Cell line enriched 8 Hep G2: 126.1
SERPINE1 PAI, PAI1, PLANH1 ENSG00000106366 Serpin family E member 1 7 101127089-101139266 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA050039, CAB068501 Uncertain Approved Cytosol Renal cancer:5.88e-8 (unfavourable), Stomach cancer:3.27e-6 (unfavourable), Lung cancer:4.41e-6 (unfavourable), Head and neck cancer:2.84e-5 (unfavourable), Colorectal cancer:2.82e-4 (unfavourable), Cervical cancer:5.01e-4 (unfavourable), Urothelial cancer:5.51e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 580.3;placenta: 600.2 adipose tissue: 215.8 Cell line enhanced TIME: 8072.1;U-138 MG: 4492.2;U-251 MG: 3465.4
SHMT1 CSHMT, MGC15229, MGC24556, SHMT ENSG00000176974 Serine hydroxymethyltransferase 1 17 18327860-18363563 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA023314 Approved Supported Nucleus<br>Cytosol Renal cancer:8.54e-6 (favourable), Liver cancer:2.52e-4 (favourable) Expressed in all Expressed in all kidney: 271.5 Expressed in all
SI ENSG00000090402 Sucrase-isomaltase 3 164978898-165078495 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011897 Enhanced Tissue enhanced Group enriched 15 duodenum: 547.3;small intestine: 493.2 rectum: 34.5 Cell line enhanced BEWO: 1.0;CACO-2: 1.3;RPMI-8226: 1.3;SH-SY5Y: 1.2
SIGMAR1 OPRS1, SR-BP1 ENSG00000147955 Sigma non-opioid intracellular receptor 1 9 34634722-34637809 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013470, HPA018002, HPA024071 Approved Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all liver: 67.8 Expressed in all
SIRT5 ENSG00000124523 Sirtuin 5 6 13574529-13615158 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA021798, HPA022002, HPA022992 Approved Enhanced Mitochondria Renal cancer:8.76e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 17.1 Expressed in all
SLAMF7 19A, CD319, CRACC, CS1 ENSG00000026751 SLAM family member 7 1 160739057-160754821 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015445, HPA055945, HPA061654 Enhanced Approved Vesicles Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable) Mixed Mixed spleen: 58.3 Group enriched 7 SK-MEL-30: 45.6;U-266/70: 216.2
SLC12A1 NKCC2 ENSG00000074803 Solute carrier family 12 member 1 15 48191664-48304078 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014967, HPA018107 Enhanced Approved Nucleus<br>Vesicles Tissue enhanced Tissue enriched 477 kidney: 780.2 testis: 1.6 Cell line enriched 19 RPTEC TERT1: 19.2
SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles<br>Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 65.4 Expressed in all
SLC12A3 NCCT ENSG00000070915 Solute carrier family 12 member 3 16 56865207-56915850 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028748 Enhanced Tissue enhanced Tissue enriched 109 kidney: 109.8 lymph node: 1.0 Group enriched 11 BEWO: 7.0;HAP1: 4.1;HeLa: 5.5
SLC12A4 KCC1 ENSG00000124067 Solute carrier family 12 member 4 16 67943474-67969601 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041138 Approved Approved Endosomes Renal cancer:2.25e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 63.9 Mixed
SLC12A5 KCC2, KIAA1176 ENSG00000124140 Solute carrier family 12 member 5 20 46021690-46060152 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA072058 Enhanced Glioma:8.45e-4 (unfavourable) Mixed Tissue enriched 8 cerebral cortex: 94.2 adrenal gland: 11.9 Cell line enhanced NB-4: 32.3;U-2 OS: 29.1
SLC18A1 CGAT, VAT1, VMAT1 ENSG00000036565 Solute carrier family 18 member A1 8 20144855-20183206 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006877, HPA063797 Enhanced Tissue enhanced Tissue enriched 11 adrenal gland: 32.6 rectum: 3.0 Cell line enriched 9 SH-SY5Y: 70.0
SLC18A2 SVAT, SVMT, VMAT2 ENSG00000165646 Solute carrier family 18 member A2 10 117241093-117279430 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA073224 Approved Mixed Tissue enhanced cervix, uterine: 47.6 adrenal gland: 19.0 Cell line enriched 18 HMC-1: 308.7
SLC22A11 OAT4 ENSG00000168065 Solute carrier family 22 member 11 11 64555626-64572875 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026076 Approved Renal cancer:3.68e-5 (favourable) Group enriched Group enriched 114 epididymis: 10.0;kidney: 26.0;placenta: 44.8 seminal vesicle: 0.2 Cell line enhanced BEWO: 1.2
SLC22A12 OAT4L, RST, URAT1 ENSG00000197891 Solute carrier family 22 member 12 11 64590641-64602353 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024575 Enhanced Renal cancer:2.63e-4 (favourable) Group enriched Tissue enriched 198 kidney: 105.0 adipose tissue: 0.5 Not detected
SLC22A6 OAT1, PAHT, ROAT1 ENSG00000197901 Solute carrier family 22 member 6 11 62936385-62984983 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA074559, CAB075704 Enhanced Tissue enriched Tissue enriched 64 kidney: 200.2 cerebral cortex: 3.1 Not detected
SLC22A8 OAT3 ENSG00000149452 Solute carrier family 22 member 8 11 62989154-63015839 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044174 Enhanced Tissue enhanced Tissue enriched 395 kidney: 339.8 cerebral cortex: 0.8 Not detected
SLC25A4 ANT1, PEO2, PEO3, T1 ENSG00000151729 Solute carrier family 25 member 4 4 185143241-185150382 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Enhanced Mitochondria Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enhanced heart muscle: 122.1;skeletal muscle: 66.2 cerebral cortex: 38.1 Mixed
SLC25A5 2F1, ANT2, T2, T3 ENSG00000005022 Solute carrier family 25 member 5 X 119468400-119471319 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable) Expressed in all Expressed in all duodenum: 769.6 Expressed in all
SLC25A6 ANT3, ANT3Y, MGC17525 ENSG00000169100 Solute carrier family 25 member 6 X 1386152-1392724 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Expressed in all Expressed in all ovary: 291.7 Expressed in all
SLC52A2 D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2 ENSG00000185803 Solute carrier family 52 member 2 8 144354135-144361272 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA063036 Approved Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 20.8 Expressed in all
SLC5A2 SGLT2 ENSG00000140675 Solute carrier family 5 member 2 16 31483002-31490860 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041603 Enhanced Not detected Tissue enriched 10 kidney: 26.5 testis: 2.7 Not detected
SLC6A1 GABATHG, GABATR, GAT1 ENSG00000157103 Solute carrier family 6 member 1 3 10992724-11039247 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013341, CAB022293 Enhanced Uncertain Mitochondria Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable) Group enriched Group enriched 5 cerebral cortex: 119.4;liver: 50.4 parathyroid gland: 16.0 Not detected
SLC6A2 NAT1, NET, NET1, SLC6A5 ENSG00000103546 Solute carrier family 6 member 2 16 55655604-55706192 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004057, HPA076311, CAB078195 Enhanced Supported Approved Mitochondria<br>Cytosol Tissue enhanced Tissue enhanced adrenal gland: 29.2;placenta: 18.4;skin: 15.7 testis: 11.4 Cell line enriched 35 SH-SY5Y: 519.4
SLC6A3 DAT, DAT1 ENSG00000142319 Solute carrier family 6 member 3 5 1392790-1445430 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA012763, HPA013602, CAB016249, CAB078172 Supported Supported Approved Vesicles Renal cancer:3.40e-7 (unfavourable) Tissue enriched Not detected thyroid gland: 0.3 Not detected
SLC6A4 5-HTT, HTT, OCD1, SERT1 ENSG00000108576 Solute carrier family 6 member 4 17 30194319-30236002 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071354, HPA074728 Supported Supported Golgi apparatus<br>Vesicles Tissue enhanced Group enriched 10 duodenum: 10.4;lung: 44.2;placenta: 26.4;small intestine: 45.3 esophagus: 3.1 Cell line enhanced BEWO: 1.9;CACO-2: 3.2;Hep G2: 7.1
SLC6A8 CRTR, CT1 ENSG00000130821 Solute carrier family 6 member 8 X 153688099-153696593 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level Renal cancer:1.53e-4 (unfavourable), Thyroid cancer:7.39e-4 (unfavourable) Expressed in all Mixed small intestine: 89.2 Mixed
SLC7A11 xCT ENSG00000151012 Solute carrier family 7 member 11 4 138164097-138242349 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA064215 Supported Vesicles Ovarian cancer:1.77e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 22.4 epididymis: 8.2 Expressed in all
SLC8A1 NCX1 ENSG00000183023 Solute carrier family 8 member A1 2 40097270-40611053 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022694, HPA070007 Uncertain Supported Nucleoplasm<br>Plasma membrane Mixed Tissue enhanced heart muscle: 78.0 seminal vesicle: 37.6 Cell line enhanced BJ: 24.4;fHDF/TERT166: 54.5
SLCO2B1 OATP-B, OATP2B1, SLC21A9 ENSG00000137491 Solute carrier organic anion transporter family member 2B1 11 75100563-75206549 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020659 Uncertain Expressed in all Expressed in all liver: 123.1 Cell line enhanced CACO-2: 75.7;HEL: 13.5;Hep G2: 14.2;HMC-1: 23.5
SMO FZD11, SMOH ENSG00000128602 Smoothened, frizzled class receptor 7 129188872-129213545 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011446 Approved Expressed in all Mixed ovary: 30.4 Cell line enhanced AN3-CA: 84.8;NTERA-2: 69.7
SMOX C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO ENSG00000088826 Spermine oxidase 20 4120980-4187747 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047117, HPA060198 Approved Supported Nucleoplasm<br>Nuclear membrane<br>Vesicles Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 49.7 gallbladder: 23.5 Cell line enhanced A549: 104.6;Karpas-707: 139.7
SMS MRSR, SPMSY, SpS, SRS ENSG00000102172 Spermine synthase X 21940573-21994835 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA029849, HPA029852 Approved Approved Nuclear bodies<br>Cytosol Liver cancer:7.79e-8 (unfavourable), Renal cancer:7.85e-5 (unfavourable), Head and neck cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all prostate: 202.4 Expressed in all
SNAP25 bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25 ENSG00000132639 Synaptosome associated protein 25 20 10218830-10307418 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level CAB000360, HPA001830 Enhanced Supported Group enriched Tissue enriched 31 cerebral cortex: 1759.0 adrenal gland: 57.2 Cell line enhanced SCLC-21H: 92.0;SH-SY5Y: 49.5;U-87 MG: 54.7
SOAT1 ACAT, SOAT, STAT ENSG00000057252 Sterol O-acyltransferase 1 1 179293714-179358680 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009533, HPA047171 Enhanced Enhanced Endoplasmic reticulum Expressed in all Tissue enhanced adrenal gland: 218.2 prostate: 45.1 Expressed in all
SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Enhanced Uncertain Vesicles<br>Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.8 Expressed in all
SRC ASV, c-src, SRC1 ENSG00000197122 SRC proto-oncogene, non-receptor tyrosine kinase 20 37344685-37406050 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004023, HPA030875 Approved Enhanced Plasma membrane<br>Cytosol Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable) Expressed in all Mixed gallbladder: 43.6 Mixed
SRD5A1 ENSG00000145545 Steroid 5 alpha-reductase 1 5 6633343-6674386 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA051402 Approved Endometrial cancer:8.73e-6 (unfavourable) Expressed in all Mixed skin: 16.8 Mixed
SRD5A2 ENSG00000277893 Steroid 5 alpha-reductase 2 2 31522480-31581067 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Group enriched Group enriched 11 epididymis: 27.9;fallopian tube: 31.6;liver: 30.6;prostate: 26.6;seminal vesicle: 24.5 testis: 2.5 Cell line enhanced RT4: 1.2
SSTR1 ENSG00000139874 Somatostatin receptor 1 14 38207999-38213067 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031506 Approved Renal cancer:4.28e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 13.6;duodenum: 14.2;stomach: 21.4 small intestine: 9.1 Cell line enhanced BJ: 102.5;BJ hTERT+: 27.1;fHDF/TERT166: 56.0
SSTR2 ENSG00000180616 Somatostatin receptor 2 17 73165012-73176633 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA007264 Uncertain Supported Cytosol Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 22.9 spleen: 5.8 Cell line enriched 9 SCLC-21H: 14.9
SSTR5 ENSG00000162009 Somatostatin receptor 5 16 1078781-1080142 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA066503 Supported Plasma membrane Mixed Tissue enhanced adrenal gland: 1.2 kidney: 0.5 Group enriched 15 Hep G2: 10.4;PC-3: 50.7
SV2A KIAA0736, SV2 ENSG00000159164 Synaptic vesicle glycoprotein 2A 1 149903318-149917882 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB002226, HPA007863 Enhanced Approved Cytosol Renal cancer:3.22e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 166.9;parathyroid gland: 72.0 epididymis: 28.2 Cell line enhanced NTERA-2: 65.6;SCLC-21H: 63.2
SYT2 ENSG00000143858 Synaptotagmin 2 1 202590596-202710417 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA030372, HPA063655 Enhanced Supported Approved Vesicles Tissue enriched Tissue enhanced adrenal gland: 1.8;cerebral cortex: 2.1 epididymis,testis: 1.0 Cell line enhanced AF22: 8.4;NTERA-2: 5.8;U-2 OS: 1.8
TAAR1 TA1, TAR1, TRAR1 ENSG00000146399 Trace amine associated receptor 1 6 132644984-132646003 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055614 Approved Tissue enhanced Group enriched 17 fallopian tube: 2.2;stomach: 7.8 duodenum,endometrium,prostate,urinary bladder: 0.2 Not detected
TACR1 NK1R, NKIR, SPR, TAC1R ENSG00000115353 Tachykinin receptor 1 2 75046463-75199700 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA074573 Enhanced Mixed Tissue enhanced cervix, uterine: 7.3 fallopian tube: 4.7 Not detected
TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles<br>Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.2 Cell line enhanced HeLa: 6.4;U-2197: 6.3
TBXAS1 CYP5, CYP5A1, THAS, TS, TXAS, TXS ENSG00000059377 Thromboxane A synthase 1 7 139777051-140020325 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031257, HPA031258, HPA031259 Enhanced Supported Vesicles Renal cancer:1.14e-4 (unfavourable) Expressed in all Mixed spleen: 56.3 Cell line enhanced NB-4: 48.5;PC-3: 22.1;U-937: 48.2
TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK receptor tyrosine kinase 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane<br>Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.9 lung: 42.6 Group enriched 8 HUVEC TERT2: 74.6;NTERA-2: 44.2;TIME: 80.0
TFPI EPI, LACI, TFI, TFPI1 ENSG00000003436 Tissue factor pathway inhibitor 2 187464230-187565760 Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA005575, CAB020842 Supported Approved Intermediate filaments<br>Cytosol Cervical cancer:2.02e-4 (unfavourable) Expressed in all Expressed in all placenta: 267.0 Cell line enhanced HHSteC: 309.8;HUVEC TERT2: 601.4;LHCN-M2: 367.6;TIME: 354.9
TH DYT5b ENSG00000180176 Tyrosine hydroxylase 11 2163929-2171877 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB002522, HPA013768, HPA061003, CAB072340 Enhanced Supported Tissue enhanced Tissue enriched 81 adrenal gland: 259.8 adipose tissue: 3.2 Group enriched 26 PC-3: 54.8;SK-BR-3: 15.7
THRA AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3 ENSG00000126351 Thyroid hormone receptor, alpha 17 40058290-40093867 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA009654, CAB023349 Uncertain Supported Cytosol Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 238.9 Expressed in all
THRB ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2 ENSG00000151090 Thyroid hormone receptor beta 3 24117160-24495282 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002008, CAB002009, HPA061035 Approved Supported Nuclear bodies Renal cancer:9.46e-8 (favourable) Mixed Mixed cerebral cortex: 36.3 Cell line enhanced K-562: 43.8;RT4: 28.1
TLR2 CD282, TIL4 ENSG00000137462 Toll like receptor 2 4 153701500-153705699 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA060231, HPA071546 Supported Nucleus<br>Mitochondria Renal cancer:1.11e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 52.7 bone marrow: 34.8 Cell line enhanced RT4: 8.5;THP-1: 25.3
TLR7 ENSG00000196664 Toll like receptor 7 X 12867083-12890380 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA059613 Enhanced Mixed Mixed placenta: 9.2 Group enriched 5 Daudi: 11.6;U-266/70: 12.4
TLR9 CD289 ENSG00000239732 Toll like receptor 9 3 52221080-52226163 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level Not detected Tissue enhanced lymph node: 3.0 spleen: 2.0 Group enriched 10 Daudi: 23.9;RPMI-8226: 14.8;U-698: 8.8
TNF DIF, TNF-alpha, TNFA, TNFSF2 ENSG00000232810 Tumor necrosis factor 6 31575567-31578336 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level Mixed Tissue enhanced bone marrow: 3.7 lymph node: 1.3 Group enriched 5 HDLM-2: 13.9;HMC-1: 12.0;NB-4: 27.3
TNFRSF8 CD30, D1S166E, KI-1 ENSG00000120949 TNF receptor superfamily member 8 1 12063377-12144207 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000016, HPA032081, HPA032082 Approved Tissue enriched Tissue enhanced appendix: 4.1 adipose tissue: 3.1 Cell line enriched 22 HDLM-2: 528.2
TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE ENSG00000120659 Tumor necrosis factor superfamily member 11 13 42562736-42608013 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009193, HPA045142 Enhanced Mixed Tissue enhanced lymph node: 17.3 appendix: 6.3 Cell line enhanced HSkMC: 1.5;NTERA-2: 3.0
TNFSF13B BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20 ENSG00000102524 Tumor necrosis factor superfamily member 13b 13 108251240-108308484 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009188 Enhanced Renal cancer:2.53e-11 (unfavourable) Expressed in all Mixed appendix: 35.3 Cell line enriched 9 U-937: 130.0
TNNC1 TNNC ENSG00000114854 Troponin C1, slow skeletal and cardiac type 3 52451102-52454070 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002450, HPA044848, HPA056897 Enhanced Approved Nucleoplasm<br>Actin filaments<br>Mitochondria Mixed Group enriched 16 heart muscle: 4938.6;skeletal muscle: 7104.7 esophagus: 383.0 Cell line enhanced CACO-2: 53.1;EFO-21: 58.5;HSkMC: 46.0;U-2 OS: 99.1
TOP1 ENSG00000198900 Topoisomerase (DNA) I 20 41028818-41124487 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB009058, HPA019039 Enhanced Supported Nucleus<br>Nucleoli fibrillar center Liver cancer:6.42e-4 (unfavourable) Expressed in all Expressed in all placenta: 71.7 Expressed in all
TOP1MT ENSG00000184428 Topoisomerase (DNA) I, mitochondrial 8 143304384-143359979 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA001915, HPA021542 Approved Supported Mitochondria Renal cancer:1.52e-7 (unfavourable) Expressed in all Expressed in all testis: 41.2 Expressed in all
TOP2A TOP2 ENSG00000131747 Topoisomerase (DNA) II alpha 17 40388516-40417950 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002448, HPA006458, HPA026773 Enhanced Approved Supported Nucleus<br>Nucleoli Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable) Expressed in all Tissue enhanced testis: 108.5 lymph node: 47.7 Expressed in all
TOP2B ENSG00000077097 Topoisomerase (DNA) II beta 3 25597905-25664907 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004601, HPA024120, HPA050441 Supported Enhanced Nucleus Liver cancer:1.86e-7 (unfavourable), Renal cancer:2.43e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 107.4 Expressed in all
TPH1 TPH, TPRH ENSG00000129167 Tryptophan hydroxylase 1 11 18017564-18042426 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010767, HPA022483 Enhanced Uncertain Cytosol Mixed Group enriched 6 colon: 8.8;duodenum: 10.2;rectum: 21.0;small intestine: 12.6;stomach: 15.5 prostate: 2.4 Mixed
TPH2 FLJ37295, NTPH ENSG00000139287 Tryptophan hydroxylase 2 12 71938846-72186618 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA046274, CAB078198 Enhanced Supported Not detected Tissue enhanced cerebral cortex: 1.0 testis: 0.2 Not detected
TPK1 HTPK1, PP20 ENSG00000196511 Thiamin pyrophosphokinase 1 7 144451941-144836395 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA021545, HPA021849 Approved Approved Vesicles Mixed Mixed duodenum: 14.4 Cell line enhanced AN3-CA: 65.0;EFO-21: 19.9
TPMT ENSG00000137364 Thiopurine S-methyltransferase 6 18128311-18155074 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA019851 Approved Endometrial cancer:8.45e-5 (unfavourable), Renal cancer:1.10e-4 (favourable), Ovarian cancer:1.41e-4 (favourable) Expressed in all Expressed in all thyroid gland: 129.8 Expressed in all
TPO TPX ENSG00000115705 Thyroid peroxidase 2 1374223-1543711 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007987, CAB009587 Enhanced Tissue enriched Tissue enriched 103 thyroid gland: 1817.4 spleen: 17.6 Cell line enhanced Karpas-707: 6.9;RPMI-8226: 2.9
TRHR ENSG00000174417 Thyrotropin releasing hormone receptor 8 109086621-109119584 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA055162 Supported Not detected Not detected thyroid gland: 0.2 Not detected
TRPA1 ANKTM1 ENSG00000104321 Transient receptor potential cation channel subfamily A member 1 8 72019917-72075617 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Colorectal cancer:6.57e-4 (favourable) Mixed Tissue enhanced urinary bladder: 29.5 gallbladder: 11.4 Cell line enriched 5 HHSteC: 21.8
TRPM8 ENSG00000144481 Transient receptor potential cation channel subfamily M member 8 2 233917398-234019522 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level Liver cancer:7.15e-4 (favourable) Tissue enriched Tissue enriched 8 prostate: 127.3 liver: 16.2 Cell line enhanced Karpas-707: 3.9;RPTEC TERT1: 6.2;SK-MEL-30: 6.6;WM-115: 5.0
TRPV1 VR1 ENSG00000196689 Transient receptor potential cation channel subfamily V member 1 17 3565444-3609411 FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level Not detected Mixed duodenum: 7.8 Mixed
TRPV3 VRL3 ENSG00000167723 Transient receptor potential cation channel subfamily V member 3 17 3510502-3557995 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA069550 Approved Plasma membrane<br>Centrosome<br>Cytosol Mixed Tissue enhanced skin: 5.1;small intestine: 4.5 duodenum: 1.7 Cell line enhanced BEWO: 3.6;RH-30: 9.0;T-47d: 3.7
TSHR LGR3 ENSG00000165409 Thyroid stimulating hormone receptor 14 80954989-81146302 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000473 Approved Tissue enriched Tissue enriched 282 thyroid gland: 445.5 lymph node: 1.5 Cell line enhanced MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TSPO BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS ENSG00000100300 Translocator protein 22 43151514-43163242 Cancer-related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB011232, HPA046260 Uncertain Approved Vesicles<br>Mitochondria<br>Cytosol Liver cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 300.6 Mixed
TUBA1A B-ALPHA-1, FLJ25113, TUBA3 ENSG00000167552 Tubulin alpha 1a 12 49184796-49189324 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB008686, HPA039247, HPA043684, HPA063394 Enhanced Enhanced Microtubules Renal cancer:2.90e-4 (unfavourable) Tissue enriched Expressed in all cerebral cortex: 1373.1 Expressed in all
TUBA4A FLJ30169, H2-ALPHA, TUBA1 ENSG00000127824 Tubulin alpha 4a 2 219249711-219278170 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004621, CAB005887, HPA039247, HPA043684, HPA063394 Approved Enhanced Microtubules Liver cancer:4.54e-6 (unfavourable) Expressed in all Expressed in all skin: 181.8 Cell line enhanced HBEC3-KT: 297.7
TUBB M40, MGC16435, OK/SW-cl.56, Tubb5 ENSG00000196230 Tubulin beta class I 6 30720201-30725426 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005417, CAB012406, HPA043640, HPA046280 Enhanced Supported Microtubules Renal cancer:2.62e-8 (unfavourable), Liver cancer:5.97e-4 (unfavourable) Expressed in all Expressed in all ovary: 72.3 Mixed
TUBB1 dJ543J19.4 ENSG00000101162 Tubulin beta 1 class VI 20 59019254-59026654 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004286, HPA043640, HPA046280 Approved Not detected Group enriched 5 bone marrow: 4.8;lung: 2.1;placenta: 1.5;spleen: 5.6;testis: 1.5 gallbladder: 0.5 Cell line enriched 20 HEL: 24.9
TUBB3 beta-4, CFEOM3, CFEOM3A, FEOM3 ENSG00000258947 Tubulin beta 3 class III 16 89921392-89938761 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043640, HPA046280 Approved Mixed Tissue enriched 6 cerebral cortex: 195.6 adrenal gland: 34.5 Cell line enhanced SCLC-21H: 490.8
TUBB4B Beta2, TUBB2C ENSG00000188229 Tubulin beta 4B class IVb 9 137241213-137243707 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB010880, HPA043640, HPA046280 Enhanced Supported Microtubules Thyroid cancer:6.36e-6 (favourable), Endometrial cancer:4.91e-4 (favourable), Liver cancer:9.98e-4 (unfavourable) Expressed in all Expressed in all testis: 786.8 Expressed in all
TUBD1 FLJ12709, TUBD ENSG00000108423 Tubulin delta 1 17 59859482-59892945 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB004609, HPA023980, HPA027090 Approved Enhanced Nucleoplasm<br>Cytosol Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 12.5 Expressed in all
TUBE1 dJ142L7.2, FLJ22589, TUBE ENSG00000074935 Tubulin epsilon 1 6 112070777-112087529 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA032073, HPA032074 Approved Expressed in all Expressed in all testis: 55.3 Expressed in all
TUBG1 TUBG, TUBGCP1 ENSG00000131462 Tubulin gamma 1 17 42609676-42615234 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004608 Enhanced Liver cancer:1.08e-8 (unfavourable), Renal cancer:6.48e-5 (unfavourable), Endometrial cancer:8.99e-4 (favourable) Expressed in all Tissue enriched 6 testis: 242.8 smooth muscle: 40.2 Expressed in all
TXNRD1 GRIM-12, Trxr1, TXNR ENSG00000198431 Thioredoxin reductase 1 12 104215779-104350305 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA001395, CAB004607, CAB015834, HPA043871 Approved Supported Nucleus Liver cancer:1.12e-5 (unfavourable), Renal cancer:1.20e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 109.1 Expressed in all
TYMS HsT422, TMS, TS, Tsase ENSG00000176890 Thymidylate synthetase 18 657604-673578 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB002784 Enhanced Liver cancer:5.10e-6 (unfavourable) Expressed in all Mixed testis: 59.1 Expressed in all
TYR OCA1, OCA1A, OCAIA ENSG00000077498 Tyrosinase 11 89177452-89295759 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000079, HPA043241, HPA050889 Enhanced Enhanced Vesicles Tissue enriched Tissue enriched 33 skin: 29.8 breast: 0.9 Cell line enriched 1211 SK-MEL-30: 256.2
UGCG GCS ENSG00000148154 UDP-glucose ceramide glucosyltransferase 9 111896766-111935369 Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024124 Approved Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable) Expressed in all Expressed in all adrenal gland: 84.1 Expressed in all
VAMP1 SYB1, VAMP-1 ENSG00000139190 Vesicle associated membrane protein 1 12 6462237-6470987 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002779, CAB016119, CAB079000 Approved Approved Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 43.5 Cell line enriched 5 U-698: 140.4
VAMP2 SYB2, VAMP-2 ENSG00000220205 Vesicle associated membrane protein 2 17 8159149-8163546 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB078785 Supported Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 483.5 Expressed in all
VDR NR1I1, PPP1R163 ENSG00000111424 Vitamin D (1,25- dihydroxyvitamin D3) receptor 12 47841537-47943048 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters Evidence at protein level CAB004617, HPA047740 Enhanced Nucleoplasm Renal cancer:4.89e-6 (favourable) Expressed in all Tissue enhanced parathyroid gland: 175.9 small intestine: 57.9 Cell line enhanced HDLM-2: 73.7;U-937: 60.2
VEGFA VEGF, VEGF-A, VPF ENSG00000112715 Vascular endothelial growth factor A 6 43770184-43786487 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005429, CAB039240, HPA069116, CAB069907 Supported Renal cancer:1.76e-5 (unfavourable), Liver cancer:2.34e-5 (unfavourable), Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.73e-4 (favourable), Cervical cancer:4.50e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 452.5 Expressed in all
VEGFB VEGFL, VRF ENSG00000173511 Vascular endothelial growth factor B 11 64234538-64238793 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level Expressed in all Expressed in all adipose tissue: 195.0 Expressed in all
VKORC1 VKCFD2 ENSG00000167397 Vitamin K epoxide reductase complex subunit 1 16 31090842-31095980 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042720 Approved Supported Endoplasmic reticulum Renal cancer:2.09e-10 (unfavourable) Expressed in all Expressed in all liver: 141.4 Expressed in all
VKORC1L1 ENSG00000196715 Vitamin K epoxide reductase complex subunit 1 like 1 7 65873267-65959563 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA053954 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all adipose tissue: 57.5 Expressed in all
VWF F8VWF ENSG00000110799 Von Willebrand factor 12 5948874-6124770 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB001694, HPA001815, HPA002082, CAB072874, CAB072875 Supported Stomach cancer:2.31e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 155.1 lung: 115.9 Cell line enriched 57 HUVEC TERT2: 468.1
XDH XO, XOR ENSG00000158125 Xanthine dehydrogenase 2 31334321-31414715 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA062641, HPA069323 Supported Supported Nucleus Urothelial cancer:8.73e-6 (favourable) Mixed Tissue enhanced breast: 48.3;duodenum: 45.6;liver: 35.9;small intestine: 54.6 colon: 11.2 Cell line enhanced HBEC3-KT: 14.4;hTERT-HME1: 23.9
YES1 c-yes, HsT441, Yes ENSG00000176105 YES proto-oncogene 1, Src family tyrosine kinase 18 721588-812546 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB004370, HPA026480 Approved Supported Plasma membrane<br>Cytosol Pancreatic cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all placenta: 62.0 Mixed